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ITHACA by C.P  Cavafy 
 
 
As you set out for Ithaka 
hope the voyage is a long one, 
full of adventure, full of discovery. 
Laistrygonians and Cyclops, 
angry Poseidon—don’t be afraid of them: 
you’ll never find things like that on your way 
as long as you keep your thoughts raised high, 
as long as a rare excitement 
stirs your spirit and your body. 
Laistrygonians and Cyclops, 
wild Poseidon—you won’t encounter them 
unless you bring them along inside your soul, 
unless your soul sets them up in front of you. 
  
Hope the voyage is a long one. 
May there be many a summer morning when, 
with what pleasure, what joy, 
you come into harbors seen for the first time; 
may you stop at Phoenician trading stations 
to buy fine things, 
mother of pearl and coral, amber and ebony, 
sensual perfume of every kind— 
as many sensual perfumes as you can; 
and may you visit many Egyptian cities 
to gather stores of knowledge from their scholars. 
  
Keep Ithaka always in your mind. 
Arriving there is what you are destined for. 
But do not hurry the journey at all. 
Better if it lasts for years,  
so you are old by the time you reach the island, 
wealthy with all you have gained on the way, 
not expecting Ithaka to make you rich. 
  
Ithaka gave you the marvelous journey. 
Without her you would not have set out. 
She has nothing left to give you now.  
  
And if you find her poor, Ithaka won’t have fooled you. 
Wise as you will have become, so full of experience, 
you will have understood by then what these Ithakas mean.   
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SUMMARY 
 
Iron overload is an inevitable consequence of repeated blood transfusions required to 
sustain life in a wide array of haematological conditions such as thalassaemia, aplastic 
anaemia, and myelodysplastic syndromes (MDS). Without iron chelation therapy, death 
from cardiotoxic effects of iron overload usually ensues in the second decade. Iron 
chelation therapy with subcutaneous Desferrioxamine (DFO) infusions at least 5 nights 
per week has been shown unequivocally to prolong life expectancy in thalassaemia 
major. However, although this molecule is remarkably free of toxic side effects at 
treatment doses, patient compliance is often poor, and iron overload still leads to death 
today. 
 
 
One of the scopes of this Ph.D. was to develop a cellular model that would allow the 
testing of novel chelating agents used alone or in combination with established 
chelators. Our in vitro model of iron overload was able to elucidate several principles 
regarding the interactions of chelators within cells. It allowed for the first time a detailed 
interrogation of synergy as opposed to additivity of action of licensed chelators when 
used in combination, which has now been published. This model is also relevant to the 
development of new chelators and was used to demonstrate the iron binding properties 
of Eltrombopag (ELT), a drug used to manage ITP, at clinically achievable 
concentrations. ELT is a powerful  intracellular iron chelator that decreases storage iron 
and enhances iron removal when in combination with commercially available iron 
chelators. In clinical use, donation of chelated iron by ELT to these chelators offers 
established routes for elimination of chelated iron. Furthermore, we extensively 
investigated the iron mobilising properties of the naturally occurring flavonoid 
quercetin and its principle metabolites. For the first time we showed that quercetin and 
its metabolites can act as a shuttle when combined with licensed chelators and provided 
a unique structure-function analysis of flavonoids with regards to iron and ferritn 
mobilisation and antioxidant capacity as a function of Fe(II) binding.  
 
 A further goal of this thesis was to establish an iron-overloaded humanised 
thalassaemia mouse model that could be used to examine whether the same principles 
which determine iron release from cell cultures also influence the oral efficiency of iron 
chelators, in vivo. We utilised iron dextran to achieve cardiac iron loading confirmed 
by histology and MRI investigations. Iron overloaded mice were treated with a 
combination of the flavonoid quercetin and the iron chelator Deferasirox (DFX), and 
we established the value of this in combination in terms of cardiac iron mobilisation. 
Our novel humanised β thalassaemia ion-overloaded mouse model demonstrating 
cardiac iron loading is a first-in-kind development, and the novel application of MRI 
will provide a useful tool for studying iron chelators, the pathophysiology and disease 
progression, blood transfusion regimens and cellular/gene therapy in iron overload in 
the future. Our findings in vivo support the contention that our cellular model is a useful 
screening tool for new compounds, both for toxicity and efficacy. 
 
Keywords: Iron, Chelator, Hepatocyte, Cardiomyocyte, Thalassaemia               
                                                                                                                                                                                         
  
 5 
Table of Contents 
 
NOVEL APPROACHES TO IRON CHELATION THERAPY: NOVEL 
COMBINATIONS AND NOVEL COMPOUNDS..................................................... 1 
ACKNOWLEDGEMENTS ......................................................................................... 3 
LIST OF ABBREVIATIONS .................................................................................... 16 
Chapter 1 INTRODUCTION ................................................................................. 17 
1.1 Objective of this work ................................................................................ 17 
1.2 The need for safe and effective iron chelation ........................................... 17 
1.3 Principles of iron chelation therapy ........................................................... 22 
1.4 Design of chelators: properties for maximal oral efficacy ......................... 27 
1.5 Properties to minimise toxicity: design of chelators .................................. 31 
1.6 Chelator Evaluation ................................................................................... 34 
1.7 Commercially available iron chelators ...................................................... 44 
1.8 Other chelators that have reached clinical trials ........................................ 51 
1.9 Conclusions ................................................................................................ 53 
Chapter 2 MATERIALS AND METHODS ........................................................... 54 
2.1 Iron chelators and substances tested for iron chelation activity ................ 54 
2.2 Cell Lines ................................................................................................... 54 
2.3 Cellular Methods ........................................................................................ 54 
 6 
2.4 Flowchart of final cellular iron loading model .......................................... 59 
2.5 Ferritin quantification ................................................................................ 59 
2.6 Determination of intracellular reactive oxygen species (ROS) levels using a 
fluorimetric method ............................................................................................... 60 
2.7 Preparation of heat-inactivated human serum ............................................ 61 
2.8 Animal Study ............................................................................................. 62 
2.9 Drug Combination Analysis ...................................................................... 66 
2.10 Statistical analysis ...................................................................................... 67 
Chapter 3 HEPATOCYTE AND CARDIOMYOCYTE CULTURES; Development 
of a model to study iron mobilisation by chelators .................................................... 68 
3.1 Introduction ................................................................................................ 68 
3.2 Iron and the human liver ............................................................................ 69 
3.3 Iron Uptake Mechanisms ........................................................................... 72 
3.4 Developing the cellular model; the approach ............................................ 76 
3.5 Establishing optimal medium for iron loading in HuH7 cells ................... 76 
3.6 Establishing the number of media changes for optimal iron loading ........ 80 
3.7 Establishing the optimal cell washing technique ....................................... 80 
3.8 Regime for iron loading and washing of H9C2 cardiomyocyte cells ........ 83 
 7 
3.9 Cell damage in HuH7/H9C2 assessed by Tryptan blue, AO/PI staining and 
LDH release ........................................................................................................... 85 
3.10 Time course of and concentration dependence of intracellular iron 
mobilisation with DFO, DFP and DFX monotherapy ........................................... 86 
3.11 Iron release with low membrane-permeable hydrophilic iron chelators ... 91 
3.12 Effect of iron loadin or iron chelation of cellular ferritin in HuH7 and H9C2 
cells. 93 
3.13 Discussion .................................................................................................. 97 
3.14 Conclusion ................................................................................................. 98 
Chapter 4 THE INFLUENCE OF COMBINATION OF COMMERCIALLY 
AVAILABLE IRON CHELATORS ON RELEASE OF CELLULAR IRON. ...... 100 
4.1 Introduction .............................................................................................. 100 
4.2 Chelator speciation plots and their relevance to synergistic chelator 
combinations ........................................................................................................ 100 
4.3 Comparison of cellular iron mobilisation with monotherapy and combinations 
in HuH7 cells ....................................................................................................... 104 
4.4 Effect of chelator combinations on the intracellular iron pool after 8 hours in 
cardiomyocytes (H9C2) ....................................................................................... 107 
4.5 Differentiation of synergy vs. additivity of chelator combinations using 
isobolograms ........................................................................................................ 109 
4.6 Indexes of synergy with the three combinations...................................... 111 
 8 
4.7 Insights into synergistic mechanisms using the hydroxypyridinones CP40 and 
CP44 as probes ..................................................................................................... 116 
4.8 Discussion ................................................................................................ 118 
4.9 Conclusion ............................................................................................... 121 
Chapter 5 ELTROMBOPAG IS A POWERFUL CHELATOR OF IRON(III), 
THAT MOBILISES INTRACELLULAR STORAGE IRON ALONE OR IN 
COMBINATION WITH CLINICALLY ESTABLISHED CHELATORS. ........... 122 
5.1 Introduction .............................................................................................. 122 
5.2 Material and methods ............................................................................... 123 
5.3 Results ...................................................................................................... 127 
5.4 Discussion ................................................................................................ 142 
5.5 Conclusion ............................................................................................... 146 
Chapter 6 THE INFLUENCE OF FLAVONOIDS ON CELLULAR IRON 
MOBILISATION ALONE OR IN COMBINATION WITH CLINICALLY 
AVAILABLE IRON CHELATORS ....................................................................... 147 
6.1 Introduction .............................................................................................. 147 
6.2 Chemistry of flavonoids ........................................................................... 148 
6.3 Dietary uptake and metabolism of flavonoids in humans ........................ 151 
6.4 Flavonoids and their biological activities ................................................ 152 
6.5 Dietary uptake, metabolism and toxicology of Quercetin ....................... 155 
 9 
6.6 Materials and Methods ............................................................................. 159 
6.7 Results ...................................................................................................... 161 
6.8 Synergistic chelation of Quercetin combined with otherwise ineffective 
hydroxyyridinone CP40 ....................................................................................... 180 
6.9 Discussion ................................................................................................ 182 
6.10 Conclusion ............................................................................................... 186 
Chapter 7 DEVELOPMENT OF AN IRON-OVERLOADED MOUSE MODEL 
FOR TESTING THE ORAL EFFICACY OF IRON MOBILISATION WITH 
FLAVONOIDS ALONE OR IN COMBINATION WITH OTHER IRON 
CHELATION ........................................................................................................... 187 
7.1 Rationale for developing a murine model where cardiac iron overload is 
achieved ............................................................................................................... 187 
7.2 Mouse models of cardiac iron-overload .................................................. 187 
7.3 Development of the iron overloaded murine mouse model ..................... 192 
7.4 Results ...................................................................................................... 195 
7.5 Discussion and conclusion ....................................................................... 209 
7.6 Testing the flavonoid quercetin in our animal model .............................. 211 
Chapter 8 CONCLUSIONS AND FUTURE PERSPECTIVES .......................... 220 
8.1 The value of the in vitro cultures and in vivo mouse model for investigating 
iron chelators ........................................................................................................ 220 
8.2 Limitations of the cellular culture system in investigating iron chelators 222 
 10 
8.3 Future developments and perspectives .................................................... 225 
8.4 Conclusion ............................................................................................... 225 
APPENDICES ......................................................................................................... 227 
 
 11 
List of Tables 
 
Table 1 Estimated global annual births with major haemoglobinopathies. ............................. 20 
Table 2 Overview of cellular systems used to study the efficacy and toxicity of chelators . 38 
Table 3 Methods used to iron-load animals. ......................................................................................... 43 
Table 4 Properties, pharmacokinetics, and metabolism of commercially available iron 
chelators. .................................................................................................................................................. 50 
Table 5 Percentage of intracellular iron removed by chelators in HuH7 and H9C2 .............. 90 
Table 6 Iron chelator characteristics. .................................................................................................... 101 
Table 7 Combination Indices of chelators in cardiomyocytes (H9C2). ...................................... 112 
Table 8   Combination indices of chelators in hepatocytes (HuH7). ........................................... 113 
Table 9 Chelator DRI in hepatocytes (HuH7). ..................................................................................... 114 
Table 10 Chelator Dose reduction in cardiomyocytes (H9C2). .................................................... 114 
Table 11 Comparison of the structure and iron binding properties of ELT and other 
chelators. ................................................................................................................................................ 128 
Table 12 Comparison of percentage of intracellular iron mobilised at 8h in a 
cardiomyocyte (H9C2) and a hepatocyte (HuH7) cell lines by clinically available 
chelators or ELT, alone (top panel) or in combination (lower panel). ........................... 131 
Table 13 Comparison of ROS generation in cardiomyocyte (H9C2) and a hepatocyte (HuH7) 
cell lines is shown after addition of clinically available chelators or ELT, alone (top 
panel) or in combination (lower panel) over 90 minutes at the concentrations shown.
 .................................................................................................................................................................... 134 
Table 14 Food sources of dietary flavonoids. ..................................................................................... 147 
Table 15 Percentage viability assessed by the LDH assay following 12 hours of treatment 
with quercetin and its metabolites at 30μΜ. ............................................................................ 162 
Table 16 Percentage iron release from hepatocyte (HuH7) and cardiomyocyte (H9C2) cells 
following 8 hours of treatment with commercially available chelators at 30μΜ ibe 
and quercetin at 30μΜ. ..................................................................................................................... 163 
Table 17 Synergy Index ‘α’ for the combination treatment of commercially available 
chelators with quercetin in cardiomyocyte (H9C2) cells. .................................................... 180 
Table 18 Heart, liver and spleen tissue iron. ....................................................................................... 198 
Table 19 Changes in haematological parameters secondary to iron loading with iron 
dextran .................................................................................................................................................... 200 
Table 20 Total 'blue' iron containing area count from the histology images in Figure 70 .
 .................................................................................................................................................................... 218 
Table 21 Total number of 'blue' pixels in the histology images in Figure 70 . ........................ 218 
 
  
 12 
List of Figures 
 
Figure 1 Illustration of the three commercially available iron chelators and their denticity.
 ...................................................................................................................................................................... 29 
Figure 2 Rhodotorulic Acid (RA) structure (Grady et al, 1979) ..................................................... 51 
Figure 3 Structures of the iron chelators Desferrithiocin, Deferitrin, Deferitazole ............... 53 
Figure 4 AO/PI staining following 8 hours of treatment with DFO at 30μM ibe. ..................... 56 
Figure 5 Trypan blue staining in HuH7 cells following 8 hours of chelator treatment. ........ 57 
Figure 6 Ferrosine assay standard curve. .............................................................................................. 58 
Figure 7 Rat (A) and human (B) ferritin standard curve. ................................................................. 60 
Figure 8 Effect of varying the concentration of DCF on ROS production in HuH7 cells. ........ 61 
Figure 9 Sample Isobologram ..................................................................................................................... 67 
Figure 10 FAC/FBS loading regime in HuH7 cells ................................................................................ 78 
Figure 11 Total iron concentration of RPMI media and RPMI media containing 10% FBS (A) 
and NTBI content (B). .......................................................................................................................... 79 
Figure 12 HuH7 iron following 1 or 2 changes of 10% FBS media, each for 10 hours. .......... 80 
Figure 13 Effect of washing HuH7 cells with PBS for different time intervals on cellular 
protein....................................................................................................................................................... 81 
Figure 14 Effect of washing HuH7 cells with different agents before and after chelator 
exposure on iron detection. .............................................................................................................. 82 
Figure 15 Iron loading of H9C2 with FAC/10% FBS-DMEM media over one (A) or two (B) 10 
hour periods. .......................................................................................................................................... 84 
Figure 16 LDH viability assay in H9C2 following 8 hours of chelator treatment ..................... 86 
Figure 17 HuH7 intracellular iron mobilisation with DFO, DFP and DFX monotherapy at 
increasing concentrations at 4 hours of treatment. ................................................................. 87 
Figure 18 HuH7 intracellular iron mobilisation time course with DFO, DFP and DFX 
monotherapy at (A) 10μΜ and (B) 30μΜ. .................................................................................... 88 
Figure 19 H9C2 intracellular iron decrements time course with DFO, DFP and DFX 
monotherapy at 30μΜ ibe. ................................................................................................................ 89 
Figure 20 H9C2 intracellular iron mobilisation at 8 hours with increasing concentrations 
of DFO, DFP, and DFX. .......................................................................................................................... 90 
Figure 21 Decrements in cellular iron after an 8 hour treatment with 100μΜ CP40/CP46 in 
A. HuH7 B. H9C2..................................................................................................................................... 92 
Figure 22 Effect of one and two 10 hours treatments of 10% FBS containing media on 
ferritin concentration in (A) HuH7 and (B) H9C2 cells. .......................................................... 94 
Figure 23 Ferritin in (A) HuH7 and (B) H9C2 cells treated with commercially available 
chelators for 8 hours. ........................................................................................................................... 96 
Figure 24 DFO, DFX, and DFP combination speciation plots at pH 7.4 ...................................... 102 
 13 
Figure 25 Treatment of HuH7 cells with a combination of (A) DFO and DFX, (B) DFO and 
DFP, and (C) DFP and DFX for 8 hours and (D) DFP and DFP for 4 hours. ..................... 104 
Figure 26 Treatment of H9C2 cells with a combination of (A) DFO and DFX, (B) DFO and 
DFP and (C) DFP and DFX for 8 hours. ......................................................................................... 107 
Figure 27 Commercial chelator combination isobolograms in HuH7 cells. ............................ 109 
Figure 28 Commercial chelator combination isobolograms in H9C2 cells. ............................. 110 
Figure 29 Synergy Index ‘α’ for the combination treatment of commercially available 
chelators in hepatocyte (HuH7) and cardiomyocyte (H9C2) cells. .................................. 111 
Figure 30 Treatment of chelator monotherapy combined with CP40 for 8 hours in HuH7 
cells........................................................................................................................................................... 116 
Figure 31 Structure of Eltrombopag and its iron complex. ............................................................ 127 
Figure 32 Cellular iron release from hepatocyte HuH7 (A) or cardiomyocyte H9C2 cells (B) 
by ELT is shown as a function of ELT concentration. ............................................................. 128 
Figure 33 Hepatocyte HuH7 (A) and Cardiomyocyte H9C2 (B) cell viability following an 8-
hour treatment with ELT. ................................................................................................................. 129 
Figure 34 Comparison of the effect of ELT on ferritin and total cellular iron mobilisation in 
hepatocyte HuH7 (A) and cardiomyocyte H9C2 cells (B) is shown. ................................. 131 
Figure 35 The time-course for ROS inhibition by ELT and other chelators. ............................ 133 
Figure 36  Rate of ROS production following chelation treatmen in (A) HuH7 and (B) H9C2 
cells........................................................................................................................................................... 134 
Figure 37 The speciation of iron(III) in the presence of ELT as a function of pH. 
[Fe]total=1μM; [ELT]total =10μΜ. ................................................................................................ 137 
Figure 38 The proportions of ELT species bound to iron(III) at equilibrium, with increasing 
ELT concentrations, in the presence of (a) 1µM DFO,) (b) 3µM DFP, (c) 2µM DFX. .... 138 
Figure 39 The effect of serum and albumin on the iron mobilisation by ELT is shown in 
HuH7 cells .............................................................................................................................................. 138 
Figure 40 Cellular iron retention mobilisation is shown in previously iron loaded HuH7 
cells, after 8 hours of exposure to ELT 3μΜ and/or CP40 33μΜ ibe as single agents 
and combination over an 8 hour period. .................................................................................... 140 
Figure 41 Core flavonoid structure. ........................................................................................................ 148 
Figure 42 Structures of the different flavonoid groups. .................................................................. 149 
Figure 43 Flavonoid binding site for trace metal ions indicated by Men+ (A)(Kumar & 
Pandey, 2013) and complexes formed between quercetin and Fe (III) and Fe (II) (B).
 .................................................................................................................................................................... 153 
Figure 44 Structure of quercetin and its principal metabolites ................................................... 157 
Figure 45 Tryptan blue viability staining in HuH7 cells following a 12 hour treatment with 
quercetin and its metabolites at 30μΜ. ...................................................................................... 161 
Figure 46 Time course of change in intracellular iron content using monotherapy with 
quercetin and its metabolites at (A) 3 μΜ and (B) 30μΜ and in HuH7 cells. ................ 165 
 14 
Figure 47 Concentration dependence for change in cellular iron at 8h after monotherapy 
with quercetin and its metabolites in HuH7 cells. .................................................................. 166 
Figure 48 Concentration dependent ROS inhibition by Quercetin and its metabolites and 
commercially available chelators in cardiomyocytes (A) and hepatocytes (B). ......... 167 
Figure 49 The time-course for ROS inhibition by DFO 1μΜ ibe, Quercetin, Quercetin-3-
glucoside and Quercetin metabolites at 1μΜ in HuH7 cells. ............................................... 169 
Figure 50 Ferritin decrements at 8h with quercetin or DFX, DFP or DFO in (A) 
cardiomyocyte H9C2 cells and (B) in hepatocyte HuH7 ....................................................... 171 
Figure 51 Ferritin decrements at 8h with quercetin and its metabolites in (A) 
cardiomyocyte H9C2 cells and (B) in hepatocyte HuH7. ...................................................... 173 
Figure 52 Decrements in HuH7 cellular iron by DFO/DFX/DFP combined with Quercetin or 
its metabolites. ..................................................................................................................................... 176 
Figure 53. Decrements in cellular iron in H9C2 cells by combinations of Isorhamnetin with 
clinically available iron chelators following 8 hours of treatment. (A) DFO-
Isorhamnetin, (B) DFP-Isorhamnetin, (C) DFX-Isorhamnetin. .......................................... 177 
Figure 54 Quercetin and commercially available chelator combination isobolograms in 
HuH7 cells. ............................................................................................................................................. 179 
Figure 55 Cellular iron mobilisation is shown in previously iron loaded HuH7 cells, after 8 
hours of exposure to quercetin 3μΜ and/or CP40 33μΜ ibe as single agents and 
combination .......................................................................................................................................... 181 
Figure 56 Schematic representation of mouse iron loading model ............................................ 193 
Figure 57 Iron in the heart, liver and spleen following iron-loading in mice and a 4 week 
re-equilibration period. .................................................................................................................... 196 
Figure 58 Perls stain of the heart of iron loaded mice demonstrating iron in the 
myocardium. ......................................................................................................................................... 197 
Figure 59 Perls stain of the heart of iron loaded mice demonstrating iron in the 
myocardium in mice sacrificed directly after the 4 week iron loading treatment or 4 
weeks later. ........................................................................................................................................... 198 
Figure 60 Comparison of the weight of mice (A) and their heart, liver and spleen weights 
(B) post sacrifice. ................................................................................................................................ 201 
Figure 61 Mice spleen volumes. ............................................................................................................... 202 
Figure 62 T2 relaxation times in iron-loaded mice. ......................................................................... 204 
Figure 63 T2* relaxation times in iron-loaded mice ........................................................................ 205 
Figure 64 T1 relaxation times in iron-loaded mice. ......................................................................... 206 
Figure 65 Cardiac function following iron loading. .......................................................................... 207 
Figure 66 Cardiac T2* to iron calibration curve. ............................................................................... 208 
Figure 67  Schematic representation of DFX/Quercetin combination treatment in iron-
overloaded mice. ................................................................................................................................. 212 
 15 
Figure 68 Tissue iron content of the (A) heart, (B) liver and (C) spleen of iron-loaded mice 
treated with DFX/Quercetin ........................................................................................................... 214 
Figure 69 Perls staining of heart, liver and spleen tissue in iron loaded mice following 
DFX/Quercetin treatment. ............................................................................................................... 216 
Figure 70  Perls stain images from Figure 69, following Image J modification to enable blue 
stained iron pixel quantification. .................................................................................................. 217 
  
 16 
LIST OF ABBREVIATIONS 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DFO Desferrioxamine 
DFP Deferiprone 
DFX Deferasirox 
ELT Eltrombopag 
FAC Ferric ammonium citrate 
HPO Hydroxypiridinone 
ip Intraperitoneal 
iv Intravenous 
LIP Labile iron pool 
LVEF Left ventricular ejection function 
MDS Myelodysplastic Syndrome 
MW Molecular weight 
NTBI Non-transferrin bound iron 
RA Rhodotorulic Acid 
RES Reticuloendothelial system 
ROS Reactive oxygen species 
sc Subcutaneous 
Tf Transferrin 
 17 
Chapter 1 INTRODUCTION 
1.1 Objective of this work 
The initial purpose of the work carried out in this thesis was to develop an in vitro 
cellular model for the screening of new iron chelators which will provide useful 
information about the likely relative efficacy and toxicology of iron chelators in vivo.  
The second purpose was to identify new approaches to iron chelation, either when used 
as monotherapy or in combination with established chelators.   A cell culture model was 
therefore developed and applied to closely compare single agent chelation with 
combined use of iron chelators.  We also wished to examine the ability of chelators to 
access intracellular iron pools and abrogate or enhance further the damaging effects of 
iron overload. Additional objectives were to develop a humanised thalassaemic murine 
model of iron overload that will allow screening of new chelators and predict toxicology 
and efficacy of chelation in humans. 
 
In this chapter, the clinical need to identify new oral iron chelators for the management 
of transfusional iron overload is discussed as well as current knowledge of the chemical 
and biological requirements of such chelators and their merits and limitations. The 
advantages and limitations of other available models for evaluating iron chelators both 
in vivo and in vitro are also discussed, in order to put into context the potential value of 
the novel hepatocyte/cardiomyocyte and animal model. 
1.2 The need for safe and effective iron chelation   
The most established application of iron chelation treatment is the management of 
transfusional iron overload. Iron overload occurs from repeated blood transfusions, but 
it can also be a result of excess absorption of iron from the gut, as is the case in 
hereditary haemochromatosis. Patients who receive 25 units of blood per year, if they 
are not treated with chelation therapy, will by the age of fifteen years be at risk from the 
effects of iron overload due to deposition in critical tissues such as the heart, since there 
is no physiological mechanism for removing this iron (Borgna-Pignatti & Marsella, 
2015). Alternatively, an excess of 100 units of blood is equivalent to 20-25g of iron, 
and will cause cellular, and organ damage through a mechanism such as lipid 
peroxidation and therefore must be removed prior to this event. Whereas iron loading 
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from excessive iron absorption can be treated by phlebotomy, transfusional iron loading 
usually results from conditions associated with anaemia, thereby precluding this option. 
Iron chelation therapy, defined as the removal of excess iron using iron-binding 
molecules, is the only therapeutic option unless the underlying cause of the anaemia is 
corrected. 
Repeated blood transfusions will in principle result in iron overload in any condition. 
There are a number of anaemias which are known to be associated with transfusional 
siderosis and patients would benefit from the availability of orally active iron chelators. 
These include aplastic anaemia, myelodysplasia, pyruvate kinase deficiency and red cell 
aplasia. Iron overload may also occur in other anaemias where sporadic transfusion is 
more typical or where transfusion is not usually given for the anaemia as such- for 
example in sickle cell disease. However, worldwide, β thalassaemia major patients are 
the ones who would benefit the most frequently from regular oral iron chelation therapy. 
Individuals with β Thalassaemia major become symptomatic of severe anaemia by 6 
months of age and requires blood transfusions to sustain life, with the rapid consequent 
accumulation of excess iron. Globally, there are more than 300,000 births annually with 
severe haemoglobinoathies. The majority of these occur in developing countries with 
low-to-middle income (Weatherall, 2010). The majority of potentially transfusion-
dependent thalassaemia patients reside in Asia, with an estimated 21,639 births annually 
with β thalassaemia (and Eβ thalassaemia) (Table 1). Despite the introduction of 
effective antenatal diagnosis and prevention programs there are still approximately 
1,347 β thalassaemia homozygote births annually in Europe (Latest World Health 
Organisation (WHO) statistics, 2008). In some countries β thalassaemia is prevalent yet 
the clinical infrastructure to support safe and regular blood transfusions is lacking 
therefore treatment with iron chelators is secondary consideration. In other countries 
transfusional support of thalassaemic patients is available, but chelation treatment for 
example with DFO is prohibitively expensive.  In the UK, in 2014 the annual costs of 
DFO, DFP and DFX treatment were approximated to £1,994- £9,303, £4,993 and 
£7,665- £20,000 respectively, excluding blood transfusion. In a Taiwanese study in 
2006, it was estimated that the lifetime cost of blood transfusions accompanied by 
chelation therapy treatment vs. haematopoietic stem cell transplantation was $363,149 
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vs. $110,588 (Ho et al, 2006). Based on economic considerations, transplantation has 
advantages over combined transfusion and chelation therapy. Favourably reported 
results include a 93% 3-year rejection-free survival in previously well-chelated patients 
without liver fibrosis and hepatomegaly (Lucarelli et al, 1993).  This compares to 91% 
survival free of cardiac disease after 15 years for patients that maintain their ferritin 
below 2500μg/L on conventional DFO treatment (Olivieri et al, 1994). While the use 
of oral chelation therapy improves patient compliance and thus prognosis, in developing 
countries with a high incidence of severe thalassaemia syndromes the health costs are 
still likely to be prohibitive. Therefore, advances in either chelation or stem cell 
transplantation need to be accompanied by an active screening and prevention program 
for thalassaemia syndromes, if the limited health resources are not to be overwhelmed 
in these countries. 
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Table 1 Estimated global annual births with major haemoglobinopathies. (World Health 
Organisation, 2008) 
Annual Births Sickle cell 
disorders 
β thalassaemias α 
thalassaemias 
Affected 
births 
(Total) 
Annual 
births 
(1000s) 
(Total) 
Africa 233 289 1 520 11 234 819 22 895 
Americas 9 047 533 422 10 022 16 483 
Eastern 
Mediterranean 
6 491 9 715 1 16 207 16 776 
Europe 1 292 1 347 162 2 800 10 459 
South-East Asia 26 037 21 693 1 383 49 114 38 139 
West Pacific 13 7 601 10 524 18 138 23 914 
Total 276 168 42 409 13 466 332 043 128 667 
 
Despite the above economic considerations, there is a major need for improvement in 
patient compliance with iron chelation therapy. There is no doubt that based on the 
accumulated clinical experience with DFO, iron chelation is of proven efficacy in 
prolonging life expectancy in thalassaemia major. The life expectancy of patients with 
β thalassaemia major did not exceed 20 years (Zurlo et al, 1989) prior to the use of DFO, 
initially by the intramuscular (i.m) (Barry et al, 1974) and later the subcutaneous (s.c) 
route (Propper et al, 1976).  
There are numerous studies showing the value of DFO in reducing liver iron (Cohen et 
al, 1989; Flynn et al, 1982; Olivieri et al, 1996) and producing negative iron balance 
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(Silvestroni et al, 1982) while prolonging life expectancy (Brittenham et al, 1994; 
Modell et al, 1982; Olivieri et al, 1994). Patients are treated lifelong for 8 hours per day, 
often overnight, with pumps which deliver DFO via subcutaneous hypodermic needles, 
which is associated with considerable challenges with compliance, particularly in older 
children and adolescents. Poor treatment compliance leads to a significant reduction in 
life expectancy (Brittenham et al, 1994; Gabutti & Piga, 1996; Olivieri et al, 1994).  
Compliance with oral chelators has been shown to be greater, with DFP showing a 95% 
compliance compared to a 70% with DFO (Olivieri et al, 1996).  
A further consideration regarding the need for new iron chelators is that as treatment is 
life-long from an early age, there is a need for a high therapeutic safety margin. For 
example, DFO is remarkably well tolerated provided doses are kept within the 
therapeutic ratio. Side effects have been observed at high doses relative to the degree of 
iron overload including ototoxicity (Porter et al, 1989a), retinal disturbances (Marcus et 
al, 1984), growth  retardation (De Virgiliis et al, 1988; Piga et al, 1988a) and bony 
deformities (Olivieri et al, 1992a). However, because of the inconvenience of 
administration, cost and poor compliance with DFO, and often the suboptimal results 
with the current oral options, there is a clear need for further affordable, safe and 
effective orally administered iron chelation. Orally absorbed chelators, namely DFP and 
DFX are now available (see below) but these agents can also have problems with patient 
acceptance and tolerability that can limit overall effectiveness.  
A large focus of this thesis is the development of a model that will screen novel iron 
chelating compounds intended for the management of excess iron, but it should be noted 
that iron chelators are of potential interest for the management of a variety of other 
disorders where there is, for example, free radical-mediated tissue damage.  Iron 
chelators have been tested for a potential role in rheumatoid arthritis (Magaro et al, 
1990; Yoshino et al, 1984), post-ischaemic perfusion injury (Badylak & Babbs, 1986; 
Niu et al, 2014), organ transplantation (Bradley et al, 1986; Schaefer et al, 2014), adult 
respiratory distress syndrome (Marx & van Asbeck, 1996; Ritter et al, 2006) and as anti-
cancer agents, due to their modulating effect on cell proliferation with promising results 
(Salis et al, 2014). However, chelators designed specifically for these various purposes 
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may require different physiochemical properties, biodistribution and enzyme 
interactions from compounds intended for the management of iron overload. 
1.3  Principles of iron chelation therapy 
There are two objectives of iron chelation treatment in the management of excess iron; 
primarily the production of a negative iron balance and thereby removal of excess body 
iron, and secondly the detoxification of the excess iron until the primary objective is 
accomplished. It is well established that iron is essential for normal cell function. Excess 
iron, however, is harmful to tissues and overwhelms mechanisms that usually protect 
against free radicals. Optimal iron chelation in iron overload should remove excess iron 
from where it is harmful without chelating it from where it is required for physiological 
function. In this chapter, the properties of iron chelation that are necessary for efficient 
chelation of iron, producing a negative iron balance without toxic effects will be 
considered. 
1.3.1 The achievement of negative iron balance and safe tissue iron 
concentrations 
Iron content is 40-50mg per kilogram of body weight in humans, on average. The 
majority of body iron is present as haemoglobin (30mg/kg) within circulating red blood 
cells. Muscle tissue contains a further 4mg/kg iron in muscle tissue, and 2mg/kg is 
present in cells as iron-containing enzymes. The remaining body iron is present in 
storage form as ferritin or haemosiderin mainly in the spleen, liver and bone marrow. 
In males, the average storage iron is 769mg and 323mg in females. By contrast, in iron 
overloaded conditions, over 25g can be found to accumulate as ‘storage iron.' This 
excess iron will be present in most body tissues. However, maximum quantity is found 
in the liver.  
In humans, iron metabolism is of a conservative nature, and there is no physiological 
pathway for elimination of this additional iron. Iron absorption is usually in the order 
of 1-2mg per day, and is matched by insensible losses. Approximately 11mg of dietary 
iron is required daily to keep pace with losses as iron absorption is relatively inefficient. 
Two-thirds of iron losses in humans are through the gut through exfoliation of mucosal 
cells and loss of red blood cells and one-third is from exfoliation of skin and urinary 
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tract epithelial cells. In women, to this may be added menstrual losses (mean 
0.6mg/day) and pregnancy (mean 2.7mg/day) (McLaren, 1980). The major turnover of 
body iron, amounting to some 20mg/day, is through the plasma compartment as iron is 
released from the breakdown of effete red cells in the mononuclear system, which is 
then released onto transferrin for subsequent delivery to bone marrow erythroid 
precursors which are found in bone marrow. Approximately 10% of recycled plasma 
iron turnover is taken up by hepatocytes.  
Increased gastrointestinal iron absorption over prolonged periods of time or ongoing 
blood transfusions will result in the development of iron overload. Iron absorption 
occurs predominantly in the upper gastrointestinal tract and is regulated by the intestinal 
mucosa. Under normal circumstances, iron absorption is in equivalence with insensible 
losses. The efficiency of iron absorption increases when iron stores are depleted, such 
as in anaemic states, but there appears to be no mechanism for shutting off iron 
absorption in iron overload states. Furthermore, iron absorption is increased in many 
conditions associated with ineffective erythropoiesis even in the presence of iron 
overload (Cavill et al, 1975).  In hereditary haemochromatosis, excess iron absorption 
occurs with normal iron content diets and without evidence of ineffective 
erythropoiesis.  
The distribution of excess iron from hereditary haemochromatosis differs from that seen 
in the early stages of transfusional iron overload. In the former, the excess 
gastrointestinal absorption results in an early accumulation of hepatocellular iron, 
whereas early transfusional siderosis begins with the excess accumulation of iron in 
mononuclear cells. However, in the majority of chronically transfusionally iron 
overloaded patients, hepatocellular iron predominates in terms of tissue iron 
concentration. The most significant clinical consequence of chronic iron deposition in 
the liver is cirrhosis, usually developing in the fourth and fifth decades of life in 
hereditary haemochromatosis. In transfusional iron overload, significant siderosis in 
myocardial tissues is usually seen after approximately 100 units of blood have been 
transfused. Myocardial damage leading to cardiac failure is a frequent cause of death in 
thalassaemia major patients in their second and third decades unless chelation therapy 
is given (Brittenham et al, 1994; Wolfe et al, 1985). The lethal concentration of 
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myocardial iron is significantly less than that of hepatocellular iron. For example, liver 
iron concentrations of 40mg/g dry weight are unlikely to cause acute liver 
decompensation in the short term but myocardial iron nearly ten times less than this are 
associated with cardiomyopathy and heart failure (Carpenter et al, 2011).  
 
Excess iron is deposited in all body tissues except for the brain, striated muscle, and the 
nervous tissue. It is unevenly distributed and has a preference for liver, endocrine 
system and myocardium. In addition to heart failure and cirrhosis, this may lead to 
multiple endocrine failures such as diabetes mellitus, hypogonadotropic hypogonadism, 
hypoparathyroidism, and hypothyroidism (Gabutti & Piga, 1996; Zurlo et al, 1989). 
Venesection is an option for patients who absorb excess iron but possess a good reserve 
of endogenous erythropoiesis, such as patients with hereditary haemochromatosis. 
However, patients with sideroblastic anaemia, often have an adequate erythropoietic 
reserve and thus do not require blood transfusion, but this is not sufficient to allow for 
venesection, and therefore also require management with iron chelation to prevent iron 
overload.  
In transfusion dependent anaemias, it has been estimated that an iron chelator must 
induce between 0.25-0.4mg/kg of iron excretion daily to prevent the accumulation of 
iron (Gordeuk et al, 1987).  A slightly higher excretion of iron will potentially be 
required in unsplenectomised thalassaemia patients. The transfusion requirements in 
unsplenectomised patients may increase by even up to threefold (Modell, 1977). Further 
to this is absorption through the gut, which accounts for a further 1-4mg/day, which can 
increase several folds in ineffective erythropoiesis (Pippard & Weatherall, 1984).  Thus 
a target in excess of 0.4mg/kg/day in splenectomised patients and typically around 
0.5mg/kg/day in patients with an intact spleen may be a more realistic estimate of the 
required iron excretion to be induced by chelators. 
Measurement of iron excreted through the urine and faeces is important in the 
assessment of iron balance, and this can vary greatly at different time points in the 
transfusion cycle and furthermore, between individuals (Pippard et al, 1982).  In 
principle, the effectiveness of iron chelators may decrease as the iron load is reduced, 
necessitating dose changes (occasionally to toxic levels) to reach a negative iron 
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balance.  Ideally, a normalisation of all tissue iron should be achieved as all excess 
tissue iron concentrations can cause harm. In principle, this can be achieved by 
matching the iron input rate from transfusion with iron excretion with chelators. In 
practice, iron chelation is limited by low efficiency of chelation and by increased 
toxicity at low levels of iron overload.  If DFO was 100% efficient (i.e., 100% of the 
administered drug was excreted bound to iron), then 6mg/kg daily would be adequate. 
However, a typically used dose is 40-60mg/kg daily, which makes it only 10% efficient. 
However, DFP, which is orally active is even less efficient at 3.8% (al-Refaie et al, 
1995).  
Normal concentrations of liver iron are 1-1.8 mg/gr liver dry weight but mildly 
increased concentrations, such as those seen in heterozygotes for hereditary 
haemochromatosis (3-7mg/g liver dry weight), do not appear to affect life expectancy 
and are not associated with cardiac or liver complications. Liver iron of 7-15mg/gr liver 
dry weight is associated with increasing likelihood of liver and cardiac injury and 
concentrations above 15mg/gr dry pose a significant threat of early death secondary to 
cardiac complications (Brittenham et al, 1994). Concentrations below the target of 3-
7mg/gr liver dry weight can be achieved using currently available chelation treatment. 
1.3.2 Minimisation of iron-mediated free radical injury 
Physiologically, the potential for iron to generate toxic free radicals is abrogated by 
being bound to ligands such as transferrin. However, in situations where there is iron 
overload, these protective mechanisms become saturated and non-transferrin bound 
plasma iron (Hershko, 1978) as well as increased quantities of intracellular iron are 
potentially available to participate in free radical generating reactions. 
Iron is particularly important as it is present at sufficient concentrations in tissues and 
because of the favorable redox potential of the Fe(II)/Fe(III) couple. The iron-catalysed 
reaction between superoxide and hydrogen peroxide was first described by Haber and 
Weiss in 1934 and involves the sequential reduction and re-oxidation of Fe(III). This 
reaction generates hydroxyl radicals that can damage a variety of biomolecules by 
peroxidations including proteins, DNA and membrane lipids. 
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Any putative chelator should make iron unavailable to participate in such reactions, 
whether present as Fe(II), Fe(III) or as larger complexes. When iron is coordinated by 
a chelator, depending on the stability of this reaction and depending on the extent to 
which the free electrons in the iron atom are protected, the iron may still have the 
potential to participate in free radical producing reactions. For example, EDTA which 
only coordinates one free electron does not diminish the reactivity of iron salts in the 
Fenton reaction and indeed may catalyse such reactions (Gutteridge & Halliwell, 1989). 
Conversely, DFO which surrounds the iron more completely is a powerful inhibitor of 
lipid peroxidation (Gutteridge et al, 1979). 
Thus, while iron chelators used clinically in the treatment of excess iron should produce 
a negative iron balance, they should also ideally decrease the propensity of iron to 
participate in free radical producing reactions. Thus while it may take a considerable 
period of time to remove all the excess iron from iron loaded patients, a well-designed 
chelator should ideally decrease the damage caused by the iron before and during the 
removal of iron. 
1.3.3 Prevention of Non-Transferrin Bound Iron (NTBI) uptake 
As part of progressing iron overload, there is an increasing saturation of transferrin 
noted, and once this exceeds 75%, there is a gradual appearance of NTBI (Le Lan et al, 
2005). Unlike transferrin, the uptake of NTBI into cells is much less regulated, similar 
to its distribution (Oudit et al, 2003). Unlike transferrin-bound iron, NTBI is taken up 
rapidly by hepatocyte cells (Brissot et al, 1985) as well as myocytes (Link et al, 1989). 
In cardiomyocytes, NTBI has been noted to be taken up 200x more rapidly than 
transferrin bound iron and participate in free radical generation, lipid peroxidation and 
organelle dysfunction (Link et al, 1989). NTBI uptake appears to be restricted to tissues 
that are normally known to accumulate iron, and L-type calcium channels (Oudit et al, 
2006) and zinc transporters (Liuzzi et al, 2006) are thought to facilitate uptake.  
 
Chelators should prevent the uptake of NTBI into parenchymal cells, as the abnormal 
pattern of iron distribution secondary to iron overload is directly correlated to this 
(Oudit et al, 2003). 24-hour protection from uptake of NTBI is a desirable property and 
an important target for chelation therapy. NTBI has a rapid turnover, however, it 
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reappears rapidly in the circulation in the absence of chelators (Porter et al, 1996). 
Standard doses of DFO are not able to eliminate NTBI, and chelation can be optimised 
by giving DFP during the day and a DFO infusion during the night, or by a once-daily 
dosing of DFX, which provides 24-hour cover (Piga et al, 2006). 
1.3.4 Further objectives of iron chelation 
Adding to the principle objectives of achieving a negative iron balance and preventing 
generation of harmful free radicals, there are a number of other desirable properties for 
chelators. A chelator should not redistribute iron in the body. Furthermore, the chelator 
should not interact unduly with essential iron-containing enzymes. The compounds 
should also be reasonably inexpensive to synthesise as they are also intended for use in 
developing countries with limited economic resources. The following section will 
consider the design of iron chelators so as to maximise iron excretion while minimising 
toxicity. 
1.4 Design of chelators: properties for maximal oral efficacy 
1.4.1 Properties for high Fe3+ affinity 
Iron commonly exists in the iron(III) (ferric), and iron(II) (ferrous) oxidative states. 
Iron(III) is the predominant species under anaerobic conditions as it is known to be 
generally more stable than iron(II). For a ligand to, therefore, be an effective chelator, 
it must be able to bind iron(III) effectively. Due to it possessing high charge density, 
the iron(III) molecule binds tightly to atoms such as hyroxypyridinones and 
catecholates. How stable an iron complex will be is determined by how many iron-
coordinating groups are provided by each iron chelating ligand. Common examples of 
electron donor atoms are oxygen and nitrogen. Nitrogen has three unpaired electrons in 
its p orbital vs. two of oxygen. 
For example,  iron(II) is in its most stable form when coordinated by 6 oxygen atoms. 
There are various ways by which these 6 oxygen atoms may be supplied., such as, for 
example, when three chelating ligands each provide two oxygen atoms (bidentate 
chelators), or two chelator molecules providing three oxygen atoms (tridentate 
chelators), or one ligand provides all six of these oxygen atoms (hexadentate chelation). 
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When a chelating molecule is hexadentate, it has a stability advantage compared to its 
bidentate counterparts (Streater et al, 1990). There is greater kinetic stability, thus 
making the complex much more stable at lower concentrations. The binding power of 
a hexadentate chelator is higher at low chelator concentrations (<20μΜ) than equivalent 
bidentate ligands and is, therefore, a more effective iron scavenger at low 
concentrations, and dissociation and redistribution of iron is much less likely within the 
body. Figure 1 shows the structures and denticity of the three commercially available 
iron chelators.  
The stability constant alone does not fully reflect this concentration dependent ‘chelate 
effect.' The use of a term called the pM, defined as –log(Fe(III) under defined conditions 
(e.g., when pH=7.4, chelator(total) =10μΜ and (Fe(III))total= 1μΜ), is in many ways more 
useful (Hider et al, 1996; Motekaitis & Martell, 1991).  A compound with a high pM, 
under these conditions (i.e. a low concentration of free metal), a compound will have 
an advantage over another with a low pM, even if the stability constant for the chelator 
in question appears less favourable. This is because the concentration of free iron is 
given by this term at physiologically relevant free iron concentrations and clinically 
achievable chelator concentrations.  The importance of this concept can be illustrated 
by contrasting the pM for the bidentate acetohydroxamic acid (pM =12.5) with that of 
DFO (pM=26.3) (Motekaitis & Martell, 1991). Thus although the difference in the 
stability constant is relatively small (28.3 for acetohydroxamic acid vs. 30.99 for DFO), 
the difference in the pM value is large; a feature resulting from the higher denticity of 
DFO. 
Another disadvantage of bidentate ligands is that they can participate in the generation 
of hydroxyl radicals. When at low concentrations there is formation of complexes which 
are partially dissociated (2:1 and 1:1). Therefore, purely from a chemical point of view, 
a chelator that is hexadentate is suited better to scavenge iron than its bidentate or 
tridentate equivalent. 
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1.4.2 Uptake through the oral route 
There are two main factors that affect oral absorption of a drug, namely its lipid 
solubility, and molecular weight. The compound may be absorbed by transcellular 
diffusion through the enterocyte or by the paracellular route. Absorption by the latter 
route is usually relatively minor as only a fraction of the surface available is used, 
compared with the transcellular route which occurs through most of the surface area 
(95%) of the small intestine. There is a molecular weight cut-off for the paracellular 
route that is thought to be approximately 400 Da and that for the transcellular route 
about 500 Da (Hider et al, 1996; Travis & Menzies, 1992). For effective treatment, large 
quantities of chelator (1-2g daily) need to be absorbed, making the necessity for 
efficient absorption particularly pertinent. Ligands that are more lipid soluble are more 
efficiently absorbed than their hydrophilic counterparts (Leo et al, 2002). When a ligand 
has a neutral charge, for example, hydroxypyridinones, it is more effectively taken up 
than, for example, DFO, which is charged in its iron free state. 
Figure 1 Illustration of the three commercially available iron chelators and their denticity. (Adapted from 
Hider & Zhou, 2005). 
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1.4.3 Access to chelatable iron pools 
It is clear that if a chelator cannot gain access to the iron pool, then it is irrelevant how 
strongly it can bind iron(III) as there will be no effective mobilisation from cells. A key 
property for an oral chelator is how effectively it can cross cell membranes, allowing it 
to be absorbed from the gastrointestinal tract and reach into tissues such as hepatocytes 
and cardiomyocytes. A large number of molecules penetrate cell membranes through 
the process of simple diffusion, and therefore, neutrally charged drugs enter the 
intracellular compartment more rapidly than charged molecules. As already stated, 
neutral charge also has the advantage of more effective gastrointestinal absorption, 
compared to charged agents. Equally, such chelators enter the cytoplasm of cells more 
easily.  For example, DFO which is a charged ligand is highly unlikely to be orally 
bioavailable. On the other hand, hydroxypyridinones that do not have a charge under 
physiological conditions are readily taken up through the gut mucosa. Furthermore, for 
a compound to be orally active, the ligand should not be broken down in the acidic 
stomach conditions, and be able to resist enzymatic action. Therefore, when designing 
chelator molecules, groups containing esters, hydroxamates and amides are not suitable. 
Following chelation of iron in the intracellular compartment, the ligand-iron complex 
should cross the cell membrane in order to exit the cell. Hence, the iron complex, as 
well as the free ligand, must be water soluble and be uncharged. Out of the iron-
chelating molecules known to possess a high affinity for binding iron, the 
hydroxamates, and the hydroxypyridinones are known to possess these properties. 
Lipid solubility is a desirable quality of the unbound chelator as it enables quicker 
access through cell membranes. However the rate of intracellular compartment entry 
should be modulated as too rapid diffusion can lead to the chelator penetrating the 
blood-brain barrier, leading to potentially serious neurotoxicity.  For the free and bound 
forms of chelator to be transported through the plasma and be excreted in the urine, a 
further requirement is that it is adequately water soluble. Thus, a tricky balance is 
required between lipid solubility that will allow penetration of cell membranes, and 
hydrophilic properties in order to limit toxicity to the central nervous system (CNS). 
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An approach that can be adopted to limit toxicity and maximise iron chelation is the 
combination of a ligand that is hydrophilic extracellularly at high concentrations, with 
a lipophilic compound at smaller quantities, aiming to obtain a synergistic mode of 
action (Vlachodimitropoulou Koumoutsea et al, 2015). A key aim of this thesis is to 
elucidate this optimal balance and to closely examine synergy/additivity of action 
between commercially available iron chelators. A further strategy would be to design a 
compound with high extraction by first-pass metabolism in the liver which is 
subsequently metabolised to a hydrophilic chelator with low penetration of other tissues 
thereby limiting the toxicity. Such a combination of properties would also minimise the 
redistribution of chelated metals (May & Williams, 1979). In this proposed scheme, 
hepatocyte iron would be excreted with the unmetabolised drug in faeces whilst 
macrophage-derived iron would be excreted by the metabolised drug in the urine. 
1.4.4 Long half-life of the free chelator 
Although DFO is a widely used iron chelator. However one of its major disadvantages 
is that its plasma half-life is particularly short, which compromises its efficiency to 
around 10%.  The longer the iron free drug circulates in the plasma, the greater the 
potential to chelate extracellular iron and to remove non-transferrin bound iron (NTBI). 
Therefore, a long plasma half-life is desirable with respect to extracellular chelation. 
For intracellular chelation, the labile iron pool is finite but constantly turned over.  
Hence a sustained uptake of chelator into cells is preferable to a short-term uptake with 
wide fluctuations in intracellular chelator concentrations. The metabolism of chelators 
and chelator complexes has a critical bearing on half-life. If the iron free ligand is 
rapidly metabolised (in liver or plasma), to a moiety which cannot bind iron, then the 
effective plasma half-life is reduced.  
1.5 Properties to minimise toxicity: design of chelators 
1.5.1 Selectivity for Fe3+ 
To minimise long-term toxicity, a ligand that is highly specific for iron(III) is desired. 
For example, even though DTPA appears to be highly selective and 11-fold more stable 
in terms of its binding to iron compared to zinc, side effects related to zinc deficiency 
are well documented in humans (Pippard et al, 1986). Above are discussed the reasons 
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why hexadentate ligands have a higher selectivity for iron(III) compared to their 
bidentate counterparts. The selectivity of a chelator is directly related to how closely 
the electron orbital configuration of the iron molecule is coordinated by oxygen atoms. 
There are certain bacterial siderophores that possess a structure which is close to ideal, 
such as enterobactin, which has a good selectivity for iron(III) and a particularly high 
affinity, possesses a particularly close fit. 
1.5.2 Limited lipophilicity 
As described above, the importance of membrane lipid solubility is pivotal for the free 
ligand to access the intracellular chelatable iron pools. However, this lipophilicity 
should be limited. Molecules demonstrate toxicity in vitro as well as in vivo, often in a 
way that directly correlates to the lipophilicity of the compound. Firstly, iron-ligand 
complexes are more likely to participate in the generation of free radicals and secondly 
access to the CNS will be greater if the compounds are lipophilic. 
1.5.3 Iron-chelator complex rapid elimination 
Following binding of the ligand to iron, there is commonly a change in the charge of 
the molecule, which can affect lipid solubility. The properties of the new molecule 
should permit excretion in the bile (faecal route) or in the urine. This is primarily to 
reduce the risk of iron redistribution if the complex is unstable and because certain 
complexes may pose a toxicity risk. Iron chelated in hepatocytes can potentially be 
excreted in the bile by an active mechanism. However, other cells lack this, and there is 
a possibility of increased toxicity by the chelator complex building up intracellularly if 
it is stable and particularly hydrophilic. 
1.5.4 Minimal reabsorption or redistribution of iron 
Following iron binding of the ligand, the charge of the complex can differ depending 
on the ratio of iron: chelator interaction and the specifics of the binding site. The 
resulting charge of the iron-ligand will have a significant impact on the distribution of 
iron. For example, DFO that forms a charged iron complex tends not to be able to cross 
cell membranes, thus posing less of a risk for iron redistribution. Furthermore, the 
potential of donation of iron to transferrin by the complexed ligand is something that 
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can affect iron redistribution and should be taken into consideration. This property 
becomes of particular importance when the saturation of transferrin is not 100%. 
Another factor that needs to be taken into account is the potential of reabsorption of iron 
via the enterohepatic system. From the moment the iron-chelate is secreted into the bile, 
there should be no re-uptake through the gastrointestinal system. A number of factors 
that limit this re-absorption, namely that if the chelator complex is not of neutral charge, 
and if there is an increase in the molecular weight. Furthermore, reabsorption of iron is 
also correlated to the stability of the new molecule during its excretion process in the 
gut. 
1.5.5 Low CSF penetration 
The penetration of molecules into the central nervous system is directly correlated to 
their lipophilicity (Levin, 1980; Oldendorf, 1974).  Previously, it has been proposed that 
the neurotoxic side effects of DFO could potentially be related to it gaining access 
through the blood-brain (Blake et al, 1985) and blood-retinal (Arden et al, 1984) barrier. 
However, it should be noted that DFO has a particularly low toxicity when used to 
manage iron overload, and this may, in fact, be related to its inability to access the 
cerebrospinal fluid (CSF) because of its high molecular weight and hydrophilicity. In 
fact, hydroxypyridinones which are more lipophilic have been linked to greater CNS 
toxicity (Gyparaki et al, 1987; Porter et al, 1990). In general, compounds which are 
hexadentate have a higher molecular weight than bidentate chelators, which limits their 
general cell membrane penetration and also their access to the CSF. 
1.5.6 No acceleration of growth of micro-organisms 
Bacterial siderophores (DFO, enterobactin, etc.) are naturally occurring and therefore 
may accelerate the growth of bacteria, something which is less likely with their non-
naturally occurring counterparts. However, Ferrioxamine (FO) has been shown to 
increase the pathogenicity of Yersinia enterocolitica in mice and to enhance its growth 
in vitro (Robins-Browne & Prpic, 1983; 1985). Future iron chelators should preferably, 
therefore, be tested for their effects on known pathogenic organism before they are 
introduced into humans. 
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1.5.7 Targeting excess iron pools while sparing iron-containing enzymes 
Iron is essential for the normal function of all cells, particularly those rapidly dividing. 
An ideal chelator should be able to target tissues where iron is present in excess but is 
not in high demand. In an ideal scenario, a chelator should spare iron chelation in areas 
of high demand such as the bone marrow where iron is both an essential part of the 
enzyme ribonucleotide reductase as well as for the production of haemoglobin in 
erythroid precursors. However, in hepatocytes iron chelation would be ideal as these 
cells are the major site of excess iron deposition and may offer an excretion pathway 
for the iron chelate complex through the bile. 
1.6 Chelator Evaluation 
1.6.1 Chelator’s coordination of iron(III) and other metals 
A key determination is the affinity constant of a molecule for iron compared to other 
biologically important metals, and it is important to establish how selective for iron(III) 
a chelator actually is.  There are a number of ways for this to be determined, and these 
include studies with EDTA or spectrophotometrically (Taylor et al, 1988) or 
potentiometric titration (Kline & Orvig, 1992).  The stability constants for the tribasic 
cations Ga3+ and Al3+ as well as dibasic Cu2+, Zn2+, Ca2+, and Mg2+, should also be 
determined to ascertain the likely specificity of iron binding. Generally speaking, 
bidentate chelators will have greater specificity for tribasic cations than dibasic cations 
(Hider & Hall, 1991).  
1.6.2 The physiochemical characteristics of the chelator 
The iron binding constant and pM are important to determine as this gives an indication 
of the efficacy of the metal binding at low chelator concentrations (Motekaitis & 
Martell, 1991). It is also important to establish the pKa values of any titratable group in 
order to calculate the proportion of chelator that possesses zero net charge at 
physiological pH. This value can be determined with potentiometric as well as 
spectrophotometric methods (Taylor et al, 1988). 
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A further useful molecular property to establish is lipid solubility. This can be expressed 
as the Kpart or otherwise known as the partition coefficient of the molecule between n-
Octanol and water (pH 7.4). This allows for an indication of how quickly a chelator will 
be able to cross cell membranes and may be determined spectrophotometrically (Dobbin 
et al, 1993). A value of 1 denoted solubility approximately equal in lipid and aqueous 
phases. Knowledge of the Kpart allows for a prediction regarding a potential oral route 
of administration of the compound. 
1.6.3 Characterising the iron(III) complex 
The Kpart of the iron(III): ligand should be calculated, and it gives an estimate of the 
speed at which the complex will cross cell membranes and be excreted via the kidney. 
The ability of ligands and their complexes to remove or donate iron to transferrin or 
ferritin respectively under a variety of chelate and protein concentrations should be 
investigated. The concentrations of chelator to be tested should be similar to the ones 
that are found in vivo. 
1.6.4 Evaluation of chelators in cells 
Once it is established that a molecule has desirable properties in terms of its affinity for 
iron and its specificity, biological pathways are required to screen often a wide variety 
of candidate molecules. A mechanism for screening of both activity and toxicity that is 
rapid and requires only small quantities of chelators in which several compounds can 
be compared simultaneously is desirable.  The above advantages are all present when 
using cell cultures as compared to in vivo models where a large number of animals are 
required for testing often of one compound. Commencing screening with a cellular 
model will allow assessing numerous chelators for efficiency and toxicity, and 
determining molecules should progress to testing in animals. Previously used models 
have included cells in culture, primary cell lines and cells in suspension, and indeed 
over the last few years the principals of the basic cellular models have not changed 
markedly, but they have developed. 
Red cells are easily accessible and are a simple system to study radiolabelled chelator 
complexes and their movement across cell membranes, as a predictor of their behaviour 
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in vivo (Hider et al, 2002). Commercially available cell lines these days are commonly 
used, and they can be easily purchased. This avoids the difficulties involved in isolating 
primary cell suspensions. They have been used to evaluate specific actions of chelators, 
particularly when large numbers of cells are required. For example, K562 ( a human 
erythroleukaemia cell line) cellular models have been used to test the interaction of 
chelators with the different iron pools (Hoyes & Porter, 1993), their effect on cell 
proliferation (Blatt & Stitely, 1987), DNA synthesis and cell cycle (Hoyes et al, 1992; 
Nocka & Pelus, 1988) and the inhibition of iron-containing enzymes such as 
ribonucleotide reductase (Cooper et al, 1996). The Caco cell line has been used to study 
successfully the properties of chelators which determine iron absorption from the gut 
(Hamilton et al, 1994). HuH7 cells have been used to investigate synergy vs. additivity 
of action of commercially available iron chelators (Vlachodimitropoulou Koumoutsea 
et al, 2015).  
Several primary cell systems have proved useful in testing compounds for the 
management of iron overload, such as hepatocytes and cardiomyocytes. Primary 
hepatocytes enable the examination of the effect of various chelators on liver 
parenchymal cells. The hepatocyte is key to the treatment of excess iron as 80% of iron 
accumulation occurs in the liver. It is also a key cell of drug metabolism. The majority 
of data concerning DFP and iron chelation has been generated in hepatocyte cellular 
models (Laub et al, 1985; Rama et al, 1981). More recently, combinations of 
commercially available iron chelators were studied in hepatocytes to distinguish 
between synergy and additivity of action with regards to iron mobilisation 
(Vlachodimitropoulou Koumoutsea et al, 2015). Kidney cells (MDCK) have been used 
to investigate the effect of naturally occurring flavonoid compounds on iron uptake 
(Vlachodimitropoulou et al, 2011). 
 Primary cardiomyocytes can be utilised to represent the effects of chelators on the 
clinically significant effects of iron overload on the heart. The effect of a series of 
hydroxypiridinones on iron mobilisation from myocytes has been studied (Hershko et 
al, 1991). Models involving macrophages have also been used to examine iron 
mobilisation by DFO (Kleber et al, 1981); in this work there was no iron shuttling to 
transferrin detected over a period of 9 hours, making the relevance of transferrin to iron 
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chelated from the spleen, liver and bone marrow seem doubtful. A similar model has 
been used to investigate the binding of iron released from macrophages onto transferrin 
(Saito et al, 1986), which suggests that binding of iron(III) to transferrin does not require 
active uptake or binding of transferrin to macrophages. Thus, chelators will bind iron 
released from macrophages independently of their ability to enter cells. Such a model 
is, therefore, unlikely to uncover any major differences between chelators with respect 
to their access to intracellular iron pools. Primary thymocytes have been used to 
compare the effects of chelators on apoptosis of these cells (Maclean et al, 2001). This 
model appears to correlate with the relative effects of iron chelators on thymic atrophy 
in vivo. An overview of the use of cells that lead to establishing the basic principles of 
action of iron chelators is given in Table 2 .  
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Table 2 Overview of cellular systems used to study the efficacy and toxicity of 
chelators 
SYSTEM PURPOSE OBSERVATIONS REF 
Myocardial 
cells 
Iron mobilisation 
 
Cell toxicity 
Hydroxypyridinones are more effective 
than DFO 
Chelators reduce lipid peroxidation 
(a) 
 
Hepatocyte 
cultures 
Iron mobilisation 
 
Cell toxicity 
 
Chelator combination 
Comparison of hydroxypyridinones, DFO 
derivatives 
Relates to lipid solubility 
 
Synergistic mode of action of 
commercially available iron chelation 
(b, c) 
 
(d) 
 
(e) 
MDCK cells Iron mobilisation by 
flavonoids 
Quercetin can shuttle iron out of cells via 
the GLUT1 transporter 
(f) 
Caco cells Chelator GI absorption Model of chelator absorption (g) 
K562 cells Cell proliferation 
 
Cell cycle 
DNA synthesis 
Subcellular 
distribution 
Ribonucleotide 
reductase 
Independent of lipid solubility with 
prolonged exposure 
Late G1/S arrest 
Parallels anti-proliferative effects 
More rapid uptake and iron release by 
hydroxypyridinones than DFO 
 
Hydroxypyridinones faster than DFO 
(h) 
 
 
 
(i) 
 
(j) 
Bone 
marrow 
Proliferation Relative in vitro effects do not parallel 
in vivo effects 
(k) 
Thymocytes Apoptosis DFO, DFP, and hydroxypyridinones 
induce apoptosis in thymocytes by 
chelating zinc and iron. 
(l) 
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Cited References: (a) (Hershko et al, 1991); (b) (Baker et al, 1985); (c) (Laub et al, 
1985); (d) (Dobbin et al, 1993); (e) (Vlachodimitropoulou Koumoutsea et al, 2015); (f) 
(Vlachodimitropoulou et al, 2011); (g) (Hamilton et al, 1994); (h) (Hoyes et al, 1992); 
(i) (Hoyes & Porter, 1993); (j) (Cooper et al, 1996);( k) (Cunningham et al, 1994);  (l) 
(Maclean et al, 2001)  
1.6.5 Evaluation in animal models 
The numerous advantages of using cells to evaluate iron chelators have been discussed 
above. However, there are several limitations of using cellular systems. Firstly, 
compound metabolism in plasma may be significant, and this will not necessarily occur 
in vitro. Secondly, the drug pharmacokinetics cannot be studied using the in vitro 
model.  Thirdly, such as for example in the case of DTPA, there are certain chelators 
that only act extracellularly yet in vivo can produce a significant amount of iron 
excretion via the urine. However, once a target organ has been identified (for example 
the bone marrow), it may subsequently be useful to study the mechanism of toxicity in 
vitro. 
Animals can be used to evaluate long or short term effects of the compounds in question. 
Short term models, in addition to comparing the efficacy and acute toxicity of novel 
compounds, can identify the main iron pools on which chelators act. Longer term 
administration is essential to uncover potential toxicity and to relate this to the effects 
on tissue non-haem iron. 
The lack of a universal animal model in assessing the relative efficacy of new chelators 
is an issue to date. Animal testing should be reasonably reproducible and allow for the 
testing of several compounds at the same time. These models generally measure urinary 
and faecal iron excretion, often using radioactive iron to label defined iron pools. In the 
first instance, the study should be able to establish if compounds are excreted in the 
urine or faeces and whether they are orally active. Subsequent aims are determination 
of tissues of action of the molecules and whether there is the danger of iron reabsorption 
and redistribution. 
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Ideally, once a test substance has been shown to significantly mobilise iron in one 
species, its effects should be confirmed in a further animal model. This is to allow for 
differences between animals such as rats and humans in the basal iron turnover and 
elimination, and in the amount of iron either excreted in faeces or urine (Finch et al, 
1978). The choice of species for longer-term evaluation of compounds is also critical 
with respect to metabolism of the drug in question. For example, with 
hydroxypyridinones, there is marked interspecies variability in toxicity which also 
parallels interspecies efficacy and correlates with the variability of inactivation of the 
drug by glucuronidation at the iron binding site (Porter et al, 1993).  With DFO, drug 
metabolism in the hamster is closer to than seen in humans than the rat and therefore is 
a more relevant model for pharmacokinetic studies as well as efficacy evaluation 
(Steward et al, 1996).  
If a compound proves comparable to current treatment progression to subacute 
evaluation will be required. Such studies identify potential target organs for toxicity and 
satisfy requirements for clinical administration of the drug. Subacute toxicity and 
efficacy evaluation needs to include a cohort of iron loaded animals in order to 
determine whether any toxicity observed is dependent on the degree of iron loading 
(Porter et al, 1993; Porter et al, 1991; Wong et al, 1997). A summary of methods which 
have been used in animal studies to investigate efficacy and toxicology of iron chelators 
will be discussed next.  
Methods of iron loading 
Initially, screening models used iron loaded animals by hypertransfusion (Grady et al, 
1976; Gralla & Burgess, 1982; Graziano et al, 1974; Hershko, 1978) or chemical iron 
loading (Awai et al, 1979; Gyparaki et al, 1987; Longueville & Crichton, 1986). The 
distribution in these models ideally should mirror human iron overload. Table 3 shows 
examples of methods used to iron-load animals. Iron loading is most physiologically 
achieved with hypertransfusion, however, in the past, there has been concern regarding 
inconsistent results with test substances in different models. Some of these can be 
attributed to the differences in re-equilibration times after hypertransfusion (Pitt et al, 
1979).  Furthermore, iron overloading using blood transfusions requires time and 
technical expertise. Because of this, some groups have used iron dextran (Bergeron et 
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al, 1992; Gyparaki et al, 1987) as a loading medium. Iron dextran is initially loaded in 
the reticuloendothelial system (RES), however, it then redistributes into cellular tissues 
after redistribution has occurred. Models using ferrocene for iron loading in rats have 
also been described (Longueville & Crichton, 1986) and are of value for assessing liver 
iron mobilisation in particular. Yet another way of loading animals with iron is using 
carbonyl iron by the oral route (Nielsen et al, 1993; Wong et al, 1997) but this takes 
longer and is less efficient than TMH-ferrocene (Nielsen et al, 1993).  
Animals with genetic mutations used to investigate iron transport 
Mouse mutants have been used for over 40 years in the investigation of iron transport. 
One of the first mutant mice was the ‘hpx mouse’ in 1978 which when homozygous 
dies secondary to severe deficiency of serum transferrin. This mouse consolidated 
knowledge regarding the essential role of transferrin and provided insight into 
atransferrinaemia (Bernstein, 1987). The ‘mk mouse’ was discovered in 1960, which 
has severe impairment in iron absorption from the gut as well as a defective iron uptake 
mechanism in erythroid precursors. Bone marrow transplant in this species showed that 
in this model the erythroid iron-uptake defect is independent of intestinal iron 
absorption (Edwards & Hoke, 1972). A number of haemochromatosis mouse models 
have been developed to investigate iron overload, mainly involving knockout of the 
HFE gene (Bahram et al, 1999; Levy et al, 1999; Zhou et al, 1998). More recently, the 
benefits of DFX were demonstrated in a mouse model of juvenile haemochromatosis 
which has iron deposition in the heart, liver, and pancreas, with a mutation in the 
haemojuvelin/(HFE2) gene (Nick et al, 2009). Organ damage and response to iron 
chelation has also been investigated in a number of thalassaemic mouse models 
(Sanyear et al, 2013; Schmidt et al, 2015; Yatmark et al, 2015), with the more recently 
developed humanised model of β-thalassaemia, which is blood transfusion dependent 
in its heterozygous form, providing a very promising model for future research (Huo et 
al, 2010).  
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Choice of further species 
Following an initial investigation in rodent models such as those described above, some 
investigators have used primate models to evaluate iron chelators prior to clinical trials 
(Bergeron et al, 1993; Bergeron et al, 1992; Bergeron et al, 1996). This is clearly very 
expensive and arguably has limitations shared with other animal models.  Firstly, the 
iron metabolism in primates is significantly less conservative (0.15% in monkeys vs. 
0.03% in humans) (Finch et al, 1978).  Secondly, the metabolism of chelators has been 
shown to have an important bearing on both the efficacy and toxicology of chelators 
but varies between species (Porter et al, 1993). Thus there is no certainty that the 
chelator metabolism in monkeys will be the same in humans. Therefore, the use of 
primates may add little to the rodent models. 
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Table 3 Methods used to iron-load animals. 
Loading Material Species Methods and effects Ref. 
Hypertransfusion Rats 2  i.v. injections of 20ml packed RBC/kg 
Days -4 & -1 
(a) 
Iron dextran 1) Mice and rats Total 180mg (9 doses over 2 weeks). Iron 
in cardiac interstitium and to a lesser 
extent in myocytes 
 
Weekly i.p. iron dextran 100mg/kg x4. 
Wait 4 weeks before animal cull. 
 
 
(b) 
 
(c)                                                                                               
 2) Gerbil 1gr/kg loading dose, followed by 
500mg/kg weekly for 6 weeks. Stable 
liver and heart haemosiderosis. Liver 
scarring 1-3 months after loading.  
 
200mg/kg for 10 weeks. Cardiomyocyte 
iron loading noted 
(d) 
 
 
(e)                                 
 3) Monkeys i.v. infusion 200-300mg/kg x3 over 10 
days. 
(f) 
TMH - Ferrocene Rats 1gr/kg of ferrocene to diet/day for 2-4 
weeks. Stable hepatocellular loading 
after ferrocene stopped. 
(g) 
Carbonyl Iron Rats 2% carbonyl iron. Hepatocellular 
carcinoma may complicate dietary 
hepatic iron overload in the absence of 
fibrosis/cirrhosis 
(h) 
(a) (Hershko, 1978), (b) (Yatmark et al, 2014), (c) (Porter et al, 1993), (d) (Otto-Duessel 
et al, 2008), (e) (WOOD et al, 2011), (f) (Bergeron et al, 1992), (g) (Florence et al, 
1992), (h) (Asare et al, 2006)  
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1.7 Commercially available iron chelators  
1.7.1 Desferrioxamine (DFO) 
DFO belongs to the hydroxamate group and possesses a high affinity and selectivity for 
iron(III). It forms complexes with iron(III) without a change in net charge on binding, 
which is ideal for clinical iron chelation. DFO is highly selective for iron(III) with a 
stability constant for the latter of 1030 (Motekaitis & Martell, 1991) compared to that of 
the next most avidly bound metal, namely aluminium with a stability constant 1025 
followed by copper with 1014 and zinc at 1011. DFO is also a hexadentate ligand so it 
will tend to scavenge iron efficiently at low concentrations of chelator (as evidenced by 
its high pM) (Table 4). The iron-chelate complex ferrioxamine (FO) will be relatively 
stable compared with bidentate ligands, limiting the potential for the redistribution of 
iron. The fact that DFO has a low lipophilicity when it is complexed with iron is also of 
importance (Porter et al, 1988), as this form does not penetrate cell membranes easily 
and therefore is less likely to re-distribute iron around the body. Thus, uptake of DFO 
is slow in cells, and this has been demonstrated in cells such as the K562 cell line in 
vitro, where concentrations approaching those outside cells are not seen for 
approximately 4hours (Hoyes & Porter, 1993) (Cooper et al, 1996). Hepatocytes, 
however, appear to have a facilitated uptake mechanism for DFO.  The FO also has a 
positive charge that tends to retard the egress of the iron complex from cells such as 
cardiomyocytes (Porter et al, 2005).  In hepatocytes, however, an active excretion 
mechanism exists for excretion in bile. Furthermore, metabolism of DFO to metabolite 
B, which has a negative charge, allows egress of this metabolite from hepatocytes 
(Porter et al, 2005).   DFO enters most cells more slowly than DFP because of its low 
lipid solubility, its high molecular weight and its charge (Porter et al, 2005).  
 
Hydroxamates have several drawbacks. They are not very resistant to gastro-intestinal 
breakdown when taken up by the oral route (Keberle, 1964; Summers et al, 1988), 
limiting their oral activity. In addition, as mentioned previously, the high molecular 
weight of DFO and its positive charge, further contribute against oral bioavailability. 
Other disadvantages of DFO are that it has a very short plasma half-life (5-10 minutes) 
(Lee et al, 1993; Summers et al, 1988) and that it promotes the growth of Yersinia 
enterocolitica in vivo (Robins-Browne & Prpic, 1983; 1985). The fact that it is rapidly 
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metabolised and excreted is clearly a disadvantage, as DFO must be administered by 
continuous s.c. or i.v. infusion. However, the long-term efficacy of DFO is well 
established (Brittenham et al, 1994; Zurlo et al, 1989). It has been shown that it prolongs 
life expectancy (Brittenham et al, 1994) and despite being administered daily over many 
years, if the doses are kept below 50mg/kg, DFO is remarkably well tolerated with 
limited side-effects. 
The large majority of toxicity noted by DFO is related to the dose; thus skeletal growth 
effects and audiometric and retinopathic toxicity are more likely at higher doses.  
Clinical presentations of ocular toxicity include night or colour vision disturbances or 
decreased visual acuity, particularly with continuous 24h infusions. These 
complications occurred not infrequently in the early phase studies which used DFO 
doses of 100 mg/kg/day, but rarely occur today as significantly lower doses are typically 
used in clinical practice (Davies et al, 1983). Drug-related ototoxicity is typically 
symmetrical, high-frequency sensorineural (Porter et al, 1989b).  Certain complications, 
such as neurotoxic effects, occur when iron levels are low, and DFO continues to be 
administered, and even coma has been described. Audiometric and retinopathic 
complications can also be seen with low ferritin levels (Porter et al, 1989b) (less than 
1000 mg/L) (Olivieri et al, 1986). If the use of DFO leads to toxic effects, treatment 
should be withheld temporarily and restarted when symptoms or signs have improved.  
In children: doses greater than 40 mg/kg have been linked to an increased risk of 
impaired growth and skeletal changes. Retardation of growth was noted when DFO was 
started  earlier than 3 years of age or at higher doses (De Virgillis et al, 1988; Piga et al, 
1988b).  A short trunk may arise because of metaphyseal changes in the spine, and a 
rickets-like picture and genu valgum may also occur (Olivieri et al, 1992b).  Other 
reactions such as skin irritation, allergies, and Yersinia enterocolitica infections, are less 
clearly dose-related.  
1.7.2 Deferiprone (DFP) 
DFP belongs to the hydroxypyridinone group, which was initially designed by Hider 
and colleagues (Hider et al, 1996) , and is a bidentate iron chelator (3:1). Due to its low 
molecular weight and uncharged nature under physiological conditions both as the free 
ligand and when complexed with iron, it has the desirable properties of rapid oral 
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absorption and subsequent biodistribution. DFP is less hydrophilic than DFO with about 
one-third of the molecular weight (Table 4) but is still not truly lipophilic, being about 5 
times more soluble in water than lipid (Porter et al, 1990). The simple stability constant 
for iron(III) is about six times higher than for DFO. However more clinically relevant 
is the pM, which is 20 and lower than that of DFO at 26.6 (Hider et al, 1996). Thus 
while iron(III) binding is efficient at high concentrations of DFP, at lower chelator 
concentrations such as 10µM and at clinically relevant iron concentrations of 1µM, 
DFO will bind iron more effectively than DFP. The lower pM also increases the 
potential to redistribute iron within the body (Pippard et al, 1989) with the potential 
formation of incomplete 1:1 and 1: 2 iron-chelate complexes which theoretically could 
participate in the generation of hydroxyl radicals (Dobbin et al, 1993). There is a 
potential advantage to the low pM, however, because as chelatable iron concentration 
fall in tissues, the risk of over-chelation, such as occurs with DFO, may be less. 
DFP was selected for studies in humans, firstly in 3 patients with myelodysplasia 
(Kontoghiorghes et al, 1987) and then in thalassaemia major patients (al-Refaie et al, 
1992; Kontoghiorghes et al, 1990a). Early short-term evaluation in previously poorly 
chelated patients showed that DFP can increase urinary iron excretion at levels 
sufficient in some cases to induce a reduction in serum ferritin and a negative iron 
balance at doses between 75 to 100mg/kg/day (Kontoghiorghes et al, 1987). In a further 
study involving previously poorly chelated patients, a dose of 75mg/kg/day resulted in 
iron excretion which correlated with reduction of serum ferritin as well as with DFO 
induced urinary iron excretion (Olivieri et al, 1990). Furthermore, DFP has proved 
superior to DFO in thalassaemia major patients in preventing cardiac events (Borgna-
Pignatti et al, 2006) and reducing cardiac iron loading assessed by MRI T2*(Pennell et 
al, 2006) and has thus has established its role in iron chelation therapy.  
In assessment of the value of DFP for clinical use, the reported efficacy has to be 
weighed against the reported unwanted effects. Animal toxicology confirms a dose and 
time-dependent suppression of the bone marrow in several animal species both in iron 
overloaded and non- overloaded states (Porter et al, 1989a) as well as thymic atrophy 
and teratogenic effects at doses close to the therapeutic dose in humans (Berdoukas et 
al, 1993).  Bone marrow related toxicity has also been reported in clinical studies, with 
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rates of agranulocytosis in subjects taking the drugs estimated to be approximately 3-
4%, and with mild neutropaenia in a further 4% (al-Refaie et al, 1995; al-Refaie et al, 
1992). Unlike laboratory animals, this effect appears unpredictable at currently 
prescribed doses. Neutropaenia may last from 7 to 127 days (Hoffbrand, 1994; 
Hoffbrand et al, 1989); reintroduction of the drug will induce a rapid reduction in the 
neutrophils and is contraindicated. Arthropathy, affecting most commonly the knees, 
may be more seen with high levels of iron overload (Kellenberger et al, 2004) possibly 
suggesting an effect of the iron complex.  The frequency of arthropathy increases over 
time, from 6% at 1 year to 13% at 4 years (Cohen et al, 2003). This often requires 
cessation of treatment and usually resolves once treatment is withheld. Other side 
effects include nausea in 8% of subjects taking current clinical doses, fluctuation in liver 
function tests (transaminases) in 44% and mild zinc deficiency in 14%. The effect of 
dose on tolerability has not been studied systematically. All patients treated with DFP 
require weekly blood tests because of the risk of agranulocytosis. Progression of liver 
fibrosis has been reported (Olivieri et al, 1998) but not confirmed in other studies 
(Wanless et al, 2002).   
1.7.3 Exjade (DFX) 
DFX has the chemical formula 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic 
acid and its molecular weight is 373 (Table 4).  The tridentate structure results in the 
chelator binding iron(III) in a 2:1 ratio. The stability of this complex as estimated by 
the pM values is intermediate between DFO and DFP (Table 4). DFX is lipophilic but 
highly protein bound in plasma. Despite the protein binding, good tissue penetration 
with faster mobilisation of tissue iron than DFO is seen (Nick et al, 2003; 
Vlachodimitropoulou Koumoutsea et al, 2015).  Mobilisation of myocyte iron appears 
to be efficient (Glickstein et al, 2006; Hershko et al, 2001) and has been confirmed in 
studies with iron overloaded gerbils (Wood et al, 2005b).   
 
The drug has low water solubility and is given as an oral suspension once daily. More 
recently a tablet preparation has been developed by the pharmaceutical company 
Novartis, and it is clinically available in the USA but not yet in Europe. 
Pharmacokinetics by the oral route were examined in the first Phase I randomised 
double-blind study using single doses, in 24 patients with thalassaemia major who 
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received single doses of dispersible tablets (2.5 to 80 mg/kg) (Galanello et al, 2003). 
Absorption was rapid with a plasma half-life of 11 to 19 hours, supporting a once daily 
administration regimen. Metabolism occurs at several sites but predominantly by 
glucuronidation in the liver at a position not involved in iron coordination (Porter et al, 
2003). Elimination of this and other metabolites was predominantly faecal. Excretion 
of DFX and its complex in the urine is limited to less than 0.1%.  The final elimination 
of DFX, the iron complex, and metabolites appears to be by hepatobiliary anion 
transport and dose adjustment is required for patients with hepatic impairment.   
 
DFX has been approved for use in the treatment of transfusional iron overload and has 
a more favourable side-effect profile compared to DFP (Goldberg et al, 2013). At the 
initial phase III trial it  showed a significant reduction in serum ferritin but failed to 
meet its primary endpoint of reduction of liver iron, likely as a result of underdosing 
(Cappellini et al, 2006b). However, subsequent studies have proven the efficacy of DFX 
in controlling as well as reducing iron burden, at doses greater than 30mg/kg/day (Porter 
et al, 2008; Taher et al, 2009a; Taher et al, 2009b). Larger prospective studies with 
defined dosing regimens then followed. 192 patients with β thalassaemia with a T2* 
from 5 to 20 ms, left ventricular ejection fraction (LVEF) of 56% or more, serum ferritin 
more than 2500µg/L, liver iron more than 10 mg Fe/gr dry weight (Pennell et al, 2010) 
patients were followed up for up to 3 years. A significant improvement in myocardial 
T2* from 14.6 to 17.4 ms was seen at 1 year at a mean dose of 33 mg/kg/day (Pennell 
et al, 2010).  In patients with baseline T2* values less than 10 ms initially, the T2* also 
significantly improved from 7.4 to 8.2 ms over  the period of a year.   The response rate 
for improvement of myocardial T2* at 1 year was 70% in this study.  In this study, 71 
subjects continued taking DFX into the 3rd year.  68.1% of patients with baseline T2* 
10 to <20 ms normalised myocardial T2* and 50.0% of patients with baseline T2* >5 
to <10 ms improved to 10 to <20 ms. There were no deaths and no significant changes 
to the function of the left ventricular function reported (Pennell et al, 2012). 
CORDELIA is a randomized controlled trial of DFX (target dose 40mg/kg) versus 
DFO, that studied myocardial iron mobilisation in β thalassaemia major (Pennell et al, 
2014). In this study, the myocardial T2* improved with DFX from 11.2ms at baseline 
to 12.6ms at 1 year (Pennell et al, 2014). At 2 years (Pennell et al, 2015) sustained 
improvement was seen with myocardial T2* increasing from 11.6 to 15.9 ms with 
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improvement across all subgroups, and with LVEF remaining stable.  These studies 
have included only patients with normal LVEFs, and no significant changes have been 
seen (Pennell et al, 2011). 
More than 3000 patients have been studied in prospective trials of DFX, where the 
frequency of unwanted effects have been reported. Most studies lasted 1 year, but 
several have been extended up to 5 years. Discontinuation rates are generally lower than 
those seen with long-term DFP administration.  The most common adverse effects are 
generally mild to moderate gastrointestinal events, such as abdominal pain, nausea and 
vomiting, diarrhoea, and constipation, occurring in approximately 15% of patients with 
thalassaemia (Cappellini et al, 2006a), and somewhat higher numbers of older patients 
with myelodysplasia.   Skin rashes occur early in approximately 10% of patients 
(Cappellini et al, 2006a).  One-third of patients had a mild dose-dependent increase in 
serum creatinine, occurring within a few weeks of starting or increasing therapy. These 
increases were usually not progressive and reversed or stabilised when doses were 
adjusted. Occasional cases of renal failure have been reported. It is important to monitor 
serum creatinine and to decrease or interrupt the dose if creatinine increments exceed 
30% or if the creatinine increases above the normal range. Failure to do this can result 
in renal injury, and regular monitoring of urinary protein is therefore recommended. 
Liver enzyme changes, judged to be related to DFX, occurred in less than 1% of 
patients. Improvement or stabilisation in liver pathology in patients with β thalassaemia 
receiving DFX for at least 3 years has been noted (Deugnier et al, 2011) Audiometric 
effects and lens opacities did not differ significantly from the control arm treated with 
DFO, (Cappellini et al, 2006a) and no clearly related drug-related agranulocytosis has 
been observed in clinical trials. In paediatric patients, growth and development 
proceeded normally (Aydinok et al, 2012b). Data from the five phase II/III studies show 
no inhibitory effects on growth (Cappellini et al, 2011).  
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Table 4 Properties, pharmacokinetics, and metabolism of commercially available iron chelators. 
Compound 
Desferrioxamine (DFO) Deferasirox (DFX) Deferiprone 
(DFP) 
Molecular weight 561 373 139 
Chelator : Iron  binding ratio 1:1 2:1 3:1 
Stability constant (log βn) 33 26.5 37.1 
pM 26.6 22.5 20.5 
Charge of free complex 1+ 1- 0 
Charge of iron complex 1+ 3- 0 
Lipid solubility of free ligand (LogKpart) -2.0 +6.3 -0.8 
Lipid solubility of iron complex (logKpart) -1.5 Not known -1.1 
Route of absorption S.C., I.V. , I.M. Oral Oral 
Route of iron excretion Urinary and faecal Faecal Urinary 
Max plasma levels (µM)  
Of iron free drug 
7-10 (Porter et al, 2005) 
 
80 (Galanello et al, 
2003) 
90-450 
(Kontoghiorghes 
et al, 1990b) 
Concentration of iron complex complex remains similar 
(about 7µM) with 
ascending doses but the 
iron-free drug and 
metabolites increase 
(Porter et al, 2005) 
 
Complex accounts 
for about 10% of 
plasma drug 
(Waldmeier et al, 
1993) 
Complex 
correlates with 
urine iron 
excretion and 
predicts response 
to therapy 
(Aydinok et al, 
2012a) 
Elimination of iron complex Urine + faeces 
Iron complex removed 
more slowly than free 
drug. 
Faeces 
 
Urine 
Metabolism Intrahepatic to 
metabolite B (Porter et 
al, 1998). 
>90% eliminated in 
faeces, 60% 
unmetabolised. 
Metabolism mainly 
in the liver to 
glucuronides. 
Oxidative 
metabolism by 
cytochrome P450 
accounts for < 
10%. (Waldmeier 
et al, 1993) 
Glucuronide 
formed in liver 
does not bind iron 
(Kontoghiorghes 
et al, 1990b) 
 
Dose mg/kg/day 30-60 
5-7 x/week 
20-40 
once daily 
75-100 
in 3 divided doses 
Chelation efficiency(%) 
(% of drug excreted iron bound)  
13 27 7 
Main Adverse effects  
 
Ocular, auditory, bone 
growth retardation 
local reactions, allergy 
Gastrointestinal 
increased 
creatinine, 
Hepatitis 
Gastrointestinal, 
arthralgia, 
agranulocytosis/n
eutropenia 
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1.8 Other chelators that have reached clinical trials 
I. Rhodotorulic Acid (RA) 
RA is a hydroxamate that occurs naturally and is produced by Rhodotorula pilimanae, 
similarly to DFO (Grady et al, 1979) (Figure 2). However, unlike DFO it is not a 
hexadentate ligand (binds in Fe2RA3 ratio), and it also has a lower water solubility. RH 
proved more effective than DFO in hyper transfused rats (Grady et al, 1979), and this 
was attributed to its higher renal excretion. Initial both long and short term toxicity 
studies including histological examination in rats, mice, and monkeys as well as 
pharmacokinetic studies in rats, monkeys, and dogs seemed encouraging. However, RA 
was eliminated from further development, as in addition to being orally inactive, clinical 
trials were associated with unacceptable inflammation at the sites of 
intramuscular/subcutaneous injections (Grady et al, 1979). 
 
Figure 2 Rhodotorulic Acid (RA) structure (Grady et al, 1979) 
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II. Desferrithiocin, Deferitrin, and Deferitazole 
 
Desferrithiocin is a naturally occurring siderophore that was isolated from Streptomyces 
antibiotics in 1865 (Bergeron et al, 1991) and is tridentate, forming 2:1 complexes with 
Fe(III) (Figure 3). It has a high binding constant (Logβ2=29.6) and a good selectivity 
form iron, similar to that of DFO but it also retains an appreciable affinity for other 
metals such as aluminium (Logβ2=22.6) and zinc (Logβ2=15.3). Desferrithiocin is three 
times more effective when administered orally than DFO given parenterally to rats 
(Longueville & Crichton, 1986).  However, it has been reported to cause CNS related 
deaths in mice, progressive weight loss, renal toxicity and neurological complications 
in animals. Further in vitro and in vivo studies suggested that the toxicity was more 
likely related to the iron complex ferrithiocin than the desferrithiocin itself (Baker et al, 
1992). 
Whilst desferrithiocin was excluded from further development, largely because of the 
renal toxicity, it was found that relatively minor modifications to the structure 
profoundly alter the activity/toxicity profile of the drug. Deferitirin which has a phenol 
ring substitution instead of the pyridyl ring (Figure 3), showed promising iron 
mobilisation in phase I clinical trials but presented unacceptable for further use in 
patients due to renal toxicity at higher doses (Barton, 2007). In order to overcome 
nephrotoxicity, a number of derivatives were created, of which Deferitazole or 
otherwise known as FBS0901or SSP-004184 or SPD602 was the most promising 
(Figure 3). A number of clinical trials involving Deferitazole were conducted around 
the world; however results appeared inconclusive resulting in treatment being stopped 
in 2014.  
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Figure 3 Structures of the iron chelators Desferrithiocin, Deferitrin, Deferitazole 
 
 
 
 
 
1.9 Conclusions 
In this chapter, the need for further safe and effective orally active iron chelators has 
been described. Furthermore, the properties of iron chelators that are needed for such a 
goal and the methods for assessing such compounds pre-clinically have been examined. 
By investigating the relationship between structure, efficacy, and toxicity of related 
compounds those with a wider therapeutic safety margin may in principle be identified. 
The primary objective of the work in this thesis has been to develop a cellular system 
for screening a large number of compounds (often available in small quantities) which 
is predictive of how such compounds will behave in vivo. In the ensuing chapters the 
development of such a model is described (Chapter 3) and its predictive value is then 
tested in our newly developed iron overloaded humanised thalassaemia mouse model 
(Chapter 7). 
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Chapter 2 MATERIALS AND METHODS 
2.1 Iron chelators and substances tested for iron chelation activity 
I. DFO, DFP, Quercetin, Isorhamnetin, Quercetin 3-β-D- glucoside  (Sigma-
Aldrich, USA) 
II. Eltrombopag (Generon, UK) 
III. Quercetin-3-D-glucuronide, (HWI Pharma Solutions, Germany) 
IV. Kaempferol (Calbiochem, Canada) 
V. DFX, CP20, and CP40 were supplied in powder form by R.C.Hider from King’s 
College London University. 
2.2 Cell Lines 
a) HuH7 hepatocyte cell line 
Tissue: Human hepatocellular carcinoma 
Organism: Homo sapiens 
Purchased: Sigma-Aldrich England, UK 
 
b)  H9C2 cardiomyocyte cell line 
Tissue: Heart/Myocardium 
Organism: Rattus norvegicus, rat 
Purchased: ATCC England, UK 
 
2.3 Cellular Methods 
2.3.1 Maintenance of hepatocyte HuH7 and cardiomyocyte H9C2 cells 
Cell culture 
HuH7 cells and H9C2 cells were grown in tissue culture flasks in RPMI 1640 containing 
L-glutamine and DMEM media respectively. The media contained 10% (vol./vol.) FBS 
and cells were maintained at 37°C in a humidified atmosphere (5% CO2). RPMI was 
supplemented with 0.02% penicillin/0.5% gentamicin while penicillin/streptomycin 
was added to DMEM. Cells were cultured at densities between 2-7 x 105 to maintain 
exponential growth. Cells were quantitated using a Neubauer counting chamber as well 
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as an automated cell counter calibrated for our cell lines as per manufacturer’s 
instructions. 
Freezing 
Cells were frozen periodically in media containing 10% FBS and 10% DMSO. They 
were plunged into liquid nitrogen (-180°C). 
Thawing 
Cells maintained in liquid nitrogen were thawed at 37°C in a water bath. Cold media 
was added to a final volume of 20ml. Subsequently, the cells were then washed twice 
with media before being suspended in culture medium and placed in a 37°C incubator. 
2.3.2 Plating procedure 
Cells were suspended in media to a final concentration of 0.4x106/ml and 0.5ml added 
to each well in a 24 well plate. Cells were cultured at a temperature of 37°C at conditions 
of 5% CO2 – 95% air. An initial series of experiments were undertaken to ascertain the 
optimal plating number of cells/well in a 24 well plate. The optimal number of cells for 
confluence is just under 1x106/well. Below this confluence fell, and above this, the cells 
became superimposed. In such cases viability was poor, and the cells failed to adhere 
during experiments.  
The plating technique was found to be critical to achieving a high-quality monolayer. 
Volumes of medium less than 0.5ml lead to a tendency for cells to be unevenly 
distributed in the well with crowding of the cells in the circumference and in the middle 
of the well. Great care was taken while plating to gently but thoroughly mix to achieve 
an even distribution, avoiding a vortex effect.  Any deviation for even plating leads to 
sheets of cells coming away at later time points.  
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2.3.3 Cell viability 
a) Dye: Fluorescence method; Acridine Orange (AO)/Propidium Iodide (PI) 
This approach was generally preferred for viability assessment and was frequently used 
to ensure viability >98% as compound cell damage causes iron release independently 
of the chelation mechanism. AO and PI are nuclear staining dyes. PI is permeable to 
dead cells and stains red while AO crosses the membranes of live/dead cells and binds 
to nucleic acids, staining green. Microscope images were captured with the aid of UV 
light where appropriate and analysed using the software Image J (Figure 4). 
 
 
 
Figure 4 AO/PI staining following 8 hours of treatment with DFO at 30μM ibe. A. Dead cells stained 
red by PI. B. Green AO staining, with dead red stained AO cells, superimposed. 
 
 
b) Dye: Trypan blue method 
A solution of 50/50 (vol./vol.) of tryptan blue solution in PBS was added, and they were 
then incubated at room temperature for 10 minutes to allow the dye to be taken up into 
non-viable cells. The cells were then counted in a Neubauer chamber or directly 
visualized under the microscope, with the dead cells appearing blue (Figure 5). 
 
 
 
A.
 
B.
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c) Lactate Dehydrogenase Assay 
Viability was also assessed using the ‘LDH Cytotoxicity Detection Kit’ by Takara Bio 
Inc, which gives a quantitative comparison of early cell damage between ‘treatment’ 
and ‘control.' This is a colorimetric assay and measures LDH activity leaked by 
damaged cells into the supernatant. 
2.3.4 Cellular protein concentration determination 
The Coomassie (Bradford) Assay protocol was used for to determine cellular protein 
(Bradford, 1976). Briefly, 250 μL of Bradford reagent was mixed with 5 μL of cell 
lysate (duplicates) on a shaker for half a minute in a 96 well plate. The mixture was left 
to stand for 10 minutes. Absorbance was recorded at 595nm and compared to standards 
of bovine serum albumin (μg/ml), used to generate a standard curve.  
A. Triton X control   
 
B. DFO 30μΜ ibe 
 
C. DFP 30μΜ ibe
 
D. DFX 30μΜ ibe
 
Figure 5 Trypan blue staining in HuH7 cells following 8 hours of chelator treatment. 
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2.3.5 The ferrozine assay  
Following treatment, the cells were washed four times including one wash containing 
DFO at 30µM ibe and 3 PBS washes and lysed with 200μl of 200 mmol/l NaOH per 
well in a 24 well plate overnight. 5 μL were isolated for protein determination in 
duplicates.  Τhe ferrozine assay (on 190μl aliquots) was used to determine iron 
concentration (Riemer et al, 2004) with modifications. Briefly, 200μL of 10mM HCL 
and 200μL of the iron-releasing agent (1.4M HCL and 4.5% (w/v) KMnO4) were added 
and incubated for 2 hours at room temperature on a plate shaker. 120 μL of iron-
detection reagent (6.5mM ferrozine, 6.5mM neocuproine, 2.5M ammonium acetate, and 
1M ascorbic acid dissolved in iron free HPLC grade water) were then added to each 
well for 30 minutes. Absorbance was recorded in a plate reader at 562nm. Standard 
curve interpolation was used to calculate the iron content. A range of atomic absorption 
iron standards (0-300μΜ) of equal volume were prepared in a similar manner to 
unknowns (Figure 6). Intracellular iron was normalised against protein content. The 
sensitivity of the assay is noted to be as low as 1μΜ. 
Figure 6 Ferrosine assay standard curve. 
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2.4 Flowchart of final cellular iron loading model 
Initial plating of HuH7/H9C2 cells  
Wash away of non-adherent cells 
Incubate with RPMI 1640/DMEM 10% FBS for 10 hours 
Fresh supply of RPMI 1640/DMEM 10% FBS for 10 hours 
Wash 1 X PBS, 1 X PBS/DFO 30μΜ ibe (iron binding equivalence), 2 X PBS 
Add medium with test chelators for desired time period  
Wash 1 X PBS, 1 X PBS/DFO 30μΜ ibe, 2 X PBS 
Lyse cells with 200mM NaOH for 24 hours 
End point: Ferrozine/protein assay 
2.5 Ferritin quantification 
Human and rat tissue ferritin were recorded by commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (Cusabio, Wuhan, China and My BioSource, San 
Diego, USA respectively)  according to the instructions provided by the manufacturer 
for recording ferritin of cell lysates. In brief, adherent cells were rinsed once with ice-
cold PBS. The cells were scraped off the plate and stored in PBS (pH 7.2-7.4) at -20°C 
overnight. 2 freeze-thaw cycles were carried out in order to disturb cell membranes, and 
the resulting lysates were centrifuged for 5 minutes at 5000 g at 2-8°C, and the 
supernatants collected. Samples as well as standards are exposed to a conjugated 
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antibody specific to ferritin. The wells are then washed to remove unbound reagent, and 
a substrate solution is added to the wells. Colour develops in proportion to the amount 
of ferritin-bound during the initial step. The colour development is stopped, and the 
intensity of the colour is measured. Figure 7 shows the standard curves for the rat (A) 
and human (B) ferritin ELISA. 
 
 
 
 
 
 
2.6 Determination of intracellular reactive oxygen species (ROS) levels using a 
fluorimetric method 
We chose the fluorescent probe 5,6-carboxy-2’,7’- dichlorofluorescein diacetate 
(DCFH-DA) (Molecular Probes, Leiden, Netherlands) to detect intracellular ROS. The 
non-fluorescent DCFH-DA is cleaved to DCFH when in the intracellular compartment 
and yields the highly fluorescent probe DCF in the presence of hydrogen peroxide 
(H2O2) intracellularly. Therefore, the dichlorofluorescein (DCF) fluorescence signal 
directly correlates to the amount of intracellular ROS. Corning 24-well plates (Sigma-
Aldrich, MA, USA) were used, and cells were pre-incubated with 6μM H2DCF-DA for 
30 minutes at 37°C. Chelators were then added and the resulting fluorescence cells 
treated with chelators as well as control were read throughout the treatment period in 
the plate reader (excitation 504 nm, emission 526 nm). The rate of change of production 
of ROS was calculated over 60 – 90 minutes. Figure 8 demonstrated the effect of 
varying the concentration of DCF on ROS production. 
 
Figure 7 Rat (A) and human (B) ferritin standard curve. 
 
BA
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Figure 8 Effect of varying the concentration of DCF on ROS production in HuH7 cells. 
 
2.7 Preparation of heat-inactivated human serum 
Following venipuncture by an experienced phlebotomist from volunteer healthy lab 
donors, following informed consent, in a red-top vacutainer tube, coagulation was 
allowed over a period of 30 minutes. The sample was then spun at 3000 rpm for 10 
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minutes, and the serum aspirated and heated in the water bath at 56°C over a period of 
1 hour.   
2.8 Animal Study 
2.8.1 Specification and Housing 
All animal work carried out conformed with the Animals (Scientific Procedures) Act 
1986 and university guidelines. A humanised mouse model of thalassaemia 
(Heterozygous knockin γHPFHδβ0/γβA thalassaemia mice) (Huo et al, 2010) was kindly 
donated by Dr. A.David from the Institute for Women's Health,  at UCL. All mice were 
male and between 4 and 5 months of age. Animals were grouped in cages having 
previously been earmarked for ease of individual identification. The environment was 
controlled, with a temperature of 25+/-2 °C and 12 hour light/dark cycles.  Standard 
chow diet (Harlan Laboratories, Inc. Stoughton Rd, USA) and water were provided ad 
libidum. Normal chow diet contains moisture 12%, crude protein 24%, fat 4.5%, fiber 
5%, metabolic energy 3040 kcal/kg, phosphorus 0.9%, calcium 1%, sodium 0.2%, 
magnesium 0.23%,  potassium 1.17%, manganese 171 ppm, copper 22 ppm, zinc 100 
ppm, iron 180 ppm, cobalt 1.82 ppm, vitamin K 5 mg/kg, selenium 0.1%, vitamin D 
4000 IU/kg, vitamin A 20000 IU/kg,vitamin E 100 mg/kg, vitamin B1 20 mg/kg, 
vitamin B2 20 mg/kg, vitamin B6 20 mg/kg, vitamin B12 20 mg/kg, folic acid 6 mg/kg, 
niacin 100 mg/kg, biotin 0.4 mg/kg and choline chloride 1500 mg/kg. 
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2.8.2 Iron loading and chelation treatment 
Establishing the iron loaded mouse model 
Humanised Control: Humanized γβA/γβA control mice (n=7). These control mice 
received 0.1ml of IP PBS  5 days/week for 4 weeks 
Iron-loaded:  Heterozygous knockin γHPFHδβ0/γβA thalassaemia mice received 
intraperitoneal injections of iron dextran solution (10mg (0.1ml) daily 
for 4 weeks (5days/week)). A further month was allowed for re-
equilibration of iron following the iron overloading. 
Thalassaemia Control: Heterozygous knockin γHPFHδβ0/γβA thalassaemia mice. These 
mice received PBS injections with the same regime as the mice 
undergoing iron loading. 
Chelation treatment  
Iron-loaded animals were randomly assigned to the following three groups: iron 
chelation treatment with DFX 30mg/kg daily (n=7), Quercetin 300mg/kg daily (n=5), 
or combination of DFX 30mg/kg and Quercetin 300mg/kg daily (n=7). Hydroxypropyl 
cellulose 0.5% was chosen as the vehicle medium as previously described (Sumi et al, 
2013), which was received by the control group (n=7). Treatment was administered 
orally by gavage and mice were observed immediately before dosing each day and again 
at least 15 minutes after the dose, for any adverse effects. Body weights were observed 
throughout and at the end of the study.  
2.8.3 In vivo Magnetic Resonance Imaging (MRI) 
This was carried out by Laurence Jackson (Ph.D. student), under the direct supervision 
of Dr. Daniel Stuckley at the Centre for Advanced Biomedical Imaging (CABI). This 
collaboration had as a primary aim to determine if MRI can be used to assess and 
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quantify excess iron distribution in a murine model of thalassaemia by comparing this 
with a histological and biochemical assessment of tissue iron.   Imaging was performed 
using a 9.4T MR system (Agilent Technologies, Santa Clara, USA) equipped with 
1000mT/m gradient inserts and a 39mm volume resonator RF coil (RAPID Biomedical, 
Rimpar, Germany). Using MRI, T1, T2, and T2* relaxation rates were measured in the 
myocardium, liver and spleen in addition to cardiac function and spleen volume 
measurements. The animals were observed using a monitoring system (SA Instruments, 
Stony Brook, NY) which recorded the ECG trace, respiration rate, and internal 
temperature. Animals were anaesthetised under a mixture of isoflurane and oxygen with 
physiological measurements used to maintain anaesthesia.  
2.8.4 Measurement of iron overload in tissues 
Animals were anaesthetized and blood drawn from within the ventricle following 
thoracotomy. The blood collection was carried out under terminal anaesthesia, which 
was achieved by the injection of 0.8 ml of 1.25% Tribromoethanol solution (Avertin 
Sigma- Aldrich, UK). From the cardiac puncture, an average of 0.5-1 ml of blood 
collection was achieved using a pre heparinised 26G syringe in 0.5ml EDTA tubes. 
Each animal was weighed, and haemoglobin (Hb) estimated using a HemoCue machine 
(Hemocue, Sweeden).  The heart, spleen, and liver were isolated, weighed and then 
stored in paraformaldehyde (PFA) 4% solution in PBS (Santa Cruz Biotechnology, 
Germany). 
2.8.5 Bothwell Method (Bothwell et al, 1964): Tissue Iron Quantification 
REAGENTS 
• Iron free reagents, water, glassware 
• Working standard iron solution (2μg/ml) 
• Acid Solution (3M hydrochloric acid and 10% trichloroacetic acid). Into a 
500ml volumetric flask containing 200ml iron free water, 50g trichloroacetic 
acid, and 1.5moles hydrochloric acid (129ml concentrated 36% hydrochloric 
acid). Dissolve and make up to volume with iron free water. (stable for 2 months 
in a dark bottle). 
• Chromogen reagent (0.1% bathophenanthroline sulphonate and 1% 
thioglycolic acid). Place 100mg disodium 4,7- diphenyl -1, 10-phenanthroline 
disulphonate in a 100ml flask which contains 50ml iron free water. Add 1ml 
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concentrated (100%) thioglycolic (mercaptoacetic) acid and make up to volume 
with iron free water. (Stable for one month in a dark brown bottle) 
• Working chromogen reagent. Prepare on the day:  
1: volume of the 0.1% chromogen reagent 
5: volumes of saturated sodium acetate (CH3COONa 3H2O) – iron content 
less than 0.0002% (0.2ppm) 
5: volumes iron free water. 
 
THE METHOD 
1. Weigh, e.g., 1g of tissue. Cut into small pieces 
2. Transfer pieces to 50ml Erlenmayer flask, add 10ml of acid solution 
3. Stopper the flask lightly with a glass stopper of large marble 
4. Place the flask in an oven at 65 degrees for 20 hours 
5. Solution 1 - After cooling to room temperature, transfer 0.2ml of the clear yellow 
solution to a test tube and add 10ml of working chromogen reagent. Mix the 
contents of the tube and allow to stand for at least 10 minutes 
6. Solution 2 – Prepare a reagent blank by adding 10ml of the working chromogen 
reagent to 0.2ml of acid solution. Following mixing, allow to stand for at least 
10 minutes. 
7. Solution 3 -Prepare a standard by adding 2ml of working iron standard solution 
to 8.2 ml of the working chromogen reagent. Mix and allow to stand for at least 
10 minutes. 
8. Measure the optical densities of the three solutions at 535μm against a distilled 
water blank 
CALCULATIONS 
Tissue iron concentration (μg Fe/g dry tissue) 
= O.D. Tissue Extract – O.D. blank/ O.D. Iron standard – O.D. blank  x 200/ Tissue 
dry weight(g) 
2.8.6 Perls’ Prussian Blue Staining 
Tissue slide preparation and staining was performed by Central Diagnostic Services, 
University of Cambridge, Queen’s Veterinary School Hospital. Liver, heart, pancreas, 
and spleen initially fixed in paraformaldehyde 4% solution in PBS were trimmed and 
embedded in paraffin. In brief, sections were washed and dehydrated with distilled 
water with xylene and ethanol. They were then stained with Prussian blue stain 
(potassium ferrocyanide and hydrochloric acid). Stained sections were further 
dehydrated by ethanol and xylene and mounted onto slides using Permount medium for 
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microscopic examination. Slides were scanned at the Center for Cell & Molecular 
Dynamics, UCL, London and analysed using the ZEN software (ZEISS, 2012). 
2.9 Drug Combination Analysis 
As reviewed by Tallarida (Tallarida, 2006), two drugs with a similar action can produce 
an exaggerated or diminished effect in combination. Isobolograms can be used to 
provide a quantitative assessment of the combined effect and provide further insight 
into distinguishing synergism vs. additivity. Making this distinction is based on the 
classic definition of additivity which explains that each constituent will be contributing 
to the resulting effect in accordance with its individual potency. Thus, the relative 
potency of each agent allows a calculation of the predicted effect of dose pairs to 
determine the equivalent contribution of either agent and ascertain the exaggerated 
component of the actual obtained effect. 
Isobolograms can be constructed for any desired chelation effect, for example, 50% of 
half maximal following the desired time of chelator treatment. If a 50% response is 
chosen, as it can be seen in Figure 9, the axis intercepts show the IC50 for each chelator 
when in monotherapy (i.e. the potency). The straight line on the graph that connects 
these two intercept points is known as ‘the line of additivity’, and shows the locus of all 
such dose pairs, which based on their known potencies should result in the exact same 
chelation effect. If the actual resulting effect of the dose pairs is noted to be above the 
line, the two compounds are antagonists, whereas when a curve is noted below the line, 
this indicates a super-additive effect and thus synergy of action of the two compounds.  
To further quantify this effect we looked at the synergy index α, which is equivalent to 
(1 − 1/R) x 100% where R= difference between the area under the line and the area 
under the curve.  This index is a way of determining how much the resulting effect 
actually surpasses the one expected by the simple additivity action of the two 
compounds. 
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2.10 Statistical analysis 
Data presented are shown as mean +/- SEM for n determinations, represented as error 
bars on the graphs. Comparisons between categorical data were conducted using the 
chi-squared test or the Fisher’s exact test in the case where the variables were 
categorical, and the Mann-Whitney U test for continuous variables. Analysis of variance 
was adopted to establish differences between groups with post-test Bonferroni 
correction, where appropriate. The statistical software packages SPSS 21 (SPSS Inc., 
Chicago, IL) and GraphPad Prism 5 were used for data analysis and construction of 
isobolograms. 
  
Figure 9 Sample Isobologram 
 
LINE OF 
ADDITIVITY 
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Chapter 3 HEPATOCYTE AND CARDIOMYOCYTE 
CULTURES; Development of a model to study iron mobilisation 
by chelators 
3.1 Introduction 
In this chapter, experiments were undertaken to develop a model that enables the study 
of chelator interactions and intracellular iron pools. Two cell lines were chosen, the 
human hepatocellular carcinoma cell line (HuH7) and the rat cardiomyocytes (H9C2). 
This system, using the cardiomyocyte cell line H9C2 was developed because heart 
failure secondary to iron overload is the main cause of death in transfusional iron 
overload.  The hepatocyte is the major cell type in which excess iron is stored and is an 
important source of iron excretion for example by DFO. As well as being the major site 
of iron storage in iron overload, the hepatocyte is an important target of iron-mediated 
damage where unstable iron laden lysosomes release their contents, thereby triggering 
a sequence of events leading to cell-mediated fibrogenesis and finally cirrhosis (Myers 
et al, 1991; Tsukamoto et al, 1995). 
Before performing experiments to examine the effect of new chelators on iron release, 
it was necessary to firstly characterise the behavior of the cardiomyocyte and hepatocyte 
culture models, with particular reference to the effect of physiological iron binding 
proteins on iron uptake and release. An important objective in designing the model was 
to identify a method of loading iron that was as physiological or 'pathophysiological' as 
possible and did not require the use of radioactive tracers. One of the first models of 
cardiomyocyte iron loading developed used radioactivity and demonstrated that non-
transferrin bound iron is taken up by an excess of 5-fold more rapidly than transferrin-
bound iron in these cells (Link et al, 1985). In hepatocytes, much more than 
cardiomyocytes, there is an abundance of saturable transferrin receptors on the cell 
surface (between 37,000 and 66,000). We initially designed our experiments using 10% 
fetal bovine serum (FBS), which contains transferrin at normal serum concentrations 
and could act as a source of iron for the cells. While much is known about iron uptake 
from transferrin into hepatocytes, mechanisms controlling iron release and the 
importance of transferrin to this process are less well understood. It was, therefore, 
important to understand the interaction of transferrin with our cells in culture and 
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develop an efficient way of iron loading, before examining how iron chelators may 
modify iron status.  
As will be shown later in the chapter, however, FBS also contains other sources of iron 
that are not bound to transferrin, namely NTBI. NTBI is a major conduit through which 
iron is taken into cells in iron overload conditions. Uptake into cells that are susceptible 
to iron overload from NTBI is very rapid. Therefore iron loading cells from serum that 
contains NTBI is potentially a 'pathophysiological' way to iron load cells that has 
clinical relevance. Other methods of loading iron such as by using ferric ammonium 
citrate (FAC) are also evaluated here. 
In this chapter, the experiments which helped to determine the optimal model to be used 
in our study of chelators will be described. Additionally, experiments will be shown 
which address how hepatocytes and cardiomyocytes differ in their interaction with 
chelators. These differences have clinical implications for the potential efficacy and 
toxicity of chelators. 
Before describing the model, I will present a brief review of intracellular iron 
metabolism with the hepatocyte as the particular reference.  
3.2 Iron and the human liver 
In humans, liver amounts to 10% of total body iron in normal subjects or about 400mg. 
Of this iron, 98% is found in hepatocytes, 1.5% in Kupffer cells and 0.5% in endothelial 
cells (Bacon & Tavill, 1984).Therefore, the hepatocytes contain the vast majority of 
liver iron. Kupffer cells contain only a small proportion of body iron in healthy 
individuals, and together with other reticuloendothelial cells in the spleen and bone 
marrow, are major sites of iron turnover where red blood cells are broken down and iron 
liberated from haemoglobin. This iron is subsequently released for binding and 
transport by plasma transferrin, which has a long plasma half-life of 7 to 10 days and 
can repeat numerous plasma to cell iron cycles (Bomford & Munro, 1985; Young & 
Bomford, 1984). 
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Within the hepatocyte, about 70% of the iron is present as storage iron (50% in the form 
of ferritin and 12% as haemosiderin), 12% in haem-containing molecules and other 
forms include transferrin and some labile plasma iron. Any remaining iron is present as 
non-haem containing enzymes (Bailey-Wood et al, 1975; Selden & Peters, 1979; Van 
Wyk et al, 1971; Zuyderhoudt et al, 1978).  
3.2.1 Storage iron 
The predominant form of iron storage is ferritin which is a large molecule of MW 
440,000 and can accommodate up to 4500 iron atoms stored in the form of polymeric 
iron hydroxide and ferric oxyhydroxide. Each ferritin molecule consists of 24 subunits 
with a varied proportion of either heavy (H) acidic subunits or lighter (L) basic subunits. 
Depending on the tissue type, these subunits vary. The H-ferritin subunits are 
predominant in the heart and kidney, whereas the L predominate in the liver and spleen. 
Plasma ferritin correlates with body iron stores and consists almost exclusively of L and 
‘G’ subunits. The ‘G’ subunit represents glycosylation of subunits (Cragg et al, 1981). 
Iron stimulates the formation of L subunits and promotes apoferritin aggregation into a 
shell. For cytosolic iron to be incorporated into ferritin, it must first be reduced to 
ferrous iron (Treffry & Harrison, 1979). Once inside the protein shell, the ferrous iron 
is oxidised back to ferric iron and following a process of hydrolysis it polymerises to 
ferric oxyhydride phosphate. Iron is incorporated faster onto partially filled ferritin than 
apoferritin (Hoy & Jacobs, 1981). The release of iron from ferritin requires reduction 
of ferric back to ferrous iron (Sirivech et al, 1974) or catabolism of the protein.  Release 
is very slow and triggered by reducing agents or low pH. Physiological release of iron 
from ferritin requires the molecule to be catabolised. 
Haemosiderin is present only in tissues, and predominately in hepatocytes and 
macrophages in the absence of iron overload. It is thought to be formed following 
degradation of ferritin by lysosomes (Weir et al, 1984). It is an insoluble deposit of 
degraded ferritin protein and ferric hydroxide polymers which give a positive Prussian 
blue reaction (Wixom et al, 1980). 
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3.2.2 Iron utilised for essential proteins and enzymes 
There are a number of haem proteins that contain iron, including haemoglobin, 
myoglobin, catalase, peroxidases and cytochromes. The relative amounts of haem 
proteins depend on the cell type. For example, in liver cells the amount of haemoglobin 
and myoglobin synthesized is insignificant. In the mitochondrion, iron distribution is 
heterogenous with one-third present as haem proteins (cytochromes), one-third in iron-
sulphur clusters (succinate dehydrogenase, reduced NADH-ubiquinone, cytochrome C) 
and one-third as non-haem, non-sulphur, transit pool. 
Iron Sulphur proteins are a large class of molecules containing iron atoms bound to 
sulphide. In eukaryotes their principle function is as redox mediators in the 
mitochondrial electron transport chain, acting together with cytochromes to facilitate 
this process. Furthermore, they are involved in the citric acid cycle which catalyses the 
stereospecific dehydration and rehydration reaction involved in the conversion of citrate 
to isocitrate (Beinert & Kennedy, 1989).  
There is also a group of non-haem, non-sulphur enzymes containing iron. This disparate 
group of enzymes is potentially important with respect to chelators because unlike haem 
iron-containing compounds, the iron on these proteins can potentially be chelatable. 
Chelation can lead to inactivation and inhibition of enzyme function and knowledge of 
this is of potential interest in view of unwanted inhibitory effects of iron chelators. An 
important member of this group is the ribonucleotide reductase responsible for the 
catalysis of the reduction of ribonucleotides to deoxyribonucleotides, and essential 
prerequisite to the synthesis of DNA (Thelander & Reichard, 1979). It is conceivable 
that the antiproliferative effects of iron chelators in tumour cells (Hoyes et al, 1992; 
Roth et al, 2012) relates to the inhibition enzymes directly by the chelators.  
There are several oxygenases in mammalian tissues that depend on ferrous iron for their 
maximal activity. Propyl and lysyl hydroxylase are essential for the synthesis of 
hydroxylysine and hydroxyproline which are unique constituents of collagen 
(Cumming et al, 1978). Phenylalanine hydroxylase has high activity in liver and 
catalyses the hydroxylation of L-phenylalanine to L-tyrosine and provides the body with 
a source of tyrosine. Tyrosine hydroxylase further hydroxylates L-tyrosine to L-Dopa, 
 72 
levels of which are low in Parkinson’s disease. Other enzymes thought to require iron 
are lipoxygenases, involved in a variety of oxygenation reaction of fatty acid substrates. 
There is interest in the design of chelators that could inhibit these enzymes for the 
treatment of atherosclerosis. 
3.2.3 Transit iron and labile iron pool (LIP) 
Delivery of iron to hepatocytes is primarily via transferrin, which is synthesized in its 
free form within the hepatocyte. Once liberated from transferrin in the acidic endosome, 
iron egress from the endosome is via the Nramp2 transporter (Fleming et al, 1998), and 
then it enters a small labile iron pool (LIP) which is destined either for incorporation 
into storage iron or is utilised in proteins and enzymes described above. A number of 
groups have provided evidence of this chelatable iron pool, in several cell types 
including reticulocytes, marrow cells, and intestinal epithelial cells. Iron entering cells 
becomes transiently chelatable before being incorporated into ferritin (Pippard et al, 
1982). This pool can be rapidly chelated with DFO, EDTA or transferrin (White et al, 
1976). Experiments using the fluorescent probe calcein have suggested that in K562 
cells LIP is present at 0.4μΜ with a transit time of 2 hours (Breuer et al, 1995). LIP 
increases with acute iron loading but rapidly reduces with a t1/2 of 27 minutes (Breuer 
et al, 1996), and is chelatable by hydroxypyridinones and other chelators (Zanninelli et 
al, 1997). 
3.3 Iron Uptake Mechanisms 
3.3.1 Iron uptake through transferrin (Tf) 
One of the major conduits through which extracellular iron enters cells is through 
transferrin. This is the primary mechanism by which iron is delivered to hepatocytes. 
Transferrin is a glycoprotein of MW 80,000, with an N and a C iron(III) binding domain. 
Each iron(III) is coordinated between two tyrosines, one histidine and one aspartic acid 
and indirectly to an arginine with bicarbonate acting as a bridging ligand (Bailey et al, 
1988). Under normal iron status, plasma transferrin is approximately saturated by one-
third. At 20% saturation, the iron-free form is predominant (57%) with only 3% diferric 
form and the remainder consisting of monoferric species FeN-Tf (14%) and FeC-Tf 
(26%). The proportion of differric TF rises with saturation (Leibman & Aisen, 1979) 
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Between 37,000 and 66,000 saturable transferrin receptors are found on each hepatocyte 
and together with unsaturable non-specific uptake processes this gives a maximal rate 
of iron uptake of 9x105 to 1x106 molecules/cell/minute (Thorstensen, 1988; Trinder et 
al, 1990; Young & Bomford, 1984). It has been previously shown in hepatocytes that 
diferric transferrin is taken up at 35x the rate of apotransferrin, and that monoferric 
transferrin uptake is twice that of apotransferrin (Young & Aisen, 1981).  Transferrin 
receptor expression reflects cellular iron requirements (Sutherland et al, 1981). Iron 
uptake from transferrin occurs through receptor-mediated endocytosis (Dautry-Varsat 
et al, 1983; Klausner et al, 1983). Diferric transferrin binds to the receptor and the 
complex becomes localized in clathrin-coated pits. These pits bud off from the cell 
surface to form clathrin-coated vesicles which loose their coats and fuse to form an 
endosome. A proton pump ATPase in the endosomal membrane acidifies the vesicle to 
approximately pH5.5. Iron dissociated from transferrin because of the acidic conditions 
and is transported across into the cytosol (Bomford & Munro, 1985). The newly formed 
apotransferrin remains firmly bound to the transferrin receptor while it remains within 
cells and is recycled to the cell surface (Dautry-Varsat et al, 1983; Klausner et al, 1983; 
Leverence et al, 2010). This process is thought to take between 3 and 5 minutes.  The 
iron removed enters the LIP prior to incorporation into ferritin, haem proteins or other 
iron-containing molecules. It was believed that apotransferrin dissociates from the 
transferrin receptor following exposure to the neutral pH at the cell membrane, 
however, it is now known that the apotransferrin- transferrin receptor complex remains 
intact until iron-loaded Tf which has a higher affinity for the receptor displaces 
apotransferrin ((Leverence et al, 2010). 
Receptor-mediated endocytosis of transferrin iron has an established role in iron uptake. 
However, there is also evidence to support an endocytosis-independent pathway of iron 
uptake from transferrin (Irie & Tavassoli, 1987; Trinder et al, 1996). Alternative 
proposed pathways include associated reduction of iron from transferrin, which is then 
transported across the cell membrane (Cole & Glass, 1983; Hodgson et al, 1994; Morley 
& Bezkorovainy, 1985; Oshiro et al, 1993; Thorstensen & Romslo, 1988; 1990). Iron 
release from Tf is a complex multifactorial process dependent on a number of factors 
including pH, anion binding, the presence of chelators, and the ‘lobe’ location of iron 
on Tf.  Release of iron from the N- lobe of the molecule is thought to be rapid at (17.7 
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+/-2.2 min) while removal of iron from the C- lobe slow (0.65 +/-0.06/min) (Luck & 
Mason, 2012). Furthermore, release of iron from the N-lobe is accelerated by the 
absence or iron from the C-lobe (Luck & Mason, 2012). 
3.3.2 Ferritin uptake, synthesis control, and turnover of iron 
Physiologically the most important pathway for iron uptake in hepatocytes is from 
transferrin; however other routes are known to contribute. These can be exploited in the 
design of in vitro models and in vivo animal models to probe the availability and the 
kinetics of iron availability from different pools to chelation. 
Ferritin from plasma is almost exclusively cleared by hepatocytes (Unger & Hershko, 
1974). Ferritin clearance is influenced by glycosylation; rat ferritin has a low 
glycosylation and is rapidly cleared by hepatocytes whereas human plasma ferritin has 
a high glycosylation and is cleared relatively slowly. This implies that in states of poorly 
controlled diabetes ferritin iron clearance will be further delayed. Liver-derived ferritin 
has a half-life of 50 hours (Worwood, 1982) vs. spleen-derived ferritin which is cleared 
more quickly (Cragg et al, 1983).  
Ferritin uptake is typically via receptor-mediated endocytosis, however, it cannot be 
rapidly exocytosed in a similar way to transferrin. Ferritin is taken from endosomes to 
lysosomes (Radisky & Kaplan, 1998) where the iron is liberated after catabolism of the 
protein coat, and the iron is incorporated into newly formed ferritin molecules of 
haemosiderin (Hershko et al, 1973). Within hepatocytes, the bulk of ferritin is turned 
over regularly and degraded by proteolysis with the subsequent release of iron to the 
labile intracellular pool.  It was previously estimated that ferritin is turned over 
intracellularly with a half-life of about 72 hours (Drysdale & Munro, 1965). Ferritin 
release from hepatocytes reflects cellular iron content or may also reflect cellular iron 
damage. 
Ferritin levels are the result of the balance between ferritin synthesis and degradation. 
Synthesis is upregulated when cytosolic iron is high to provide capacity for storage iron. 
Iron binding proteins bind to iron-responsive elements (IREs) on ferritin mRNA, 
enhancing ferritin synthesis (Rouault, 2006).  In conditions of iron demand, ferritin is 
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degraded by a process known as autophagy, where it is delivered to lysosomes (Radisky 
& Kaplan, 1998). This process is modulated by cargo molecules such as NCOA4 
(Mancias et al, 2014). Ferritin is depleted of iron and then ubiquitinated followed by 
degradation (De Domenico et al, 2006). 
3.3.3 Uptake of plasma NTBI 
Iron that is non-transferrin bound is often present in pathology and is also taken up by 
cells (Baker et al, 1981; Fawwaz et al, 1967). NTBI appears in plasma when influx 
exceeds iron efflux, and when Tf saturation is >75%. NTBI is known to be increased in 
iron overload, decreased transferrin iron clearance, ineffective erythropoiesis as well as 
erythroid hypoplasia. NTBI is multispecied and can take a number of forms such as 
iron-citrate, bound albumin complexes, glycated protein-iron complexes or iron-chelate 
complexes (Garbowski et al, 2016). NTBI uptake often requires calcium (Oudit et al, 
2003; Wright et al, 1986), and can be inhibited by divalent cations such as zinc and 
manganese (Wright et al, 1986). In iron overloaded mice with cardiomyopathy, tissue 
iron was shown to be significantly decreased in mice by blocking of L-type voltage-
dependent Ca2+ channels (LVDCC) with amlodipine and verapamil (Oudit et al, 2003). 
ZIP 14 is another metal iron transporter present in the liver, heart, and pancreas that has 
been identified as a candidate route for NTBI (Pinilla-Tenas et al, 2011). The rate of 
hepatocyte uptake of NTBI is increased in perfused livers of iron deficient animals 
(Zimelman et al, 1977) although the opposite effect is seen in intact animals, where iron 
overload increases liver uptake and iron deficiency decreases liver uptake. Similarly, 
high rates of iron uptake are observed if iron is complexed to citrate or fructose (Brissot 
et al, 1985).  In hepatocytes, NTBI delivered is found within lysosomes (Batey et al, 
1981) as ferritin within 30 minutes (Wright et al, 1986).  
3.4 Developing the cellular model; the approach 
In view of the importance of hepatocytes as cells for iron storage, iron uptake and as a 
major source of chelatable iron, it was decided to commence the development of our 
cell system using HuH7 cells and then extend our study to cardiomyocytes inorder to 
study the effects of iron chelators on iron mobilisation.  The journey to establishing our 
model consisted of numerous experiments undertaken over a period of  5-6 months, 
 76 
looking at the most effective and physiological form of iron for loading, different 
regimes for cell washing and viability challenges following chelator treatment. 
3.5 Establishing optimal medium for iron loading in HuH7 cells 
A monolayer cell culture system was chosen in an attempt to create a reliable model for 
the study of iron release with chelators by minimising cell membrane damage, viability 
loss, and iron leakage, as is seen for example when agitating cells in suspension (Bailey-
Wood et al, 1975; Baker et al, 1985). For the above reasons, a density of 200,000 cells 
per well was noted to be the most appropriate in 24 well plates. The cells were then 
allowed to settle for 24 hours reaching an average of 60% confluency, and non-adherent 
or partially adherent dead cells were washed off. The monolayers were then pulsed with 
RPMI 1640 media containing either 20μΜ FAC or 10% FBS for 24 hours. The 
supernatant was then aspirated, and a fresh supply of RPMI 1640 was added containing 
either 20μΜ FAC or 10% FBS for a further 24 hours.  At the end of the 48 hours in total 
cells were noted to have reached 90% confluency; the medium was decanted and the 
cells rinsed on two occasions with PBS solution followed by a wash with PBS/DFO 
30μΜ ibe and a final PBS wash. Iron content was determined via the ferozine assay as 
described in the methods Section 2.3.5 and adjusted for protein, following overnight 
cell lysis with 200mM NaOH.  
The iron content of cells was shown to be tripled in the presence of FAC and almost 
quadrupled in the presence of 10% FBS following two 24 hour incubations (Figure 10).  
The iron content of RPMI 1640 supplemented with 10% FBS was 25μM.  The NTBI 
content was kindly measured by Dr. M. Garbowski in our laboratory, and the method is 
described in Section 5.2.7. In 100% FBS, the NTBI content was 3.31±0.23 μM, and 
0.29±0.05 μΜ in RPMI media containing 10% FBS (Figure 11). Whilst Τf uptake is a 
known mechanism of iron acquisition, NΤΒΙ is a very rapidly taken up form of iron 
(Brissot et al, 1985). Using serum known to contain transferrin to effectively iron load 
cells was particularly appealing as we aimed to use physiological iron binding proteins 
and mechanisms as much as possible to examine iron uptake and release. Ferric 
ammonium citrate (FAC) also proved to be effective in increasing intracellular iron 
content. However, there was concern regarding iron binding on the extracellular 
membrane as well as on plastic wear, introducing error in intracellular iron assessment. 
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Hepatocytes have between 37,000 and 66,000 transferrin receptors on the cell surface 
(Young & Bomford, 1984), and transferrin is the major uptake pathway for iron in these 
cells, as described above (Section 3.3.1).  
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Figure 10 FAC/FBS loading regime in HuH7 cells. Cells were treated with RPMI media containing 
10% FBS or 20μΜ FAC for 24 or 48 hours.  Adherent cells were rinsed four times, including one wash 
containing DFO at 30µM ibe and 3 x PBS washes. The cells were then lysed with 200mM NaOH.  
Intracellular iron concentration was determined using the ferrozine assay and normalised for total cellular 
protein in each well. Results are mean +/- SEM of quadruplicates in one experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
Figure 11 Total iron concentration of RPMI media and RPMI media containing 10% FBS (A) and 
NTBI content (B). The ferrozine assay described in the methods Section 2.3.5 was used to determine 
media iron content. 
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3.6 Establishing the number of media changes for optimal iron loading  
We investigated the number of changes of FBS containing media required to iron load 
the cells, and whether a shorter time period than the 24 hours used above could be 
adopted. HuH7 cells were exposed to RPMI 1640 media supplemented with 10% FBS 
changed once or two times, for 10-hour treatments. Cells were then washed as above 
(PBS solution followed by a wash with PBS/DFO 30μΜ ibe and a final PBS wash). 
Total iron content was determined via the ferozine assay as described in the methods 
Section 2.3.5 and adjusted for protein, following overnight cell lysis with 200mM 
NaOH. The findings (Figure 12) indicate that two ten hour incubations with RPMI 1640 
containing 10% FBS doubled the initial iron content. The intracellular iron content, in 
this case, was similar compared to two 24 hour treatments (Figure 10), indicating that 
a shorter time of iron loading can be adopted. 
Figure 12 HuH7 iron following 1 or 2 changes of 10% FBS media, each for 10 hours. Cells were 
treated with RPMI media containing 10% FBS for zero, one or two 10- hour periods.  Adherent cells 
were rinsed four times, including one wash containing DFO at 30µM ibe and 3 x PBS washes. The cells 
were then lysed with 200mM NaOH.  Intracellular iron concentration was determined using the ferrozine 
assay and normalised for total cellular protein in each well. 
 
 
 
 
 
 
 
 
 
 
 
 
3.7 Establishing the optimal cell washing technique 
It should be taken into account when estimating iron release that in a culture system that 
various iron species may be adherent to the cell membrane or the plastic wear. It was 
thus important to establish an optimal washing regimen that would not lead to excessive 
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cell loss and would minimise this bias. Hepatocytes were pulsed as previously described 
with RPMI containing 10% FBS for two ten hour intervals.  Figure 13 shows the results 
of protein loss following PBS washing for 0, 1, 5 and 15 minutes. Washing with PBS 
for longer than 5 minutes compromised cellular protein by more than 5%, indicating 
cell loss due to increasing proportions of non-adherent cells during this washing 
process.   
Figure 13 Effect of washing HuH7 cells with PBS for different time intervals on cellular protein. 
24 hours after plating, cells were washed with PBS for 0, 1, 5 and 15 minutes and cellular protein 
quantified as described in methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to establish the best approach to minimising non-specific extracellular iron 
adherence to cell membranes, iron-loaded HuH7 cells were then washed at room 
temperature prior as well as following an 8 hour DFO 30μΜ treatment using a variety 
of regimens. These included 4 x PBS, PBS/DTPA (+3 x PBS), PBS/DFO (+3 x PBS), 
and 4 x RPMI media (see Figure 14). Following iron loading with two 10-hour changes 
of RPMI media containing 10% FBS, the cellular iron content is 36μΜ+/-2.1 An 
expected decrease in intracellular iron following treatment with DFO 30μΜ ibe for 8 
hours was best noted when washing was carried out with PBS/DTPA and PBS/DFO. 
Each wash had a duration of about a minute.  Washing with media and PBS were likely 
not effective at removing extracellular iron and reflect the iron-releasing effects of DFO. 
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Furthermore, further washing with media could potentially prove to be a further source 
for NTBI leading to further iron contamination (See Section 5.2.7 for calculation of 
NTBI concentration in media). Based on the above data, the washing regime was 
finalised to 1 x PBS, 1 x PBS/DFO 30μΜ ibe, 2 x PBS prior to as well as post-chelator 
exposure. PBS/DTPA wash was not adopted, aiming to keep exposure to different 
chelators to a minimum. 
 
Figure 14 Effect of washing HuH7 cells with different agents before and after chelator exposure on 
iron detection. 24 hours after plating, cells were iron loaded with two ten-hour changes of 10% FBS-
containing RPMI media. Cells were then washed with PBS, PBS DTPA (30μΜ ibe), PBS/DFO (30μΜ 
ibe), and RPMI media before and after 8 hours of 10μΜ DFO treatment. The cells were then lysed with 
200mM NaOH. Intracellular iron concentration was determined using the ferrozine assay and normalised 
for total cellular protein in each well. 
 
 
 
 
 
 
 
 
 
3.8 Regime for iron loading and washing of H9C2 cardiomyocyte cells  
Despite the much-reduced expression of transferrin receptors on the cell membrane of 
cardiomyocytes in G0 phase compared to hepatocytes (Gatter et al, 1983), it is known 
that they play an important role in cardiac iron uptake as their absence leads to 
cardiomyopathy and heart failure in mice (Xu et al, 2015), most likely as a consequence 
of NTBI uptake when transferrin becomes saturated (Oudit et al, 2006). A model of iron 
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pre-loading of H9C2 cells was developed so as to load iron into cells at sufficient final 
concentrations for intracellular iron to reach levels where reliable cellular iron 
determination could be obtained using the ferrozine assay. When 10% FBS is added to 
DMEM, the total iron concentration in the media increases from an average of 1µM to 
22µM. The NTBI content of DMEM containing 10% FBS was 0.33μM ±0.04 and was 
kindly measured by Dr M. Garbowski in our laboratory (the method is described in 
Section 5.2.7). When the total cellular iron accumulation was compared using FAC or 
10% FBS, 10% FBS incubations resulted in more reproducible and higher final cellular 
iron concentrations than those achieved with FAC both with one and two 10 hour 
treatments (Figure 15 A, B).  It was found that adequate iron loading was achieved after 
two changes of incubation medium (Figure 15 B). Furthermore, washing with 1 x PBS, 
1 x PBS/DFO 30μΜ ibe, 2 x PBS proved superior at removing extracellular iron 
compared to PBS alone (Figure 15 A, B). In subsequent experiments reported, pre-
loading of H9C2 was achieved using two 10 hour changes of media containing 10% 
FBS, also improving consistency between experiments across cell lines.  
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Figure 15 Iron loading of H9C2 with FAC/10% FBS-DMEM media over one (A) or two (B) 10 hour 
periods. Cells were treated with DMEM media containing 10% FBS for one or two 10- hour periods and 
were rinsed four times. Intracellular iron concentration was determined using the ferrozine assay and 
normalised for total cellular protein in each well. 
 
 85 
3.9 Cell damage in HuH7/H9C2 assessed by Tryptan blue, AO/PI staining and 
LDH release 
The viability of hepatocytes has a critical influence on cellular iron release (Porter et al, 
1988), as any compound leading to cell damage can cause iron release independently of 
the chelation mechanism. Prior to comparing chelator iron release effects we thus 
ensured that viability was consistently > 98%. Dye exclusion techniques provide a good 
estimate of cell viability and membrane integrity, and this was tested using both 0.4% 
Trypan blue solution as well as Acridine Orange (AO)/Propidium Iodide (PI) (Section 
2.3.3) viability staining.  The commercially available colorimetric LDH assay was also 
used (Section 2.3.3).  
 
Following loading of HuH7/H9C2 as described above (Section 3.8) with two 10 hour 
treatment periods with RPMI/DMEM containing 10% FBS, cells were incubated with 
media without FBS, but with the maximum intended for use concentration of iron 
chelators. A sample of viability testing using Tryptan blue solution in hepatocytes can 
be seen in Figure 5, and using the Acridine Orange (AO)/Propidium Iodide (PI) 
viability staining in Figure 4. A further sample of the LDH colorimetric viability assay 
using maximal concentration of iron chelators in cardiomyocytes is shown below 
(Figure 16).  Viability was maintained >98% with all three licensed chelators in both 
cell types, and was re-assessed when using novel compounds or chelator combinations. 
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Figure 16 LDH viability assay in H9C2 following 8 hours of chelator treatment. Cells were iron 
loaded with two 10-hour changes of 10% FBS containing media and rinsed as in Figure 15. Cells were 
then treated for 8 hours with the maximum experimentally used concentration of DFO/DFX and DFP. % 
cellular LDH release was calculated using the LDH assay as described in the methods (Section 2.3.3) 
 
 
 
 
 
 
 
 
 
3.10 Time course and concentration dependence of intracellular iron 
mobilisation with DFO, DFP and DFX monotherapy 
The cellular iron content expressed as nmol/mg of cell protein has been investigated as 
a function of time in the presence of DFP, DFX or DFO in hepatocytes and 
cardiomyocytes. The cells were exposed to two 10 hour treatment periods with 
RPMI/DMEM containing 10% FBS to iron load the cells, and were then incubated with 
media without FBS, but with chelators at either 10μΜ ibe or 30µM ibe for different 
time periods. At 4h a significant decrease in cellular iron is seen with DFP and DFX as 
low as 10µM ibe but DFO shows minimal effect in HuH7 cells at this time (Figure 17).  
However by 8h DFO was as effective as DFP and DFX in hepatocytes (Figure 18 A,B, 
Table 5). Similar findings at 8h are seen in cardiomyocytes where DFO shows similar 
iron release as DFX and DFP (Figure 19, Figure 20). Iron mobilisation as a proportion 
of baseline cellular iron was found to be between 18.6 % and 25.9 % in cardiomyocytes 
and 39.0 % to 47.2 % in hepatocytes (Table 5). The results are consistent with a slower 
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access of DFO to intracellular iron pools than the other chelators (Hoyes & Porter, 1993; 
Porter et al, 2005; Vlachodimitropoulou Koumoutsea et al, 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 HuH7 intracellular iron mobilisation with DFO, DFP and DFX monotherapy at increasing 
concentrations at 4 hours of treatment. Cells were loaded with iron using two 10-hour changes of 10% 
FBS containing media, rinsed before and after chelation treatment, exposed to chelators for 4 hours, and 
cellular iron/protein determined as in Figure 15. 
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Figure 18 HuH7 intracellular iron mobilisation time course with DFO, DFP and DFX monotherapy 
at (A) 10μΜ and (B) 30μΜ. Cells were loaded with iron using two 10-hour changes of FBS containing 
media, rinsed before and after chelation treatment, exposed to chelators for 0, 1, 4 and 8 hours, and 
cellular iron/protein determined as in Figure 15. Results shown are the mean ± SEM of 4 replicates in 
one experiment. 
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Figure 19 H9C2 intracellular iron decrements time course with DFO, DFP and DFX monotherapy 
at 30μΜ ibe. Cells were loaded with iron using two 10-hour changes of FBS containing media, rinsed 
before and after chelation treatment, exposed to chelators for 0, 1, 4 and 8 hours, and cellular iron/protein 
determined as in Figure 15. Results shown are the mean ± SEM of 3 replicates in one experiment. 
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Figure 20 H9C2 intracellular iron mobilisation at 8 hours with increasing concentrations of DFO, 
DFP, and DFX. Cells were loaded with iron using two 10-hour changes of 10% FBS containing media, 
rinsed before and after chelation treatment with 3x PBS washes and one containing PBS/DFO 30μΜ ibe, 
exposed to chelators for 8 hours, and cellular iron/protein determined as in Figure 15. Results shown are 
the mean ± SEM of 4 replicates in one experiment. 
 
 
 
Table 5 Percentage of intracellular iron removed by chelators in HuH7 and H9C2. Cells were loaded 
with iron using two 10-hour changes of FBS containing media, rinsed before and after chelation 
treatment, exposed to chelators for 8 hours, and cellular iron/protein determined as in Figure 15. Results 
shown are the mean ± SEM of 4 replicates in one experiment. 
 
 
% iron removed following 8 hours of chelator 
monotherapy at 30μΜ ibe 
 
Hepatocytes (HUH7) Cardiomyocytes (H9C2) 
DFO 39.0 +/- 2.1 20.3 +/- 0.9 
DFP 44.4 +/- 3.2 25.9 +/- 2.2 
DFX 47.2 +/- 2.9 18.6 +/- 0.9 
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3.11 Iron release with low membrane-permeable hydrophilic iron chelators 
Hydroxypyridinones with low cell penetration, such as CP40, CP44 or CP46 are known 
to not access intracellular pools directly due to their high hydrophilicity (pK) and thus 
cannot mobilise iron at observable rates in the cell culture system (Table 6). These were 
predicted to have negligible iron mobilising properties as shown previously with radio-
labelled cells (Porter et al, 1988). However, we wished to confirm that the current cell 
system behaved as we predicted and that factors such as leaky cell membrane or 
extracellular iron adherence to the cell membrane did not contribute to iron mobilised 
from cells.  In Figure 21 it can be seen that unlike DFO, no recordable iron chelation 
effect was noted following 8 hours of treatment with CP40/CP44/CP46. This 
demonstrates that our washing techniques adequately remove any extracellular iron that 
could be available for chelation and be mistaken for an intracellular iron removal effect 
and further validates the integrity of the cell membrane in the cell culture model, 
because any cells with damaged or leaky cell membranes would allow intracellular iron 
to be chelated by the hydrophilic chelators.  This also allows us to conclude that in our 
assay the chelation effects of DFO, DFX and DFP observed in Figure 17, Figure 18 , 
Figure 19, Figure 20, are exclusively of the intracellular iron pools. This is consistent 
with observations using other models where these chelators had little or no effect (Porter 
et al, 1988). 
 
.  
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Figure 21 Decrements in cellular iron after an 8 hour treatment with 100μΜ CP40/CP46 in A. HuH7 B. 
H9C2. Cells were loaded with iron using two media changes containing 10% FBS.  Cells were loaded with iron 
using two 10-hour changes of FBS containing media, rinsed before and after chelation treatment, exposed to 
chelators for 8 hours, and cellular iron/protein determined as in Figure 15. Results shown are the mean ± SEM of 
3 replicates in one experiment 
B                                                  H9C2 
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3.12 Effect of iron loading or iron chelation of cellular ferritin in HuH7 and 
H9C2 cells. 
3.12.1 Effect of iron loading on cellular ferritin in HuH7 and H9C2 cells. 
It is important to understand whether the total cellular iron mobilising effects of 
chelators above are associated with changes in storage iron and in particular cellular 
ferritin. Iron in ferritin is predicted to be less rapidly accessible to chelation than other 
iron pools such as labile intracellular iron, but ultimately storage iron must be decreased 
if iron overload is to be treated clinically.  Using iron loading established previously in 
the chapter, changes in cell ferritin were measured by ELISA which was species specific 
for HuH7 (Human) and H9C2 (Rat) (see Section 2.5). 
 
For the iron loading experiments, cells were cultured as described in previous sections 
and monolayers treated with one or two 10 hour applications of media containing 10% 
FBS. Two changes of FBS media increased the ferritin concentration in human HuH7 
hepatocytes by 2.5-fold (250%) and 1.5-fold (150%) in rat H9C2 cardiomyocytes 
(Figure 22). It is also clear however that ferritin content adjusted for total cell protein 
is about 3 times higher at baseline in HuH7 cells than H9C2 cells as well as being more 
responsive to the effects of iron loading. This is consistent with the known iron storage 
function of hepatocytes in iron overload conditions which is not a feature of 
cardiomyocytes. It is also of interest that under similar iron loading conditions with two 
changes in FBS, the increments in total cellular iron noted in Section 3.6 in HuH7 cells 
and H9C2 cells were 2.33 fold (230%)  and 1.6 fold (160%) respectively (Section 3.8). 
Thus the relative increments in cell ferritin parallel the increments in total cell iron in 
each cell type, with the increments in both cell iron and ferritin being greater in HuH7 
cells that H9C2 cells.  
 
It appears therefore that in this model increments in cell ferritin respond proportionately 
to iron loading in both cell types. The lower proportion and absolute increase in cell 
iron and ferritin in H9C2 cells is consistent with their less specialised role in iron storage 
than hepatocytes. Ferritin degradation involves autophagic and non-autophagic 
pathways, and turnover of the ferritin protein is a constant process in the cell. Autophagy 
is upregulated in iron deficiency increasing iron availability by reducing storage 
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capacity (Mancias et al, 2014). In iron excess, non-autophagic pathways predominate, 
modulating factors such as the nuclear receptor coactivator 4 (NCOA4), leading to less 
ferritin breakdown and upregulating synthesis. Chelators such as DFO and DFX have 
been shown to modulate NCOA4 (Mancias et al, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Effect of one and two 10 hours treatments of 10% FBS containing media on ferritin 
concentration in (A) HuH7 and (B) H9C2 cells. Cells were loaded with iron 1 or 2 ten hour changes 
of 10% FBS containing media and were rinsed four times, including one wash containing DFO at 30µM 
ibe and 3 PBS washes. Ferritin concentration was determined using commercially available ELISA kits 
as described in the methods, and adjusted for cellular protein 
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3.12.2 Effect of chelator treatment on cellular ferritin in HuH7 and H9C2 cells 
The response of cellular ferritin to iron chelators in is studied in HuH7 (Figure 23 A) 
and H9C2 (Figure 23 B) cells. Decrements with commercially available chelators were 
clear in both cell types. In HuH7 hepatocytes, 10μΜ ibe of commercially available 
chelators lead to ferritin decrements of almost 50% (Figure 23 A) with a 30% reduction 
in total cellular iron. However, in H9C2 cardiomyocytes ferritin decrements appeared 
both proportionately smaller as well as smaller in absolute terms: 30μΜ ibe of chelators 
was required to reduce cellular ferritin by 10-35% (Figure 23 B) and total cellular iron 
by18-26%.  In both cell types, ferritin decrements are proportionately greater in HuH7 
than H9C2 cells. Evidently, therefore, hepatocyte ferritin is more responsive, both to 
iron loading and iron unloading than in cardiomyocytes. This is consistent with the 
known high iron storage capacity of hepatocytes compared with cardiomyocytes.   
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Figure 23 Ferritin in (A) HuH7 and (B) H9C2 cells treated with commercially available chelators for 8 hours. 
Cells were loaded with iron with two 10-hour incubations with media containing 10% FBS.  Adherent cells were 
rinsed four times, including one wash containing DFO at 30µM ibe and 3 PBS washes, and subsequently exposed to 
chelators at 10μM for 8 hours.  Chelator supernatants were then removed, and the cells washed four times as above. 
Ferritin concentration was then determined using a commercially available ELISA kit as described in the methods, 
and adjusted for cellular protein. 
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3.13 Discussion 
From the work in this chapter, it is clear that treating cells with media containing 10% 
FBS offers an optimal and physiologically and pathophysiologically relevant method 
for obtaining a high enough iron concentration in hepatocytes as well as cardiomyocytes 
to study iron release with chelators. This is likely attributed to a greater extent to NTBI 
uptake as opposed to transferrin iron uptake found in the fetal bovine serum. In RPMI 
1640 for example, supplemented with 10% FBS, the total cellular iron was 25μΜ with 
a concentration of 0.29μΜ NTBI. Whilst Τf uptake is a known mechanism of iron 
acquisition, NΤΒΙ is very rapidly taken up form of iron (Brissot et al, 1985). 
Furthermore, the increase in total cellular iron noted in cardiomyocytes (Figure 15) and 
not just in hepatocytes supports this, as the presence of transferrin receptors in 
cardiomyocytes during G0 phase is limited (Gatter et al, 1983). In both cell types, total 
cellular iron increased to a greater extent when treating with media containing 10% FBS 
than when treating with FAC (Figure 11, Figure 15). Indeed the iron in FAC can be 
considered a species of NTBI; however, this is likely to be of a different form to that 
present in the FBS containing media. Regarding the washing of cells prior to and after 
chelator treatment, a 30μΜ DFO containing wash together with three PBS washes was 
chose, as this method proved to be the most effective at ensuring removal of 
extracellular iron, which can interfere with assessment of intracellular iron (Figure 14).  
All licenced chelators were effective as monotherapy in this cell system, at 
concentrations that are clinically relevant. The studies on the effect of chelators on 
cellular iron mobilisation show some important contrasts amongst chelators which are 
in agreement with findings in other cell models. Very little iron removal occurs with 
DFO before 4 hours of treatment, findings consistent with previous studies reporting a 
much slower access to intracellular iron than for example with DFP and other 
hydroxypyridinones (Cooper et al, 1996; Hoyes & Porter, 1993). Factors such as the 
positive charge of DFO, its low lipid solubility, and larger size than DFP influence its 
uptake and distribution in cells (Porter et al, 1996; Porter et al, 2005). Furthermore, the 
Ferrioxamine complex (DFO-Fe) has a much slower egress rate from cells (Cooper et 
al, 1996; Hoyes & Porter, 1993). Similar to previous studies, the hydrophilic chelators 
CP40 and CP46, which are otherwise similar to DFP in terms of iron binding, induce 
no iron mobilisation as monotherapy treatment ((Dobbin et al, 1993; Porter et al, 1988). 
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This highlights the necessity of chelators to access the intracellular iron directly by 
crossing the cell membrane both in the free form as well as when bound to iron. The 
relative ranking order of chelators in terms of iron mobilisation showed only small 
differences at 8h, with DFP being the most effective in H9C2 cells but not in HuH7 
cells. As will be discussed in a later chapter (Chapter 5) in more detail, HuH7 cells 
possess metabolic pathways lacking or relatively diminished in H9C2 cells. As DFP is 
metabolised by glucoronidation at an iron binding site, and enzymes responsible for its 
metabolism are much more widely available in the liver, its chelating and iron 
mobilising action is more likely to be reduced here.  
In this chapter, I have shown that ferritin increases significantly in both hepatocytes and 
cardiomyocytes following treatment with 10% FBS containing media. The relative 
ferritin increments parallel the increase in total cellular iron in each cell type, with 
increments of both total iron and ferritin being greater in HuH7 cells.  Following 
chelator treatment for 8 hours, ferritin decreases significantly in both cell lines. 
Decrements are significantly larger in hepatocytes compared to cardiomyocytes and 
reflect the larger iron storage capacity of this cell type. As ferritin concentration is a 
function of ferritin synthesis and opposing degradation, the decrease in its 
concentration, in this case, is likely to be due to an increase in degradation as a result of 
chelator-induced ferritin entry into lysosomes (De Domenico et al, 2009).      
3.14 Conclusion 
In this chapter, a model for evaluating iron release from hepatocytes and 
cardiomyocytes by iron chelators, without the need for radioactive tracers has been 
presented. This model looks at total cellular iron and not only at radio-labelled iron 
pools. Ferritin changes parallel iron loading and unloading (measured biochemically), 
supporting the interpretation that intracellular iron is being recorded and that loading 
and unloading reflects predominantly changes in storage iron pools. Using two different 
cell types provides further insight into the effects of drug metabolism and cellular iron 
mobilisation. This model aids the selection of iron chelators designed to fulfill particular 
requirements as well as the development of novel chelators. The next chapter addresses 
the comparison between synergy and additivity of licensed chelator action on iron 
release, while closely studying chelator physiochemical properties.  
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Chapter 4 THE INFLUENCE OF COMBINATION OF 
COMMERCIALLY AVAILABLE IRON CHELATORS ON 
RELEASE OF CELLULAR IRON. 
4.1 Introduction 
In clinical practice, iron chelators are increasingly used in combination, but the optimal 
conditions required for maximal cellular iron mobilisation and actual mechanisms of 
interaction between chelators are unclear.  Examination of speciation plots for iron(III) 
binding of paired combinations of the commercially available iron chelators DFO, DFP, 
and DFX can suggest the conditions under which chelators can combine and act as 
‘shuttle’ and ‘sink’ molecules. However, this approach does not consider their relative 
access and interaction with cellular iron pools. I addressed this issue using a sensitive 
ferrozine-based detection system for intracellular iron removal from the human 
hepatocyte (HuH-7) and cardiomyocyte (H9C2) cell lines (see previous chapter).  I 
distinguished between antagonism, synergism or additivity of action of paired chelator 
combinations using mathematical isobologram analysis, over clinically relevant 
chelator concentrations.  
4.2 Chelator speciation plots and their relevance to synergistic chelator 
combinations 
Speciation plots for combination pairs of chelators predict the binding of iron(III) by 
each chelator at equilibrium under defined conditions, namely 10µM iron(III) and at pH 
7.4. These concentrations provide an indication of which chelator has the potential to 
act as a ‘shuttle’ or as a ‘sink’ for chelatable iron over the range of concentrations of 
each chelator pair shown.  These proportions are calculated based on the known stability 
constants and chelation denticity (ratio of binding for chelator: iron) for each chelator. 
This analysis does not take into account the rate (kinetics) of this interaction or the 
restrictions to chelation imposed by the cellular compartmentalisation of iron in cells or 
elsewhere. The speciation plots were created by Prof. Hider from King’s College 
London University using HYSS (2016b), in which the concentration of iron and the 
concentration of the second chelator are varied. The stability constants used for the 
calculations are from published data shown in Table 6 (Motekaitis & Martell, 1991).   
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The molar fraction of 10µM iron(III) bound to 10µM DFO in the presence of increasing 
concentrations of DFX is presented in Figure 24 A.  It can be seen that at 10µM DFO, 
equilibrium favors the formation of iron complexes of DFO until those of DFX exceed 
about 15µM. This predicts that DFX will act as a shuttle for iron(III) onto DFO at 
concentrations below 20µM but at higher concentrations may compete with DFO as a 
sink for iron(III) binding.  Thus at clinically achieved trough concentrations (about 
20µM) (Galanello et al, 2006; Waldmeier et al, 2010), using standard daily dosing of 
DFX, about half of iron(III) is predicted to be bound to DFO and half to DFX in solution 
at neutral pH such as plasma. At peak clinical concentrations of DFX (about 60µM), 
equilibrium will favour the predominance of DFX iron complexes over those of DFO. 
Thus, trough concentrations of DFX will have the potential to donate iron(III) to DFO 
whereas this is less likely to happen at peak concentrations of DFX.  It is important to 
realise that this prediction is for a cell-free system and does not predict the rates at which 
equilibrium is obtained. Hence the need to examine chelator interactions in a cell based 
system (see below).  
 
The influences of varying the concentrations of DFP and DFX on the proportion of 
iron(III) bound to mixtures of each chelator is presented in Figure 24 B, C. Figure 24 
B shows the molar fraction bound to 30µM DFP at increasing concentrations of DFX. 
This plot indicates that at equilibrium, and at for example 10µM DFX, about half of the 
iron(III) is bound to each chelator but when DFX exceeds 10µM the iron complex of 
DFX increasingly predominates. Thus at clinically relevant trough and peak 
concentrations of DFX about 40% and >98% respectively of iron(III) is predicted to be 
bound to DFX at equilibrium in a cell-free system.  Figure 24 C shows the speciation 
of iron-chelate complexes at constant concentrations of 20µM DFX with increasing 
concentrations of DFP. These confirm the analysis in Figure 24 B but also allow 
examination of higher concentrations of DFP.  Peak clinical concentrations of DFP of 
100µM have been reported (Jirasomprasert et al, 2009; Limenta et al, 2011b) and under 
these concentrations and at trough concentrations of DFX about 60% of iron(III) is 
predicted to be bound to DFP in a cell-free system. This analysis suggests a ‘push–pull’ 
effect for iron-free binding over the range of clinically achieved concentrations of the 
two drugs, providing a circumstance under which both shuttle and sink effects may 
occur.  
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The speciation plot for the molar fraction of iron(III) bound to DFO at increasing 
concentrations of DFP is presented in Figure 24 D and has been previously published 
by our group (Evans et al, 2010).  It can be seen that at clinically relevant concentrations 
of 10µM iron(III) and 10µM DFO, the iron binding will be predominantly to DFO until 
the concentration of DFP exceeds 1mM, a DFP concentration not achieved clinically.  
At clinically relevant peak DFP concentrations of 100µM, about 5% of iron(III) will be 
bound by DFP at equilibrium. This implies that a considerably higher concentration of 
DFP is required than that of DFX to compete with DFO for iron(III). Thus in a cell-free 
system, combinations  of DFO with DFX or with DFP differ, because while the iron(III) 
complexes of DFO will predominate at all clinically achievable concentrations of DFP, 
iron(III) will bind preferentially to either DFX or DFO depending on whether DFX is 
at peak or trough levels. The effects of these considerations on iron release from cells 
are examined below.  
Table 6 Iron chelator characteristics. (Vlachodimitropoulou Koumoutsea et al, 2015) 
Chelator Molecular 
Weight 
Chelator : 
iron(III) 
binding 
ratio 
Stability 
Constant 
log βn 
pM Charge 
of free 
ligand 
Charge 
of iron 
comple
x 
Lipid 
Solubility 
of free 
ligand 
(Kpart) 
Lipid 
Solubility 
of iron 
complex 
(K part) 
DFO 561* 1 : 1   33 (1) 26.6 1+ 1+ 0.01 0.03 
DFP 139 3 : 1 37.2 20.5 0 0 0.17 0.08 
DFX 373 2 : 1 26.5 22.5 1- 3- 6.3 NK 
CP40 169 3 : 1 36.7 19.9 0 0 0.08 0.001 
CP46 182 3 : 1 36.5 20.1 1+ 3+ 0.008 0.0007 
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Figure 24 DFO, DFX, and DFP combination speciation plots at pH 7.4. 
 (Vlachodimitropoulou Koumoutsea et al, 2015) 
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4.3 Comparison of cellular iron mobilisation with monotherapy and 
combinations in HuH7 cells 
HuH7 cells were iron loaded as described in the methods section. Intracellular iron was 
determined using the ferrozine assay following 8 hours of treatment of chelator 
monotherapies and combinations. Intracellular iron is shown in Figure 25 A, B, C, D 
as a function of ibe vs. iron/protein. In these experiments, the concentration of one of 
the two chelators is kept constant.  Monotherapy treatment with DFO showed a 
concentration-dependent cellular iron removal at 8 hours (A) in contrast to findings at 
4 hours (Figure 17). Iron mobilisation with DFX or DFP (Figure 18, Figure 19, Figure 
20, Figure 25) also showed concentration dependence in monotherapy. When a second 
chelator was added, there was a significant additional decrease in intracellular iron, 
noted across the range of concentrations of the first chelator. This was the case for all 
combinations of the three commercially available chelators.  Using non-linear 
regression, small increments of one chelator have statistically and biologically 
significant chelation effects. Figure 25 D shows that at 4hours when DFO alone is not 
able to mobilise iron, a significant additional iron removal is seen when combined with 
DFP. Thus, DFO can act as an extracellular sink at short time intervals, when cell uptake 
and direct access to intracellular iron with DFO is limited. 
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Figure 25 Treatment of HuH7 cells with a combination of (A) DFO and DFX, (B) DFO and DFP, 
and (C) DFP and DFX for 8 hours and (D) DFP and DFP for 4 hours.  
Cells were loaded with iron with two 10-hour treatments of 10% FBS containing media.  Adherent cells 
were rinsed four times, including one wash containing DFO at 30µM ibe and 3 x PBS washes, and 
subsequently exposed to chelators for 8 hours.  Chelator supernatants were then removed, and the cells 
washed four times as above before lysing with 200mM NaOH.  Intracellular iron concentration was then 
determined using the ferrozine assay and normalised for total cellular protein in each well. Results shown 
are the mean ± SEM of 4 replicates in one experiment. 
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4.4 Effect of chelator combinations on the intracellular iron pool after 8 hours 
in cardiomyocytes (H9C2) 
 
H9C2 cells were iron loaded with serial media changes as described in the methods 
section and exposed to chelator combinations of DFP, DFX, and DFO at different 
concentrations over a period of 8 hours. This response is plotted in Figure 26 A, B, C 
as a function of chelator iron binding equivalents (ibe) vs. iron/protein.  In contrast to 
the findings at 4h, DFO mobilised cellular iron in a concentration dependent manner at 
8h (Figure 26 A, B). Iron mobilization with DFX (Figure 26 A, C) or DFP (Figure 26 
B, C) was greater than monotherapy at 4h and showed concentration dependence.   
There was a significant reduction in intracellular iron, with increasing concentrations of 
each one of the chelators while the other chelator was kept constant. Statistical analysis 
of the curves in Figure 26 A, B, C using non-linear regression analysis was performed, 
and it was demonstrated, similarly to hepatocytes, that small increments of one chelator 
in cardiomyocytes were sufficient to elicit statistically significant chelation effects for 
the combination as a whole, and were detected well above the sensitivity of our assay.  
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Figure 26 Treatment of H9C2 cells with a combination of (A) DFO and DFX, (B) DFO and DFP 
and (C) DFP and DFX for 8 hours. Cells were loaded with iron, treated with chelators and intracellular 
iron/protein determined as in Figure 25. 
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4.5 Differentiation of synergy vs. additivity of chelator combinations using 
isobolograms 
The issue of synergy vs. additivity was further addressed by the use of isobolograms. 
Two drugs with similar actions can sometimes produce an exaggerated or diminished 
effect when used in combination. As discussed in the methods section, the isobologram 
is a mathematical model used to distinguish between synergistic, additive or sub-
additive response of drug combinations (Tallarida, 2006) where rectangular coordinates 
of dose combinations (a,b) that produce the same chosen effect level are shown; in this 
case 50% of the maximum response.  Figure 9 in the methods section shows the classic 
isobologram plot a straight line of additivity connecting the x and y-intercepts that 
represent the IC50 values of each chelator monotherapy. This line is the reference for 
distinguishing additive from synergistic or sub-additive interactions.  
 
Figure 27 shows the isobolograms for combinations of the three commercially used 
chelators for a 50% chelation effect (defined as half maximal of the total chelatable 
cellular iron pool). The cells were iron loaded with serial media changes and treated 
with chelators for 8 hours. The axis intercepts represent the IC50 for each chelator in 
this cell type when used in isolation (i.e., the potency; e.g., 12.5μΜ ibe for DFX). The 
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straight line of the isobologram connecting these intercept points is known as the line 
of potential additivity. This straight line represents the locus of all such dose pairs, 
which based on their known potencies, should give the same 50% chelation effect when 
used in combination.  In all three cases, when the commercially available chelators were 
combined, a curved response was produced below the line of additivity, indicating a 
synergistic action. 
 
Figure 28 presents the isobolograms constructed for the combinations of the three 
commercially used chelators in H9C2 cells. These were constructed once again for the 
50% chelation effect (half maximal of the chelatable iron pool) following 8 hours of 
chelator treatment; the axis intercepts again represent the IC50 for each chelator 
compound when used in isolation (i.e., the potency; e.g., 25μΜ ibe for DFX).  Similarly 
to hepatocytes, in all three cases, combined use of chelators produce a curved response 
below the line of additivity, indicating synergism. The degree of synergism in both 
hepatocytes and cardiomyocytes is further examined below by looking at the synergy 
index α, combination index, and dose reduction index. 
 
 
  
Figure 27 Commercial chelator combination isobolograms in HuH7 cells. 
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4.6 Indexes of synergy with the three combinations 
4.6.1 Synergy Index α 
This index is an indication of how much the obtained effect exceeds that expected by 
additivity of the two compounds. To further quantify this effect we looked at the 
synergy index α, which is equivalent to  (1 − 1/) 	 100  where R = difference of area 
under the line and area under the curve of the isobologram. This index has been 
previously used to further examine synergy(Tallarida, 2001), and was derived using 
data generated from the program ‘Prism 5’ which was used to create the isobolograms. 
It was noted that when DFX and DFO are combined, 37% of the chelation effect is due 
to synergy in cardiomyocytes vs 56% in hepatocytes. In the DFP-DFO combination, 
47.4 % of the total effect was due to synergy in hepatocytes vs 54.1% in 
cardiomyocytes. Most interestingly, in both hepatocytes and cardiomyocytes the 
synergistic effect is even greater, at 51.5% and 63% respectively in the case of the two 
oral chelators DFP and DFX when in combination (Figure 29).    
Figure 28 Commercial chelator combination isobolograms in H9C2 cells. 
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Figure 29 Synergy Index ‘α’ for the combination treatment of commercially available chelators in 
hepatocyte (HuH7) and cardiomyocyte (H9C2) cells. 
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4.6.2 Combination index 
This data above showing synergistic action of chelators is supported by analysis of the 
combination effects in cardiomyocytes and hepatocytes using the software calcusyn 2.1 
purchased from www.biosoft.com (2016a). This software was used to provide a 
combination index 'CI' for each chelator set. A CI < 1 indicates synergy while a CI > 1 
indicates antagonism. Thus, the lower the CI value <1, the greater the synergistic effect. 
The CIs for a 20% (ED20), 30% (ED30) and a 50% (ED50) effect are shown in Table 
7 for cardiomyocytes and Table 8 for hepatocytes. The combination with the lowest CI 
and hence greatest synergy is DFP plus DFX, in both cell types. It was once again 
indicated that the most synergistic pair was the combination of the two oral chelators 
DFP and DFX with a CI of 0.26 in cardiomyocytes (Table 7) and 0.38 in hepatocytes 
(Table 8).  
 
Table 7 Combination Indices of chelators in cardiomyocytes (H9C2). 
 
Chelator 
Combination 
Combination Index (CI) 
 
ED
20
 ED
30
 ED
50                          
R (each 
combination fit) 
DFO + DFX          0.87 0.62 0.29 0.94 
DFO + DFP          0.98 0.71 0.31 0.88 
DFX + DFP           0.79 0.58 0.26 0.91 
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Table 8   Combination indices of chelators in hepatocytes (HuH7). 
 
 
 
4.6.3 Dose reduction index 
To demonstrate how combined chelation could impact on the dose of a chelator required 
to achieve a given effect, a dose reduction index was calculated. Table 9 shows the dose 
reduction index (DRI) for all combinations of commercially used iron chelators in 
combination in hepatocytes. The dose reduction index (DRI) is a measure of the 
absolute dose reduction of one chelator required to produce a 50% of maximal chelation 
effect when the concentration of the other is increased. Looking at Table 9, for the 
combination of the two oral chelators, when DFP is added to DFX, the dose of DFX 
can be reduced by 3.8 fold when only 1μΜ ibe DFP is achieved in the blood. This 
suggests that the typical dose of 25mg/kg/day of DFX can be reduced to about 
5mg/kg/day if DFP is added to the regime, achieving the concentration shown in column 
3 of Table 9. We further proceeded to analyse the DFP/DFX combination of the two 
oral chelators in cardiomyocytes (Table 10). In this cell line, we also calculated what 
reduction in oral dose of DFX this combination corresponds to, given that a once daily 
dosing regimen of 20mg/kg of DFX leads to trough plasma levels of 20μΜ (Galanello 
et al, 2006). It can be seen that the presence of 10μΜ DFP can reduce the dose of DFX 
required to produce a 50% of the maximal chelation effect by 23.9 mg/kg.  This 
concentration of DFP is clinically achievable (Bellanti et al, 2014; Limenta et al, 
2011a). 
These three indexes provide novel evidence to suggest that combined use of DFP and 
DFX will be particularly effective at mobilising cellular iron.  
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Table 9 Chelator DRI in hepatocytes (HuH7). 
Chelator 
Combination 
Dose 
Reduction 
Index (DRI) of 
sink chelator 
Shuttle Chelator 
Concentration (μΜ 
ibe) when in 
combination 
Sink Chelator 
Concentration (μΜ 
ibe) when in 
combination 
DFO + DFX 3.2 (DFO) DFX    1.8μΜ ibe DFO   5μΜ ibe 
DFO + DFP 2.8 (DFO) DFP   1.2μΜ ibe DFO 5.7μΜ ibe 
DFX + DFP 3.8 (DFX) DFP   0.9μΜ ibe DFX 3.4μΜ ibe 
 
Table 10 Chelator Dose reduction in cardiomyocytes (H9C2). 
 
4.7 Insights into synergistic mechanisms using the hydroxypyridinones CP40 
and CP44 as probes 
The highly hydrophilic bidentate hydrypyridinine chelators CP40 and CP44 were used 
to probe the mechanism of combined chelator actions because they have previously 
been shown to mobilise no iron from hepatocytes or in iron-overloaded mice. This is 
due to low lipid solubility relative to the closely related DFP and consequent inability 
DFP 
Concentration 
(μΜ ibe) 
DFX Chelator 
Concentration (μΜ 
ibe) required when in 
combination with 
DFP to achieve a 
50% effect 
DRI: (DFX dose 
in combination 
required to 
achieve 50% 
effect) 
Reduction of oral dose 
of DFX required to 
achieve  50% chelation 
effect in the presence 
of DFP 
0 25.1 - 
 
1 10.0 15.1 15.1 mg/kg 
5 7.2 17.9 17.9 mg/kg 
10 1.2 23.9 23.9 mg/kg 
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to penetrate the cell membrane (Porter et al, 1988) (Porter et al, 1990).  In Figure 21 
and Figure 32, it can be seen that, in contrast to DFO, CP40 and CP44 do not enhance 
cellular iron removal confirming previous observations in primary hepatocytes (Porter 
et al, 1990).  When CP40 100μΜ was combined with DFO, no increased iron release 
was observed over that seen with DFO alone over an 8 hour period in hepatocytes 
(Figure 30). When CP40 was combined with DFP or DFX however, a small increase 
in cellular iron removal was seen.   This provides mechanistic insight into how 
combinations of chelators interact. Firstly it supports the concept that the role of DFO 
in combined therapy is to act as an acceptor or ‘sink’ for iron(III). DFO can only act as 
an acceptor for iron(III) due to its hexadentate structure and high pM (Table 6, Figure 
24). Thus because CP40 has very little access to intracellular iron when used alone, it 
cannot act as an intracellular iron shuttle onto DFO.  As the properties of CP40 are 
similar to DFP, these observations also support the notion that the additional iron 
mobilisation seen when DFP when combined with DFO is to shuttle intracellular iron 
onto DFO, which is predominantly extracellular, particularly at short time intervals.   
 
The small increase in cellular iron mobilisation observed when CP40 100μΜ was 
combined with DFX 10μΜ ibe Figure 30 is likely due to an increase in the ‘sink’ total 
concentration in the extracellular medium. Consideration of the speciation plots in 
Figure 24 for DFP (which has similar iron binding properties to CP40) suggests that at 
30µM DFP and 30µM DFX, about 20% of the iron(III) will bind to DFP (and hence 
CP40) rather than DFX. The small increase in iron mobilisation when CP40 is added to 
DFP is also consistent with an increase in the concentration of ‘sink’ chelation in the 
extracellular medium. Here DFP can act as an intracellular shuttle onto CP40, which 
remains exclusively extracellular.  
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Figure 30 Treatment of chelator monotherapy combined with CP40 for 8 hours in HuH7 cells. Cells 
were loaded with iron, treated with chelators and intracellular iron/protein determined as in Figure 25. 
 
4.8 Discussion 
The findings with chelator monotherapies provide a framework for understanding the 
potential effects for combined pairs of chelators. This system was developed using the 
cardiomyocyte cell line H9C2 and the hepatocyte cell line HuH7. It was developed 
because heart failure secondary to iron overload is the main cause of death in 
transfusional iron overload.  This system has the advantage of measuring total cellular 
iron and does not require radioactive tracers.  In this system, all three clinically available 
chelators are effective as monotherapy at cellular iron mobilisation and at clinically 
relevant concentrations. However, very little cellular iron removal is seen with DFO 
before 4 hours which is consistent with previous reports of slower access of DFO to 
intracellular iron than that with DFP or other hydroxypyridinones (Cooper et al, 1996; 
Hoyes & Porter, 1993) and is attributable to the relatively low lipid solubility of DFO 
and its larger size than DFP (Porter et al, 2005).   Furthermore, the iron complex of DFO 
is slow to egress from cells (Cooper et al, 1996; Hoyes & Porter, 1993) due to its 
positive charge and low lipid solubility (Cooper et al, 1996) (Porter et al, 2005).  As 
with previous studies, the highly hydrophilic chelators CP40 and CP46, which in other 
aspects of chelation are similar in their iron binding properties to DFP, were found to 
have no effect on iron release when used as monotherapies (Porter et al, 1988) (Dobbin 
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et al, 1993). This has been previously attributed to the necessity of chelators to access 
intracellular iron directly by transiting the cell membrane in the iron free and complexed 
states.  
 
For paired combinations of these three clinically licensed chelators, our findings are 
consistent with synergistic interaction and to our knowledge, this is the first attempt 
made to formally distinguish between synergy and additivity of these commercially 
used chelators.  Concentrations of chelators for these experiments were chosen to be 
clinically relevant.  The conclusion of synergy is based firstly on the shapes of 
isobologram plots using established general methods for comparing drug interactions 
(Tallarida, 2006). Secondly, this is supported by the results with the combination index, 
which is a computed method designed to assess interactions of pairs of drugs. This is 
further supported by the synergy index findings derived from the isobolograms. In all 
three analyses, the combination of DFX and DFP shows greater effects than the other 
combinations at 8 hours, although all combinations appear synergistic.    
Our overall results suggest that the mechanisms and consequences of chelator 
interaction depend on their relative concentrations, their iron binding affinities, and their 
ability to access intracellular iron pools directly. At least one of the paired chelators 
needs to enter cells and exit bound to iron for synergistic interaction to take place. 
Synergism with DFO and DFP combinations is consistent with rapid access of DFP to 
intracellular iron and the subsequent donation of iron(III) to DFO, the latter providing 
a predominantly extracellular sink for chelated iron. This mechanism has been 
previously demonstrated for NTBI in a cell-free system where DFP can access some 
NTBI species more rapidly than DFO (Evans et al, 2010).  DFP by virtue of its low 
molecular weight, neutral charge and lack of extreme hydrophilicity can enter cells and 
exit rapidly as the iron complex. Additionally, it has more rapid access to iron pools 
within (Hoyes & Porter, 1993) (Porter et al, 2005)  (Glickstein et al, 2005)  (Glickstein 
et al, 2006) and outside cells (Evans et al, 2010) more rapidly than DFO and is thus an 
ideal molecule for shuttling purposes.  Inspection of speciation plots shows that at 
equilibrium, iron is ultimately destined to binding to DFO when paired with DFP.  
 
The synergism seen when DFX is combined with DFO  depends firstly on the faster 
access to cellular iron of DFX than DFO and then the faster rate of egress of iron-chelate 
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complex of DFX. For synergism to occur, this chelated cellular iron then needs to be 
donated to DFO extracellularly. The higher lipid solubility and lower molecular weight 
of DFX compared with DFO is predicted to allow faster access to intracellular iron, and 
this is shown in the monotherapy experiments. The subsequent donation of chelated 
iron to DFO is consistent with the speciation plots and iron binding stoichiometry of 
these two chelators. Because of the hexadentate iron binding of DFO, the iron 
complexes are highly stable at neutral pH and will not act as an iron ‘shuttle’. However 
because of it’s tridentate 2:1 stoichiometry, the iron complex of DFX is less 
thermodynamically stable than iron complexes of DFO and hence some or all of the 
iron chelated by DFX (depending on relative concentrations) is donated onto DFO.  This 
provides the circumstances for shuttling and hence for synergy with this combination. 
Nevertheless, the speciation plots suggest that within cells DFX may compete to some 
extent for iron binding with DFO when DFX concentrations exceed about 10µM.  
However, the main mechanism for the observed synergy is for DFO to provide an 
extracellular sink as an acceptor for some or all of the iron rapidly chelated by DFX, 
subsequently freeing DFX to shuttle back for further rounds of intracellular chelation. 
 
Closely looking at the synergistic action of DFP when combined with DFX it is evident 
that this is more complex because both chelators can rapidly access intracellular iron 
and both are able to act as either shuttles or sinks for iron(III), depending on their 
relative concentrations. These orally absorbed chelators can access cellular iron 
including the cytosol and organelles much faster than the larger parenterally 
administered DFO  (Hoyes & Porter, 1993) (Porter et al, 2005)  (Glickstein et al, 2005)  
(Glickstein et al, 2006), due to their lower molecular weight they have relatively higher 
lipid solubility.  The monotherapy data in Figure 20 shows that DFX monotherapy 
gains sufficient intracellular access to mobilise iron with similar kinetics to DFP.  
Consideration of speciation plots shows that the propensity of the two chelators to act 
as ‘shuttles’ or ‘sinks’ for iron(III) will depend on their relative concentrations over 
clinically relevant ranges: depending on when the last dose of each chelator was taken, 
relative concentrations can favor either chelator as a shuttle or sink. For example,  over 
typical ranges seen clinically with DFX (20-60µM), speciation plots suggest that DFX 
will act more as a ‘sink’ for iron chelated by DFP except at peak concentrations of DFP 
(100µM) where this molecule will compete with DFX.  The speciation analysis does 
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not take into account the rates of access or the compartmentalisation of chelatable 
cellular iron and it is possible that DFP can access additional intracellular iron pools 
that are only slowly available to DFX (Glickstein et al, 2005)  (Glickstein et al, 2006).   
 
The findings with CP40 and CP46 provide further mechanistic insight into the actions 
of DFP is combination therapy, particularly when DFP is combined with DFX.  Even 
though CP40 and CP46 cannot gain access to intracellular iron when used alone (Figure 
21), when combined with a chelator that can shuttle iron (DFX or DFP but not DFO) 
they increase cellular iron release (Figure 32). Speciation plots suggest for CP40 or 
CP46 (not shown, generated by R. Hider, King’s College London, and are very similar 
to DFP) that CP40 and CP46 have the potential to contribute to an extracellular sink for 
iron chelated by DFX.  For example at 20µM DFX, even at low concentrations of a 
hydroxypyridinone (10µM) about 10% of iron(III) will be bound to a 
hydroxypyridinone (Figure 24 C). Furthermore, at 100µM about 40% of the iron will 
bind to the hydroxypyridinone thereby effectively increasing the ‘sink’ chelator 
concentration. This extracellular ‘sink’ effect for CP40 and CP46 will also be seen with 
DFP when combined with DFX.  Hence when combined with DFX, DFP has the 
potential to act both as a shuttle and a sink for iron(III). This may contribute to this 
combination being particularly effective. 
 
In summary, these findings suggest that all three licenced chelators can act 
synergistically when their use is combined but that the combination of DFP with DFX 
is likely to be the most potent one. The presence of the clinically achievable 10μΜ DFP 
can lead to a reduction of 23.9 mg/kg of the daily dose of DFX to produce a 50% 
chelation effect. Further well-controlled clinical trials that also examine the safety of 
this combination are warranted.   
4.9 Conclusion 
In hepatocytes as well as cardiomyocytes, all combinations showed synergistic cellular 
iron mobilisation at 8h with clinically achievable concentrations of the ‘sink’ chelator 
and ‘shuttle’ chelator. The greatest synergism was achieved by combining DFP with 
DFX, where about 60 and 65% of the mobilised iron was attributable to synergistic 
interaction in hepatocytes and cardiomyocytes respectively. Our findings predict that 
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the dose of DFX had to be reduced by 3.8 fold to produce a half-maximal effect when 
the concentration of DFP is just 1μΜ in hepatocytes. Furthermore, It was noted that the 
presence of 5μΜ DFP could reduce the dose of DFX required to produce a 50% of the 
maximal chelation effect by 17.9 mg/kg in cardiomyocytes.  This concentration of DFP 
is clinically achievable (Limenta et al, 2011a). Mechanisms for the synergy have been 
suggested by consideringg the iron-chelate speciation plots in conjunction with the size, 
charge and lipid solubilities for each chelator molecule.  Hydroxypyridinones CP40 and 
CP 44 with low lipid solubilities but otherwise similar properties to DFP were used to 
validate the assay.  These studies confirm that for synergistic cellular iron mobilisation, 
one chelator must have the physicochemical properties to enter cells, chelate 
intracellular iron and subsequently donate iron to a second ‘sink’ chelator.   
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Chapter 5 ELTROMBOPAG IS A POWERFUL CHELATOR OF 
IRON(III), THAT MOBILISES INTRACELLULAR STORAGE 
IRON ALONE OR IN COMBINATION WITH CLINICALLY 
ESTABLISHED CHELATORS. 
5.1 Introduction 
Eltrombopag (ELT) is a thrombopoietin receptor agonist that also decreases labile 
intracellular iron.  Here we examine the previously undescribed iron(III) co-ordinating 
and cellular iron mobilising properties of ELT.  Clinically achievable concentrations 
(1µM) mobilised total iron from hepatocyte and cardiomyocyte cell lines, while also 
rapidly decreasing intracellular reactive oxygen species (ROS). Decrements in cellular 
ferritin accounted for the majority of cellular iron removal, particularly in hepatocytes.  
Intracellular iron mobilisation by ELT was inhibited by free extracellular iron present 
in culture media but not by fresh human serum.  Iron mobilisation from cardiomyocytes 
exceeded that obtained with deferiprone, desferrioxamine or deferasirox.  When 
combined with these, ELT increased iron mobilisation 4-6 fold above single agent 
chelators. A synergistic mechanism, with ELT acting as a 'shuttle', is suggested by 
enhanced iron mobilisation when combined with the otherwise ineffective 
hydroxypyridinone, CP40. The high iron(III) binding constant (Log  β2 34.9) and 
speciation plots, demonstrate equilibrium binding consistent with synergistic iron 
shuttling when combined with these chelators. ELT is a powerful intracellular iron 
chelator that decreases storage iron and also enhances iron removal with other chelators.  
In clinical use, donation of chelated iron by ELT to these chelators offers established 
routes for elimination of chelated iron.  
ELT is an orally bioavailable small molecule approved for the treatment of Idiopathic 
Thrombocytopaenia (ITP) and thrombocytopaenia associated with chronic hepatitis C. 
An under appreciated property of ELT is its binding to metal irons and in particular to 
iron(III).  It was reported that oral consumption of ELT with calcium, aluminium, and 
magnesium containing foods reduced absorption of these metals (Williams et al, 2009; 
Wire et al, 2012) and it was suggested that this could be due to chelation of metal ions 
(Williams et al, 2009).   ELT has also been found to decrease labile iron within leukemia 
cells (Roth et al, 2012) and in principle, iron chelating properties of ELT may be 
relevant to antiproliferative and apoptotic effects in acute myeloid leukemia (AML) 
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(Roth et al, 2012) (Kalota et al, 2015) as well as its role in the treatment of hepatocellular 
carcinoma (Kurokawa et al, 2015).  Some of the beneficial effects on haematopoiesis in 
MDS (Svensson et al, 2014) and aplastic anaemia (Leitch & Vickars, 2009) could also 
derive from an iron chelating mechanism.  Preliminary findings by our group suggested 
that ELT at low concentrations could effectively mobilise iron from cardiomyocytes in 
culture (Vlachodimitropoulou et al, 2014) (Vlachodimitropoulou et al, 2015).  However 
remarkably little is known about the iron binding properties of ELT.  These unknowns 
include the iron coordination mechanism, iron(III) binding constant, effects on iron-
induced ROS, effects on storage iron, relative interaction with different cell types and 
mechanisms of interaction with other iron chelators.    
Here we have characterised the iron chelating properties of ELT in a cell-free system as 
well as in cell lines of two key cell types that are targets for iron overload, namely 
hepatocytes and cardiomyocytes.  We have examined the ability of ELT to chelate 
cellular storage iron and to diminish intracellular ROS. An ability of ELT to act in 
concert with other chelators, by donating chelated iron to such molecules, could be 
important for the efficient elimination of chelated iron in urine or faeces because it is 
not known whether and how iron complexes of ELT would be eliminated. We have 
therefore also examined the ability and conditions under which ELT can shuttle iron out 
of cells and onto clinically licensed iron chelators. 
5.2 Material and methods 
5.2.1 The cellular model 
 The rat cardiomyocyte cell line (H9C2) and a human hepatocarcinoma (HuH7) 
cell line were chosen for investigation. Cardiomyocytes are a target tissue for 
transfusional iron overload and provide a particular therapeutic challenge. Hepatocytes 
represent the cell type with the largest quantity of iron deposition.  HuH7 or H9C2 cells 
were plated at 200 000 cells/well in RPMI 1640 medium/DMEM supplemented with 
10% fetal bovine serum (FBS). Cells were treated with DMEM media containing 10% 
FBS for one or two 10- hour periods and rinsed four times, including one wash 
containing DFO at 30µM ibe and 3 x PBS washes. The cells were then lysed with 
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200mM NaOH.  Intracellular iron concentration was determined using the ferrozine 
assay and adjusted for cellular protein (Vlachodimitropoulou Koumoutsea et al, 2015).  
5.2.2 Cell damage and viability  
Viability has a critical influence on cellular iron release (Porter et al, 1988), and >98% 
was achieved in all reported experiments. Viability was assessed using the ‘LDH 
Cytotoxicity Detection Kit’ by Takara Bio Inc, which gives a quantitative comparison 
of early cell damage between ‘treatment’ and ‘control.' This is a colorimetric assay and 
measures LDH activity leaked by damaged cells into the supernatant (W.J. Reeves Jr., 
1966). 
5.2.3 Determination of Intracellular Iron – The Ferrozine Assay 
Cells were lysed overnight with 200μl of 200 mmol/l NaOH. Τhe ferrozine assay (on 
190μl aliquots) was performed as previously described (Riemer et al, 2004) as well as 
in the methods Section 2.3.5.  In brief, An aliquot (120 μl) of iron detection reagent was 
added for 30 min. Absorbance was recorded at 562 nm and lysate iron content calculated 
by standard curve interpolation against atomic absorption iron standards. Intracellular 
iron was normalized against protein content.  
5.2.4 Protein assay 
The Coomassie (Bradford) protocol was used to determine cellular protein. Briefly, 
250μl of Bradford reagent were added to 5μl of cell lysate and absorbance recorded at 
595 nm. 
5.2.5 Detection of Reactive Oxygen Species using a fluorimetric method 
To monitor the intracellular ROS, we utilised a cell-permeable oxidation-sensitive 
fluorescent probe 5,6-carboxy-2’,7’- dichlorofluoresceindiacetate (DCFH-DA); 
(Molecular Probes, Leiden, Netherlands) as previously described. Nonfluorescent 
DCFH-DA, hydrolyzed to DCFH inside of cells, yields highly fluorescent DCF in the 
presence of intracellular hydrogen peroxide (H2O2). Therefore, the dichlorofluroescein 
(DCF) fluorescence intensity is proportional to the amount of intracellular ROS. Cells 
in Corning 24-well plates (Sigma-Aldrich, MA, USA) were preincubated with 4 mM 
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H2DCF-DA for 30 minutes at 37°C as per protocol. Chelators were then added, and the 
plate placed into the plate reader where fluorescence was recorded over a period of 1 
hour (excitation at 504 nm, emission at 526 nm). The time between the addition of 
chelators and commencing ROS level recording was between 3 and 5 minutes at room 
temperature. The rate of ROS production was compared between chelator treated and 
untreated cells.   
5.2.6 Ferritin Quantification 
Human and rat tissue ferritin were measured using commercially available enzyme-
linked immunosorbent assay (ELISA) kits (Cusabio, Wuhan, China and My BioSource, 
San Diego, USA respectively) according to the instructions provided by the 
manufacturer for recording ferritin of cell lysates. 
5.2.7 NTBI iron content of FBS, albumin, and human plasma 
This was kindly performed by Dr. Garbowkski at UCL Cancer Institute, London. Free 
iron in media or sera (NTBI) was quantified as previously described (Gosriwatana et al, 
1999) with slight modifications. On the day of the assay centrifugal filters (Modified 
PES 30K, 500µL low protein binding, VWR) were washed with 10mM NTA (200µL) 
and spun at 20300g for 10 min at 4°C followed by 2 rinses with 400µL HPLC-grade 
water and vacuum-aspirated till dry. Then 180µL serum was added in duplicate 
followed by admixture of 20µL 800mM NTA (containing 20µM Fe). This was left to 
equilibrate at 22°C for exactly 30 minutes; thereafter the ultrafilters were centrifuged at 
20300g for 60 min at 4°C. Clear ultrafiltrate (about 180µL) was recovered and where it 
was yellow (indicating a breach of the membrane), the samples were redone. 100µL of 
unknowns or standards, 100µL 5mM chelexed MOPS pH 7.4, 50µL of 1:1 v/v mixture 
of 60mM BPT (bathophenanthroline disulphonic acid, or 4,7-Diphenyl-1, 10-
phenanthrolinedisulphonic acid, disodium salt, Sigma) and 120mM TGA (thioglycolic 
acid or mercaptoacetic acid, Sigma) were added to an acid-washed 96-well plate and 
incubated on a shaker for 30 minutes to allow BPT-Fe complex formation and colour 
development. Standards were prepared using AA ferric chloride in 80mM NTA (0-
20µM f.c.). Absorbance was recorded at 537 nm. The 800mM NTA solution used to 
treat the samples and prepare the standards is treated with up to 20μM iron to normalise 
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the background iron that contaminates reagents. This means that the zero standard gives 
a positive signal since it contains the added background iron as an NTA–complex. Free 
iron content of media in µM were as follows: water 0.12±0.1, RPMI 0.57±0.4, 10% 
FBS RPMI 0.29±0.05 (100%FBS 3.31±0.23, 40g/L rHSA (recombinant human serum 
albumin) in RPMI (without FBS) 0.79±0.15, normal human serum NTBI -1.7±0.12. 
5.2.8 Spectrophotometric method for pKa and iron stability constant 
measurements 
This was kindly performed by Dr. Chen under the direction of Prof. Hider at King’s 
College London. An automated titration system (Ma et al, 2014) was utilised under the 
conditions of constant temperature at 25°C and constant ionic strength at 0.1 M, using 
0.1 M KCl, 0.1 M HCl, and 0.1 M KOH. The pH electrodes were calibrated using the 
GLEE program (2016c; Gans & O'Sullivan, 2000). The titration data were analysed 
using the pHab program (2016c). Species plots were calculated using the HYSS 
program (Alderighi et al, 2016). Analytical grade reagent materials were used in the 
preparation of all solutions.  
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5.3 Results 
5.3.1 ELT effectively decreases hepatocellular and myocardial iron 
The cellular iron release was studied in iron loaded HuH7 hepatocyte-like cells and the 
H9C2 cardiomyocyte cell line using a protocol developed by our group to investigate 
other chelators (Vlachodimitropoulou Koumoutsea et al, 2015). The ELT 
concentrations used for these experiments were informed by reported Cmax plasma 
values achieved clinically after oral ELT administration at 30, 50, and 75 mg/day in 
patients with ITP which correspond to blood plasma levels of 8, 18, and 28 μΜ, 
respectively (Gibiansky et al, 2011). As we wished to identify the lowest concentration 
of ELT that would induce effective cellular iron mobilisation, initial experiments were 
performed at 10µM ELT, but subsequently, concentrations as low as 1µM were used.  
Based on the predominant 2:1 binding of ELT to iron(III) identified in this paper 
(Figure 31, Table 11), ELT  has an iron binding equivalent (ibe) of 0.5µM.   Following 
8 hours of ELT treatment in HuH7 cells, intracellular iron was decreased in a dose-
dependent manner with significant iron removal at clinically achievable concentrations 
(Figure 32 A).  In cardiomyocytes, a time course showed iron mobilisation by as little 
as 1μΜ ELT at only 1hour (Figure 32 B). In Table 12, iron mobilisation by 1µM ELT 
at 8h as a single agent is compared with DFP, DFO and DFX as single agents at 1µM 
ibe. It can be seen that in cardiomyocytes ELT mobilises more iron at 8h than DFO, 
DFX or DFP. In hepatocytes at this low ELT concentration, iron mobilisation is less 
effective. For reasons discussed in detail below, this is likely to reflect greater 
metabolism of ELT within HuH7 cell than H9C2 cells, and the effects of metabolism 
are more likely to be identified at low chelator concentrations.  However, this relatively 
low iron mobilisation in hepatocytes can be overcome at higher concentrations (Figure 
32 A). 
As the viability of cells may influence cellular iron release, independently of the 
chelation mechanism, experiments were therefore only performed where baseline 
viability exceeded > 98%, as assessed by the LDH assay described in the methods 
section. Hepatocytes showed no signs of toxicity following 8 hours of ELT treatment at 
concentrations up to 30μΜ (Figure 33 A). By contrast cardiomyocyte viability after 8 
hours of exposure to 30μΜ ELT was compromised to 93% (Figure 33 B). Thus some 
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effects of iron release in cardiomyocytes noted in Figure 32 B by ELT at concentrations 
of 30µM could be partially attributed to toxicity of the drug on the monolayer.  Such 
effects are not seen at 1µM and 10μΜ.  
 
 
  
  
Figure 31 Structure of Eltrombopag and its iron complex. The free ligand possesses 2 tautomers (1 and 2).   Three 
iron(III) complexes have been identified 3 (FeELT), 4 (FeELT2H) and 5 (FeELT2)  
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Table 11 Comparison of the structure and iron binding properties of ELT and other chelators. The relative stabilities 
of iron(III) binding are represented by the pFe, where the pFe of a given chelator for iron(III) is the negative log of the 
uncoordinated metal concentration under defined conditions (Martell, 1981). The higher pFe values, the lower the 
concentration of uncoordinated iron(III) and hence the greater stability for the iron-chelate complex.  When pairs of chelators 
are combined in solution, iron(III) will bind preferentially to the chelator with the higher pFe value. This is highest for DFO 
and lowest for DFP, with DFX having an intermediate value. (Ihnat et al, 2002) (Motekaitis & Martell, 1991) (Nick et al, 
2002). 
 
 
 
Figure 32 Cellular iron release from hepatocyte HuH7 (A) or cardiomyocyte H9C2 cells (B) by ELT is shown as a 
function of ELT concentration. Cells were loaded with iron as described in methods.  Adherent cells were rinsed four times, 
including one wash containing DFO at 30µM ibe and 3 PBS washes, and subsequently exposed to ELT and other chelators 
for the times shown.  Chelator supernatants were then removed, and the cells washed four times as above before lysing with 
200mM NaOH.  Intracellular iron concentration was then determined using the ferrozine assay and normalised for total 
cellular protein in each well. Results shown are the mean ± SEM of 6 replicates in one experiment. 
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Figure 33 Hepatocyte HuH7 (A) and Cardiomyocyte H9C2 (B) cell viability following an 8-hour treatment 
with ELT. Following iron loading and chelator treatment as described in Figure 32, supernatants were removed 
and viability compared using the LDH assay as described in the methods section. 
 
 
 
 130 
5.3.2 ELT decreases intracellular ferritin  
We wished to understand whether the decrease in cellular iron seen above is 
predominantly due to mobilisation of storage iron (ferritin).  HuH7 cells and H9C2 cells 
were iron-loaded as described in the methods section above using two media changes 
containing 10% FBS. This increased tissue ferritin by 75% in hepatocytes and by 33% 
in cardiomyocytes (data not shown), and increased total cellular iron by 4 and 2.5 fold 
respectively. Cells were then treated with ELT for 8 hours and cellular ferritin assayed 
as described in methods. In HuH7, 10μΜ ELT achieved a decrease of 85% in tissue 
ferritin compared with 46% decrease in H9C2 cardiomyocytes (Figure 34).  In 
cardiomyocytes, there was a 46% reduction in ferritin with a 65% of total cellular iron.  
Thus chelation with ELT decreases both total cellular iron and cellular ferritin in both 
cell types with ferritin decrements being proportionately greater in HuH7 than H9C2 
cells. Evidently, therefore, hepatocyte ferritin is more responsive, both to iron loading 
and iron unloading than in cardiomyocytes, which is consistent with the known high 
iron storage capacity of hepatocytes compared with cardiomyocytes.   
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Table 12 Comparison of percentage of intracellular iron mobilised at 8h in a cardiomyocyte (H9C2) 
and a hepatocyte (HuH7) cell lines by clinically available chelators or ELT, alone (top panel) or in 
combination (lower panel). Chelator concentrations are expressed as iron binding equivalence (ibe). Cells 
were pre-loaded with iron, rinsed, incubated with chelators and cellular iron determined as described in Figure 
32. Results shown as the % iron released expressed as a % of T0 cellular iron and are the mean ± SEM of 4 
replicates in one experiment. 
 
 
Figure 34 Comparison of the effect of ELT on ferritin and total cellular iron mobilisation in 
hepatocyte HuH7 (A) and cardiomyocyte H9C2 cells (B) is shown.  
Following iron loading as described in the methods section, the cells were rinsed four times including 
one wash containing DFO at 30µM ibe and 3 PBS washes and subsequently exposed to ELT over an 8 
hour period. At the end of the incubation, the supernatant was removed, and the cells further washed four 
times as above. Iron content was assessed using the ferrozine assay as described in methods. Ferritin was 
quantified using commercially available ELISA kits appropriate for our rat and human cell lined, as 
described in methods. The results are the mean ± SEM of 3 replicates in one experiment. 
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5.3.3 ELT decreases ROS rapidly compared with other chelators 
Intracellular ROS generation by iron is predominantly determined by the concentration 
of the intracellular labile iron pool (Cabantchik, 2014). Unlike measurement of total 
cellular iron or ferritin iron, continuous real-time measurement of ROS is achievable, 
allowing insight into the kinetics of intracellular chelation.  A cell-permeable oxidation 
and hydrolysis sensitive fluorescent probe was used for this purpose as described in 
methods. After preloading cells with the non-fluorescent DCFH-DA (Molecular Probes, 
Leiden, Netherlands)  for 30 minutes at 370C, allowing time for commencement of 
hydrolysis to the highly fluorescent DCFH, chelators were added to each well and then 
placed into the plate reader where fluorescence was recorded over 1 hour at 37oC. The 
interval between addition of chelators and commencing ROS recording on the plate 
reader was between 3 and 5 minutes.  
 In Figure 35 it can be seen that the rate of ROS generation is decreased by ELT in 
HuH7 and H9C2 cells compared with control.  Even at the first measurable time-points, 
the fluorescence signal with ELT is less than control, suggesting very rapid entry of 
sufficient ELT to decrease ROS. It is also clear that inhibition of intracellular ROS 
generation by DFO is relatively slow and that DFP and DFX have intermediate effects 
on the rates of ROS generation.  In Figure 36 the relative inhibitory effects of different 
chelators on the rates of ROS generation are summarised for HuH7 and H9C2 cells. In 
these experiments 10µM ELT was used and 10µM iron binding equivalents of other 
chelators (except CP40 where 100µM (33μΜ ibe) was used).  It can be seen that the 
rate of ROS generation is inhibited with ELT by 73% in HuH7 and by 61% in H9C2 
cells, which is more than that obtained with other chelators, even though these were 
used at higher iron binding equivalents.  In Table 13, experiments are shown which 
were conducted at even lower chelator concentrations of ELT (1µM) with exposure for 
1hour. It can be seen that among the chelator monotherapies, ELT again has the greatest 
rate in decreasing ROS generation in both cell types studied.  The ROS decrease is 
similar in cardiomyocytes and hepatocytes, unlike effects of iron mobilization, which 
were greater in cardiomyocytes. This is consistent with rapid access of ELT to labile 
iron pools before significant metabolism has taken place in HuH7 as detailed in the 
discussion below.  
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Figure 36  Rate of ROS production following chelation treatmen in (A) HuH7 and (B) H9C2 cells. 
Rate of ROS generation determined as in Figure 35.  ROS rate inhibition at 1h with CP40, DFO, DFP, 
DFX, and ELT are shown at 10µM ibe for each chelator, 10µM ELT and 33µM ibe CP40. Results are the 
mean ± SEM of 4 observations in one experiment. 
 
 
Table 13 Comparison of ROS generation in cardiomyocyte (H9C2) and a hepatocyte (HuH7) cell lines 
is shown after addition of clinically available chelators or ELT, alone (top panel) or in combination 
(lower panel) over 90 minutes at the concentrations shown. Experimental design and determination of ROS 
is otherwise as described in Figure 5. Results are the mean ± SEM of 4 observations in one experiment. 
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5.3.4 Iron contamination in albumin or BSA inhibits cellular iron mobilisation 
by ELT 
Following reports that serum may inhibit the thrombopoietin agonist effects of ELT 
(Kalota et al, 2015), we reasoned that free iron contamination in media (unbound to 
transferrin) could be available for binding to ELT and that such binding might account 
for loss of action. We, therefore, investigated the inhibitory effects of several media or 
media supplements on cellular iron mobilisation by ELT.   
An inhibitory effect of serum (FBS) on the iron mobilisation properties of ELT was 
noted in HuH7 cells (Figure 38 A). This effect was greater with increasing %FBS 
concentrations in the media, leading to a 4 fold inhibition at 25% FBS (Figure 39 A). 
As 100% FBS contains 3.31±0.23µM of free iron (see methods), the concentration in 
25% FBS will be approximately 0.8µM and sufficient to partially inhibit 1µM ELT.  
However in order to ensure that the inhibition of ELT action was not secondary to 
protein binding, we examined the effects of recombinant albumin and fresh human 
serum on cellular iron mobilisation by ELT Recombinant human albumin at 40g/L in 
RPMI contained 0.79±0.15µM iron and inhibited iron mobilisation from HuH7 cells by 
10µM ELT (5µM ibe) by about 50% (Figure 38 B). By contrast, fresh human serum 
contained no measurable free iron (only transferrin bound iron), had negligible iron 
releasing properties of its own (about 2%) and also had no inhibitory effects on iron 
release by ELT (Figure 38 C).  We, therefore, conclude that inhibitory effects of sera 
and protein containing media on the iron mobilising effects of ELT are due to iron 
contamination in media and not from protein binding. These observations could also be 
important to studies where the thrombopoietin agonist effect of ELT is investigated.  
This is because 'free' iron contamination in media will lead to complexation of ELT by 
iron(III) (Figure 31) which is likely to abrogate interaction with the thrombopoietic 
receptor. In patients where plasma NTBI is present, higher concentrations of ELT may 
be needed than would be the case in patients lacking NTBI to induce iron cellular 
mobilisition or indeed effects resulting from binding to the thrombopoietin receptor.   
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5.3.5 Iron(III) binding and speciation plots for ELT alone or combined with 
other chelators 
In order to explain the observations in cell culture, we wished to formally establish the 
iron(III) binding properties of ELT in a cell-free system, as these have not been 
previously reported.  The approach for determining iron(III) binding is briefly described 
in methods. The normal chemical representation of ELT is presented in structure 1 
(Figure 31), this lacks a high-affinity iron(III) binding site. However, ELT can be 
represented as a mixture of two tautomers which are in K = 43.4 and K =
34.9 equilibrium with each other; the second tautomer 2 possesses a potential tridentate 
iron(III) binding site and is fully conjugated. Titration with iron(III) yielded three 
equilibrium constants, K = 25.6, K = 43.4 and K = 34.9; and ELT has 
three pKa values 2.6, 8.7, 11.1. Using this data, a pFe value of 22.0 was determined 
which is greater than that of deferiprone (20.4) and very similar to that of DFX (23.1). 
The speciation plot for iron(III)/ELT (Figure 37) indicates that a mixture of the 1:1 and 
2:1 complexes are present at pH 7.4. Significantly the 1:1 complex (3) possesses zero 
net charge and has a molecular weight lower than 500 and so like the deferiprone iron 
complex, the 1:1 ELT iron complex is predicted to readily permeate membranes. The 
pFe value for ELT as well as for DFO, DFX, and DFP is presented in Table 11. The 
pFe value is the negative log of the iron(III) concentration under defined conditions 
(1µM iron(III) and 10µM chelator) (Vlachodimitropoulou et al, 2015).  The pFe (pM) 
for ELT is 22.0, which is greater than that of DFP but less than that of DFX and DFO, 
the consequences of which are shown in Figure 39 as speciation plots of iron(III) (1µM) 
binding at increasing concentrations of ELT (1-10µM) in the presence of (a) DFO 1µM 
(b) DFP 3µM (c) DFX 2µM.  It can be seen in (a) that at equilibrium under these 
conditions, ELT will donate iron(III) to DFO over the entire range of ELT 
concentrations, with ELT acting as a shuttle and DFO as the sink for iron(III). By 
contrast, when combined with DFP (b), ELT will act as a sink for iron(III) when ELT 
concentrations exceed 1µM.  However, in (c) it can be seen that ELT, when in the 
presence of DFX (Exjade), can act as either a shuttle or a sink for iron(III) depending 
on the relative concentration of ELT and complexation to ELT will be favoured when 
ELT concentrations exceed 7µM. The exchange of iron(III) from the ELT FeL complex 
(3) to competing ligands is likely to be fast as only 3 iron coordination sites are occupied 
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by ELT. The remaining 3 sites are occupied by water (3) and will be readily available 
for displacement by strong iron chelating ligands. 
 
 
 
 
 
 
  
Figure 37 The speciation of iron(III) in the presence of ELT as a function of pH. [Fe]total=1μM; 
[ELT]total =10μΜ. (Kind donation of Professor Hider, King’s College London). 
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Figure 39 The effect of serum and albumin on the iron mobilisation by ELT is shown in HuH7 cells. Following 
iron loading and rising as described above cells were subsequently exposed to ELT at 30 μΜ in RPMI over an 8 hour 
period with media containing (A) increasing concentrations of FBS (0-25%): (B)  Recombinant Human Albumin 
(rHSA) (Sigma) (C) heat-inactivated human serum (see methods). Cellular iron content at 8h was determined as 
described above. Results are mean +/- SEM of 4 observations in one experiment. 
 
 
 
 
Figure 38 The proportions of ELT species bound to iron(III) at equilibrium, with increasing ELT 
concentrations, in the presence of (a) 1µM DFO,) (b) 3µM DFP, (c) 2µM DFX. Proportions are calculated from 
the iron binding constants for iron chelate complexes of the respective chelators shown in Table 11. (Kind donation 
of Professor Hider, King’s College London). 
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5.3.6 Combination of ELT with clinically available chelators enhances iron 
mobilisation  
The relative effects of chelator combinations with ELT on cellular iron removal are 
shown in Table 12 for the two cell lines.  Findings are consistent with the predictions 
from speciation plots shown above. Thus when ELT at just 1μΜ is combined with DFO, 
DFP, and DFX at 1µM ibe, iron mobilisation is between 4 and 6 times greater than 
monotherapy of commercially available chelators.  In both cell lines, the most effective 
combination appeared to be that of ELT and the orally available chelator DFX. Based 
on speciation plots in Figure 39, the mechanism for enhanced iron mobilisation is 
predicted to be the shuttling of iron(III) between chelators.  Under the conditions of 
these experiments at 1µM ibe of these clinically available chelators, the speciation plots 
predict that ELT will behave as iron(III) shuttle to these chelators acting as sinks. Under 
the conditions used in Table 12, DFP is predicted from speciation plots to be a less 
effective sink chelator than DFX, which could explain the lower efficacy of this 
combination. However at transient peak concentrations of DFP reported clinically of 
approximately 100µM will have significant 'sink' effect. Iron release observed in Table 
12 when ELT is combined with DFO is consistent with speciation data in Figure 39 A 
which predicts that DFO will be an effective sink for iron(III) forming ferrioxamine 
(FO) when combined with ELT. The reason that ELT is less effective in combination 
with DFO than DFX is most likely related to slow rates of access of DFO to intracellular 
iron (Hoyes & Porter, 1993) and slow egress of intracellular FO from cells (Cooper et 
al, 1996) as previously described.  
5.3.7 Synergistic chelation of ELT combined with otherwise ineffective 
hydroxypyridinone CP40 
In order to demonstrate synergistic iron chelation when ELT is combined with a second 
chelator, we examined a hydroxypyridone chelator with a high iron binding constant 
that is ineffective at mobilising cellular iron due to its inability to permeate cell 
membranes (Porter et al, 1988; Porter et al, 1990).  In Figure 40, it can be seen that 
CP40 alone does not enhance cellular iron removal, confirming previous observations 
in primary hepatocytes (Porter et al, 1988; Porter et al, 1990). When CP40 was 
combined with ELT, however, an increase in cellular iron removal was seen, greater 
than with ELT alone.  This provides mechanistic insight into how combinations of 
 140 
commercial chelators with ELT interact. Firstly it supports the concept that the role of 
ELT in combined therapy is its potential to act as an iron shuttle. In monotherapy, CP40 
has very little access to intracellular iron and thus it cannot act as an intracellular iron 
shuttle but can act as a passive extracellular acceptor of iron when delivered by another 
chelator.  The increase in cellular iron mobilisation observed when CP40 33μΜ ibe was 
combined with ELT 3μΜ is likely due to an increase in the ‘sink’ availability in the 
extracellular medium as described for other chelator combinations (6). Here, therefore, 
ELT can shuttle iron intracellularly onto CP40, which remains exclusively extracellular.  
 
Figure 40 Cellular iron retention mobilisation is shown in previously iron loaded HuH7 cells, after 
8 hours of exposure to ELT 3μΜ and/or CP40 33μΜ ibe as single agents and combination over an 
8 hour period. Chelator supernatants were then removed and cellular iron determined as described above.  
Results are the mean ± SEM of 4 replicates in one experiment. 
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5.4 Discussion 
In this paper, we have demonstrated progressive removal of total cellular iron by ELT 
in both cardiomyocyte (H9C2) and hepatocyte (HuH7) cell lines. This iron removal is 
associated with lowering of intracellular ferritin, consistent with decrements in storage 
iron in both cell types. Surprisingly ELT proved superior at mobilising cellular iron in 
the cardiomyocyte cell line to iron chelators that are currently used in clinical practice, 
namely DFO, DFP and DFX , and at remarkably low concentrations (1µM) (Table 12).  
Iron removal from the hepatocellular line (HuH7) was less effective than from H9C2 
cardiomyocytes at low concentrations of 1µM (Table 12) but at higher concentrations, 
ELT were increasingly effective (Figure 32 B). The greater efficacy in cardiomyocyte 
than hepatocyte cell lines at low ELT concentrations may relate to greater rates of ELT 
metabolism in hepatocytes than in cardiomyocytes.  It is know that ELT is metabolised 
by mono-oxygenation, glucuronidation, hydralazine cleavage and conjugation in the 
liver before being fully eliminated in faeces and urine (Deng et al, 2011). 
Glucuronidation and ELT cleavage will generate metabolites which are unable to bind 
iron(III). Liver hepatocytes are typically more active in drug metabolism than 
cardiomyocytes, and it is known that HuH7 cells contain most of the Phase I and Phase 
II enzymes that are present in hepatocytes (Guo et al, 2011).  Thus greater metabolic 
inactivation of ELT would be expected in HuH7 cells than H9C2 cells. Indeed, while 
CYP2B1, 2B2, 2E1, and 2J3 are expressed in H9C2 cells and heart myocardium at 
comparable levels, these are significantly lower than in the liver (Zordoky & El-Kadi, 
2007).  Therefore the greater relative iron mobilisation from H9C2 than HuH7 cells, at 
low ELT concentrations, is consistent with greater metabolic inactivation in HuH7 than 
H9C2 cells.  In clinical use, however, metabolic inactivation of ELT is unlikely to be a 
major issue limiting iron chelation, as unmetabolised ELT accounts for >94 % of drug 
at 4h with 64% remaining unmetabolised at 24h (Deng et al, 2011).  
The data with ROS add insight into the interaction of ELT with iron pools in hepatocytes 
and cardiomyocytes.  The kinetics of ROS inhibition with ELT in both cell types are 
rapid, occurring at the first measurable time point after addition of ELT (Figure 35) and 
consistent with the high pM value and low molecular weight of ELT (Table 11) 
allowing rapid access of ELT to intracellular iron pools. These findings are also 
consistent with Kalota et al. where, while investigating antiproliferative effects of ELT 
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in acute myeloid leukaemia cells, demonstrated rapid ROS decrements with a decreased 
H202 levels (Kalota et al, 2015).  By contrast, total cellular iron removal is gradual and 
progressive (Figure 32 B) allowing time for metabolism and inactivation of ELT 
particularly in the HuH7 hepatocyte-like cells. Thus while ELT-induced ROS 
decrements are rapid and similar in H9C2 and HuH7 cells (Figure 36) (Table 13), the 
total cellular iron mobilisation from HuH7 is less than in H9C2 cells, due to the slower 
rate at which storage iron is removed and the opportunity therefore afforded for ELT 
metabolism, particularly in HuH7 cells.  
The iron binding and speciation data for ELT show Fe2LH to be the predominant 
species at physiological pH, indicative of tridentate chelation (Figure 33). The free 
ligand possesses 2 tautomers (1 and 2).   Three iron(III) complexes have been identified 
3 (FeELT), 4 (FeELT2H) and 5 (FeELT2) Figure 39). The overall pFe for ELT is 
greater than DFP but less than for DFX and DFO (Table 11). This has implications for 
iron shuttling helps to explain the observed relative cellular iron release when ELT is 
combined with these chelators. The phenomenon of iron shuttling has been described 
with other chelator combinations (Srichairatanakool et al, 1997) (Giardina & Grady, 
2001) (Vlachodimitropoulou Koumoutsea et al, 2015) (Evans et al, 2010), where one 
chelator possessing rapid access to iron pools subsequently donates iron to a 'sink' 
chelator that possesses greater stability for iron(III) binding but slower kinetic access. 
Iron(III) shuttling could occur both within or outside cells and it is not essential for the 
sink chelator to enter cells for synergism to occur (Vlachodimitropoulou Koumoutsea 
et al, 2015).  The neutral charge of ELT as an iron complex is a characteristics well 
suited for iron shuttling across cell membranes (Vlachodimitropoulou Koumoutsea et 
al, 2015) when the sink chelator has slow intracellular access. A good example of such 
enhanced synergistic chelation is when CP40 (Figure 40) which has no inherent iron 
mobilising effects of its own, is combined with ELT.  Such shuttling onto CP40, acting 
as a sink, has been previously described with other iron chelator combinations 
(Vlachodimitropoulou Koumoutsea et al, 2015).    
For combinations of ELT with other chelators, the speciation plots (Figure 39) predict 
that at 1µM iron and 1µM iron binding equivalents of DFO or DFX, that iron can be 
shuttled onto these chelators by ELT at 1-10µM but that ELT is more likely to act as a 
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'sink' when combined with DFP (at the concentrations described in Figure 39 B). Our 
iron(III) release data (Table 12) show that while benefits of combining ELT with DFO 
and DFP appear additive in both cardiomyocytes and hepatocytes, with DFX, this 
exceeds the additive effects of either drug, suggesting synergism (Table 12).  For 
example in hepatocytes, ELT alone had a small iron mobilising effect (7% reduction), 
and DFX alone had 23% reduction, but the effect of the two combined was suggestive 
of synergism with 51% reduction. Interestingly, in contrast when ROS decrements at 
1hour are considered for the ELT and DFX combination, the effects seem merely 
additive (Table 13).  This is because while the inhibition of ROS is dependent on the 
summated iron binding capacity within cells, net cellular iron mobilisation over time is 
less limited by the iron binding capacity of intracellular chelation as, once ELT has 
donated iron to a second chelator, the free ligand is again available for a fresh round of 
chelation. Greater iron release with combinations of ELT and DFX than of ELT with 
DFO are not explained by speciation plots, as DFO is a highly effective sink for iron(III) 
(Figure 39 B). Rather this could be explained by faster access of DFX to intracellular 
iron pools (Glickstein et al, 2006) when compared with the slower access by DFO 
(Hoyes & Porter, 1993). Intracellular as well as extracellular iron shuttling from ELT 
onto DFX would explain the difference from ELT with DFO, where shuttling is likely 
to be predominantly extracellular.  At steady state clinical concentrations of DFX 
(20µM) (Galanello et al, 2003) (Piga et al, 2006), DFX is likely to be an even more 
effective sink for iron(III).  Combination of DFP with ELT was less effective than for 
ELT with DFX, and this is most likely explained by the speciation data rather than 
access to intracellular iron pools, which for DFP is known to be rapid.  Figure 39 shows 
that DFP is a less effective sink (B) than DFX (C) under the conditions shown. 
However, at the high transient peak plasma concentrations reported clinically for DFP 
(al-Refaie et al, 1995) it is likely that the 'sink' properties of DFP will be enhanced. 
 Our data are consistent with the iron chelating effects of ELT being independent of the 
TPO-R effect because the latter is highly species specific. The thrombopoietic actions 
of ELT occur only in humans and primates with no effect in rodents, whereas the iron 
mobilising effects in our experiments were seen both in human HuH7 cells and murine 
H9C2 cardiomyocyte cells. This suggests that the mechanism of action for iron removal 
is distinct to its thrombopoietic effect. It has been suggested (Kalota et al, 2015) that the 
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thrombopoietic actions of ELT could be inhibited by binding to plasma proteins. Our 
experiments show that inhibition of cellular iron mobilisation by ELT is a consequence 
of the binding of ELT to 'free' non-transferrin bound iron that contaminates FBS and 
albumin preparations rather than to albumin itself.  Fresh human serum has no inhibitory 
effects on the iron removal properties of ELT. Thus when transferrin is not fully 
saturated, it is unlikely that serum will inhibit the actions of ELT.  When NTBI is present 
in patient's serum, higher concentrations of ELT may be required to achieve the desired 
effect, be it iron chelation or enhanced thrombopoiesis. However as NTBI values rarely 
exceed 5µM in iron overload, and thus plasma concentrations of ELT to overcome this 
effect should be obtainable.  
The chelating actions of ELT have not been explored clinically but may be beneficial 
in several settings. An obvious application would be the treatment of transfusional iron 
overload or patients with dysregulated cellular iron metabolism, such as in sideroblastic 
anaemia.  The elimination of route for iron complexes of ELT is unknown and requires 
studies in animal models and in humans. However if iron chelated by ELT were donated 
to another chelator, as suggested by our cell culture experiments, then the iron complex 
of ELT would not need to be eliminated in urine or faeces directly but through the 
second chelator, for which elimination routes are well established.   Other consequences 
of iron chelation by ELT require consideration.  In addition to increasing platelet counts, 
ELT can also increase red blood cell and neutrophil counts and has recently been 
approved in the US for the treatment of severe aplastic anaemia (Design, 2016).  Some 
of the beneficial effects of ELT on haematopoiesis in MDS and aplastic anaemia could 
also be derived from this iron chelating mechanism.   Antileukemic effects mediated 
through modulation of intracellular iron content have also been postulated (Roth et al, 
2012). The antioxidant and iron chelation properties of ELT are tightly linked to cell 
death in leukaemia cells (Roth et al, 2012) as the anti-proliferative and apoptotic effects 
of iron chelators are well described (Maclean et al, 2001) , through mechanisms that 
include inhibition of ribonucleotide reductase  (Hoyes et al, 1992; Kayyali et al, 2001). 
However, in patients with ITP, iron chelation could create or exacerbate iron deficiency, 
and this needs to be explored. Importantly the 1µM concentration of ELT which was 
effective at mobilising cellular iron is nearly twenty-fold less than peak plasma 
concentrations obtained following 30mg ELT orally, a dose used to treat 
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thrombocytopenia (Gibiansky et al, 2011).  At this dose, increments in platelet counts 
do not typically exceed 1.2 x the baseline values in healthy volunteers with repeat 
dosing (Jenkins et al, 2007).  Hence it is predicted that effective chelating doses of ELT 
could be given without promoting unacceptably thrombocytosis, although this would 
require careful study before making recommendations. In principle, still lower 
concentrations could be used for iron chelation if ELT were combined with another 
clinically licensed iron chelator. ELT has been generally well tolerated, in long-term 
clinical treatments (Saleh et al, 2013). The most common reported adverse events with 
ELT are headache, gastrointestinal symptoms, and upper respiratory tract infections, 
occurring in up to 26, 14, and 23% of patients, respectively (Saleh et al, 2013).  
Regarding the risk of thromboembolic events, published studies (Bussel et al, 2007; 
Bussel et al, 2009; Bussel et al, 2013; Cheng et al, 2011) did not demonstrate any 
correlation between ELT treatment and occurrence of such events. This suggests that 
ELT doses could be administered to patients without thrombocytopenia that induced 
significant intracellular chelation, without appreciable increments in platelet counts. 
5.5 Conclusion 
We have demonstrated the iron binding properties of ELT in solution and the iron 
mobilising properties from cells for the first time.  Remarkably low concentrations of 
ELT are required to mobilise cellular iron; single agent ELT is at least as effective as 
clinically licensed iron chelators at mobilising cardiomyocyte iron. Additive or 
synergistic intracellular chelation is shown when ELT is combined with clinically 
available chelators. The doses of ELT, alone or in combination with other chelators, are 
sufficiently low to suggest ELT could be used as an iron chelator in patients who are 
not thrombocytopenic.  
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Chapter 6 THE INFLUENCE OF FLAVONOIDS ON CELLULAR 
IRON MOBILISATION ALONE OR IN COMBINATION WITH 
CLINICALLY AVAILABLE IRON CHELATORS 
6.1 Introduction 
I have developed a cellular model of iron overload in hepatocyte (HuH7) and 
cardiomyocyte (H9C2) cells that can accurately reflect iron mobilisation by chelating 
molecules at clinically relevant concentrations. In previous chapters, this model was 
used to look closely at interactions between chelators when in combination and to 
distinguish between the principles of ‘synergy’ and ‘additivity’ of chelator action. This 
system was then utilised to interrogate the potential of a drug (Eltrombopag), typically 
used to manage ITP, to act as a ‘shuttle’ of iron onto ‘sink chelators’. A novel finding 
was its potential application in the management of transfusional iron overload.   
 
In this chapter, I have now applied the above system to examine a group of compounds 
that possess iron chelating properties that occur naturally in the daily human diet, 
namely the flavonoids.  These are known to have both iron-chelating 22 as well as anti-
oxidant properties, but the extent to which these two broad properties functionally 
overlap is not fully understood. In principle, the system that I have developed, whereby 
the iron chelating properties of such compounds can be examined independently from 
real-time effects as antioxidants in the same cells, provides an opportunity to study 
structure-functions relationships of flavonoids. The metabolism of these compounds 
yields structures where the iron binding sites are modified, thus abrogating iron 
binding, but where the basic structure of the flavonoids is otherwise unperturbed. In 
principle, therefore, it is possible to dissect the iron binding properties from the 
antioxidant properties. It was reasoned that this would provide insight into how these 
common components of the human diet contribute anti-oxidant versus iron chelating 
effects and may suggest how these overlapping properties might best be applied 
selectively to benefit human health.  
6.2 Chemistry of flavonoids  
Flavonoids are abundant micronutrients in the diet of humans that have attracted 
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increasing attention in the recent years due to their iron chelating (Guo et al, 2007), 
antioxidant, anti-inflammatory and  anticarcinogenic properties (Middleton, 1998).  
Their potential protective role has also been postulated in oxidative stress-related 
chronic diseases such as diabetes and ischaemic heart disease (Yao et al, 2004). 
Quercetin is one of the predominant flavonoids present in the diet, with the richest 
sources being in red wine, onions, apples and tea (Boots et al, 2008).  Table 14 shows 
the classification, structure and most common food sources of some of the dietary 
flavonoids. The flavonoid structure is based on the flavonoid nucleus consisting of 
three phenolic rings A,B and C (Figure 41). The bioavailability, biological activity, 
and metabolism are highly dependent on the configuration of the molecule, the number 
of hydroxyl groups, and the substitution of functional groups about their nuclear 
structure. Flavonoids in the diet (Hollman et al, 1999) are commonly present in their 
glycosylated form. The aglycone, glycoside as well as methyl, glucuronide and 
sulphate conjugates  (Mullen et al, 2006) forms have been reported in human plasma 
after ingestion of flavonoids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14 Food sources of dietary flavonoids. (Figure adapted from Kumar and Pandey, 2013)  
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There is a great variety of phenolic structures amongst the molecules that come under 
the flavonoid category, and to date, more than 4000 varieties have been identified 
(Middleton, 1998). Their structure is based on a fifteen carbon backbone that consists 
of two benzene rings, named A and B, which are linked by one pyrene ring (C).  
Flavonoids can be divided into a number of classes, namely flavones, flavonols, 
flavanones, isoflavones, etc. (Figure 42). These classes differ between them in the 
substitution pattern and level of oxidation of the C ring. However, differences between 
molecules within a class differ in the substitution pattern of the A and B rings. 
Furthermore, flavonoids can occur as aglycones, glycosides, and methylated 
derivatives. Spectroscopic studies have revealed that flavonoids exhibit two major 
absorption bands: Band I (320-385nm) corresponding to the A ring absorption and 
Band II (250-285nm) representing the B ring absorption. The functional groups 
attached to the different derivatives cause a shift in the absorption spectra, e.g., 
kaempferol 367nm (3,5,7,4’-hydroxyl groups) to 371 for quercetin (3,5,7,3’,4’-
hydroxyl groups) and 374 (3,5,7,3’,4’, 5’-hydroxyl groups) for myrecetin (Yao et al, 
2004). 
 
 
 
 
 
 
 
 
 
Figure 41 Core flavonoid structure. 
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Figure 42 Structures of the different flavonoid groups. 
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6.3 Dietary uptake and metabolism of flavonoids in humans 
As with any molecule, the oral bioavailability of flavonoids is greatly dependent on 
molecular size, lipophilicity, configuration, solubility, and pKa. Following dietary 
consumption, certain flavonoids are taken up via the small intestine whilst others have 
to go through the colon. This is greatly dependent on whether the flavonoid is in its 
glycosylated form or aglycone, which can be easily taken up by the small intestine. 
Glycosylated compounds must be converted to the aglycone form prior to absorption 
(Hollman et al, 1999). 
The hydrophilic flavonoid glucosides, such as quercetin, are transported through the 
Na+ powered glucose cotransporter (SGLT1). Alternatively, glucosides are 
commonly hydrolysed by the enzyme lactase phloridzin hydrolase (LPH), a β-
glucosidase commonly found on the brush border of the small intestine (Day et al, 
2000). Once the aglycone is liberated, it can then be absorbed across the small 
intestine. The glycosides that are not substrates of LPH are transported towards the 
colon where there are bacteria with the ability of molecule hydrolysis and release of 
the aglycone, however often the aglycone itself will also be degraded (Scheline, 1973). 
As a result, there is only minimal absorption of glycosides in the colon compared to 
the small intestine. 
Following absorption, the flavonoids are generally conjugated by the liver via 
glucuronidation, sulphation or methylation or are further metabolised to smaller 
phenolics. If a flavonoid is secreted in the bile, and it cannot be absorbed by the small 
intestine, it will subsequently be degraded in the colon by the intestinal microflora that 
will also destroy the flavonoid ring structure. Oligomeric compounds may be 
hydrolised to monomers in the acidic conditions of the stomach and larger molecules 
may reach the colon and be degraded by bacteria. Dimerisation is thought to reduce 
bioavailability (Spencer et al, 2000). Despite the relatively low molecular weight of a 
number of the flavonoids, their low solubility in water coupled with a short residence 
time in the intestine may significantly reduce their therapeutic efficacy and presents a 
problem for medicinal application.  
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6.4 Flavonoids and their biological activities 
Antioxidant activity 
Acting as an antioxidant is probably one of the best-described properties of flavonoids. 
Antioxidant activity amongst the group can be variable and is highly dependent upon 
the availability of hydroxyl groups as well as the configuration of the molecule and 
the biotransformations and substitutions. The core structure of flavonoids favours 
electron delocalisation and allows for greater flavonoid radical stability due to the 
configuration of its π bonds in the carbon backbone which are in line (Figure 41) and 
allow electron spread across the molecule. The most important groups that allow ROS 
scavenging, as reported in the literature, are located on the B ring of the structure 
(Kumar & Pandey, 2013), and this involves the donation of a hydrogen and an electron 
to stabilise other groups such as hydroxyl, peroxyl and peroxynitrite radicals.  
Flavonoids and quercetin, in particular, are strong inhibitors of lipid peroxidation 
because of their capacity to reduce radicals such as hydroxyl and superoxide radicals 
by hydrogen atom donation, forming stable flavonoid radicals  themselves (Mishra et 
al, 2013a).  It has been reported that antioxidant activity of the molecule declines 
proportionately to the number of glucose moieties present (Ratty & Das, 1988). 
However, antioxidant activity is not only limited to ROS suppression by free radical 
scavenging, but it is often closely related to chelation of elements which are 
themselves involved in ROS generation. In the presence of transition metals, the extent 
that iron chelation and free radical scavenging each contribute to the antioxidant 
effects of a molecule are unclear, and this will further be addressed in this chapter.  
Iron chelation 
Iron chelating and ion stabilising properties of flavonoids, quercetin, in particular, 
have been previously well documented, independent of its antioxidant effects. Metals 
bind at specific points of the structure, as indicated in Figure 43 A.  The ratio of iron 
binding to quercetin and binding constants for Fe(II) and Fe(III) were first 
characterised by Guo et al. in 2009 using electrospray ionisation mass spectroscopy 
(Guo et al, 2007). There are three iron-binding motifs on the quercetin molecule that 
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can bind iron strongly under physiological conditions.  Quercetin can form 1:1 
complexes and 1:2 complexes with Fe(III). Similarly, 1:1 (binding constant 2x106/M) 
and 1:2 (binding constant 5x1010/M2) complexes are formed with Fe(II), but also 2:3 
ratio complexes (Guo et al, 2007)  (Figure 43 B). The iron binding constants of Fe(II) 
for the 3 different iron binding sites are all similar for a 2:1 complex but follow the 
following order of preference: 1) 3-hydroxyl and carbonyl site C ring 2) 5-hydroxyl 
and carbonyl site A and C rings) and 3) 3′,4′-dihydroxy site on the B ring. The order 
of binding constants for Fe(III) for a 1:1 complex has been proposed by some authors 
to possibly  follow a different order: 3′,4′-dihydroxy site on the B ring > 3-hydroxyl 
and carbonyl site on the C ring (Guo et al, 2007).  Quercetin has also been noted to 
bind Ga3+ and Zn2+. Interestingly, quercetin binds Fe(II) more strongly than the 
chelator ferrozine and it is also known to completely suppress Fenton reactions at only 
μΜ concentrations. In this thesis, we investigate the potential role of quercetin and its 
metabolites in shuttling iron out of cells and the extent by which inhibition of chelation 
properties by substitution at the chelation sites with different moieties impacts on the 
antioxidant capacity of these naturally occurring compounds. 
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Figure 43 Flavonoid binding site for trace metal ions indicated by Men+ (A)(Kumar & Pandey, 
2013) and complexes formed between quercetin and Fe (III) and Fe (II) (B). (Guo et al, 2007) 
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Hepatoprotective, antibacterial, anti-inflammatory, anti-cancer and anti-viral 
properties 
A number of flavonoids including quercetin, catechin and rutin have been reported in 
the literature to have hepatoprotective activity (Tapas et al, 2008). This probably 
involves mechanism such as ROS suppression, decreased lipid peroxidation and 
inhibition of release of pro-inflammatory cytokines (Tapas et al, 2008).  Furthermore, 
several flavonoids including flavonol glycosides and isoflavones have been known to 
be potent antimicrobials in vitro. This is not surprising given that they are known to 
be synthesised by plants in response to infection (Abhay K. Pandey, 2010; Mishra et 
al, 2011; Mishra et al, 2013a; Mishra et al, 2013b). This property is most likely related 
to inactivation of enzymes and transport proteins. Apart from their antioxidant effects, 
other pathways for the anti-inflammatory actions of flavonoids have also been 
postulated, such as suppression of the inflammatory gene microRNA-155 in murine 
macrophages, and reduction of mRNA and protein levels of tumour necrosis factor 
alpha and interleukin 1β and interleukin 6 (Boesch-Saadatmandi et al, 
2011).Consumption of fruit and vegetable is inversely linked to cancer of the prostate, 
lung, stomach and breast (Brusselmans et al, 2005). Proposed mechanisms involved 
include quercetin metabolites inducing G2/M arrest by upregulating PPAR-gamma 
expression in human lung cancer cells (Yeh et al, 2011), tyrosine kinase inhibition, 
downregulation of the mutant p53 protein, and inhibition of oestrogen receptor 
binding capacity, even though this is debatable as even the quercetin metabolites have 
been shown to mimic the actions of endogenous oestrogens and stimulate oestrogen 
receptors in a human breast cancer cell line (Ruotolo et al, 2014). Lastly, the antiviral 
activity of flavonoids was recognised in the 1940s. Quercetin has been shown to have 
viral neutralisation effects against dengue viral infection and mouse hepatitis virus in 
vitro (Chiow et al, 2016). 
6.5 Dietary uptake, metabolism, and toxicology of Quercetin 
The estimated dietary intake of all flavonoids is 200-350mg/day, and intake of 
flavonols is 20mg/day of which quercetin amounts to over 50%, making its daily 
intake approximately 10 -16 mg/day (Kawabata et al, 2015; Nishimuro et al, 2015). 
However, due to its wide presence in numerous fruits and vegetables such as apples, 
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berries, and onions, high consumption could increase intake to over 200mg/day. 
Quercetin is one of the most abundant and, best studied and metabolically active 
flavonoids.' The most prevalent form of quercetin in food is not the aglycone, but the 
glucoside (Kawabata et al, 2015), however, the aglycone is often purchased as a 
dietary supplement. Quercetin is deglycosylated by enzymatic pathways prior to its 
passive uptake through the small intestine. As mentioned above, enzymes that 
participate in this initial reaction include LPH or other gut-derived microbial enzymes. 
Naturally, the glucose moiety can substitute the hydroxyl group either at the 4’ site on 
the B ring or site 3 on the C ring. The latter structure was used in the experiments to 
follow in this chapter. 
Once it is deglycosylated in the small intestine, the quercetin aglycone undergoes 
significant biotransformation mainly by glucuronidation, sulphation, and methylation, 
involving the phase II enzymes UGT (uridine 5’-diphosphoglucuronosyltransferase), 
SULT (sulfotransferase), and COMT (catechol-O-methyltransferase).  Isorhamnetin 
is the methylated derivative of quercetin, at the 3’ site of the B ring whilst quercetin 
glucuronide has a glucuronide substitution at site 3 of the C ring. Kaempherol has a 
hydrogen substitution at the 3’ hydroxyl group site on the B ring. 
Figure 44 shows the structure of quercetin aglycone and its principle metabolites that 
are derived from some of the above biotransformation reactions. A number of animal 
studies mainly in rats and pig have shown the presence of quercetin in several tissues 
including the lung, kidney, liver as well as the brain (de Boer et al, 2005). Diet-derived 
quercetin is present in the plasma at concentrations in the nanomolar range (<100nM), 
however, this is increased by supplementation of the glucoside or the aglycone to 
about 5μM (Conquer et al, 1998; Manach et al, 2005).  Supplementation of quercetin 
leads to the presence of similar metabolites in the mouse, rat as well as the gerbil, to 
humans (Yeh et al, 2016). The plasma half-life of quercetin is between 11 and 28 
hours, making further increases to plasma concentration feasible (Manach et al, 2004; 
Manach et al, 2005). There is some controversy regarding the presence and 
concentration of the quercetin aglycone found circulating in plasma (Kelly, 2011; 
Shanely et al, 2010), however, the metabolite moieties such as the methylated and 
glucuronidated form are prominent. Nonetheless, studies have previously supported 
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the antioxidant and other beneficial effects of not only the aglycone but also its 
metabolites (glucuronidated, sulphated, methylated) in vitro and in vivo (2014; 
Boesch-Saadatmandi et al, 2011; Moon et al, 2001; Shirai et al, 2006; Yeh et al, 2011). 
Quercetin and 12 of its metabolites have been identified in urine, within 24 hours of  
onion consumption in humans (Mullen et al, 2006). 
The toxicological profile of quercetin is virtually unremarkable as previously 
documented in the literature (Harwood et al, 2007; Shirai et al, 2006). Similarly to 
other flavonoids, quercetin has a number of reported beneficial effects relating to the 
cardiovascular system, cancer, diabetes and the nervous system (Boots et al, 2008; 
Kelly, 2011; Russo et al, 2012). We are particularly interested in the ion chelating 
properties of quercetin and its metabolites, and the potential of these molecules to act 
as ‘shuttles’ of iron(III), and therefore be candidates for combination treatment to 
current chelation therapy. 
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6.6 Materials and Methods 
6.6.1 Flavonoid compounds 
VI. Quercetin, Isorhamnetin, Quercetin 3-β-D- glucoside  (Sigma-Aldrich, USA) 
VII. Quercetin-3-D-glucuronide, (HWI Pharma Solutions, Germany) 
VIII. Kaempferol (Calbiochem, Canada) 
6.6.2 The cellular model 
The rat (H9C2) cardiomyocyte cell line and a human hepatocellular carcinoma 
(HuH7) cell line were chosen for investigation of the iron mobilisation properties of 
quercetin and its metabolites. Cardiomyocytes are a target tissue for transfusional iron 
overload and provide a particular therapeutic challenge, and hepatocytes represent the 
cell type with the largest quantity of iron deposition. The development of our 
HuH7/H9C2 cell models to assess iron mobilisation has previously been described in 
Chapter 3; a brief description of the finalised model is given below. Cells were plated 
at 200 000 cells/well in RPMI 1640 medium (HuH7)/DMEM (H9C2) supplemented 
with 10% fetal bovine serum (FBS) and allowed to attach for 24 h. In these 
experiments, the supernatant (media/10% FBS) was changed twice at 10-hour 
intervals. A threefold increase in intracellular iron concentration was achieved by this 
method in hepatocytes and a two-fold in cardiomyocytes (data not shown). The cells 
were sequentially washed with phosphate-buffered saline (PBS), 30 μΜ DFO ibe/PBS 
for 1 min then 2x PBS. After incubation with test compounds, further washes with 
PBS, 30 μΜ DFO ibe/PBS then 2x PBS were performed. Cellular iron loading and 
iron mobilisation were measured as a decrease in cellular iron content using the 
ferrozine assay (Section 2.3.5), adjusted for cellular protein (Vlachodimitropoulou 
Koumoutsea et al, 2015). 
6.6.3 Cell damage and viability 
As described in Chapter 3, viability is of critical importance when addressing iron 
release (Porter et al, 1988). Viability was ensured > 98% using the ‘LDH Cytotoxicity 
Detection Kit’ by Takara Bio Inc, which gives a quantitative comparison of early cell 
damage between ‘treatment’ and ‘control.’ This is a colorimetric assay and measures 
LDH activity leaked by damaged cells into the supernatant (W.J. Reeves Jr., 1966). 
The tryptan blue solution of 50/50 (vol./vol.) in PBS assay was also used, where non-
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viable cells take up the dye and appear blue when directly visualised under the 
microscope. 
6.6.4 Determination of intracellular iron – The ferrozine assay 
The ferrozine assay is described in detail in the methods Section 2.3.5. In brief, cells 
were lysed overnight with 200μl of 200 mmol/l NaOH and iron detection reagent (6.5 
mmol/l ferrozine, 6.5 mmol/l neocuproine, 2.5 mol/l ammonium acetate and 1 mol/l 
ascorbic acid dissolved in iron-free high-performance liquid chromatography grade 
water) was added for 30 min. Absorbance was recorded at 562 nm and lysate iron 
content calculated by standard curve interpolation against atomic absorption iron 
standards. Intracellular iron was normalised against protein content using the 
Coomassie (Bradford) assay. 
6.6.5 Detection of ROS using a fluorimetric method 
As previously described in Section 2.6, we utilised a cell-permeable oxidation-
sensitive fluorescent probe 5,6-carboxy-2’,7’- dichlorofluoresceindiacetate (DCFH-
DA) (Molecular Probes, Leiden, Netherlands) to monitor the intracellular rate of ROS 
production. Cells in Corning 24-well plates (Sigma-Aldrich, MA, USA) were pre-
incubated with 4μM H2DCF-DA for 30 minutes at 37°C as per protocol. Test 
compounds were then added, and fluorescence was recorded continuously over a 
period of 1 hour (excitation at 504 nm, emission at 526 nm). The time between the 
addition of chelators and commencing ROS level recording was between 3 and 5 
minutes at room temperature. The rate of ROS production was compared between 
chelator treated and untreated cells.   
6.6.6 Ferritin quantification 
The ferritin quantification method is described in Section 2.5. Commercially available 
enzyme-linked immunosorbent assay (ELISA) kits (Cusabio, Wuhan, China and My 
BioSource, San Diego, USA) were used to measure human and rat tissue ferritin 
respectively in cell lysates, according to the instructions provided by the manufacturer. 
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6.7 Results 
6.7.1 Viability of hepatocytes and cardiomyocytes following exposure to 
quercetin and its metabolites 
As the viability of cells may influence cellular iron release, prior to conducting iron 
mobilisation studies with quercetin and its metabolites, we ensured that viability was 
maintained >98% using the Tryptan blue and LDH assays following treatment. HuH7 
showed no signs of toxicity following 12 hours of treatment with all metabolites at 
30μΜ using the LDH assay (Table 15) as well as the Tryptan blue method (Figure 
45). Similarly, quercetin, as well as the tested metabolites, did not appear to be toxic 
to H9C2 cells (Table 15) at the concentrations evaluated. 
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Figure 45 Tryptan blue viability staining in HuH7 cells following a 12 hour treatment with 
quercetin and its metabolites at 30μΜ. Cells were loaded with RPMI media containing 10% FBS 
(2x 10 hour changes).  Adherent cells were rinsed four times, including one wash containing DFO 
at 30µM ibe and 3 x PBS washes, and subsequently exposed to test compounds for 12 hours.  
Supernatants were then removed, and the cells stained with Tryptan blue as described in the methods.  
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Table 15 Percentage viability assessed by the LDH assay following 12 hours of treatment with 
quercetin and its metabolites at 30μΜ. Cells were loaded with iron and treated with metabolites as in 
(Figure 45). Supernatants were then removed, and viability determined using the LDH assay as described 
in the methods. 
 
 
% viability following 12 hours of treatment at 30μΜ 
using the LDH assay 
 
Hepatocytes          
(HuH7) 
Cardiomyocytes 
(H9C2) 
Quercetin 98.1 +/- 0.2 99.2 +/- 0.6 
Isorhamnetin 99.2 +/- 1.1 98.7 +/- 0.8 
Quercetin-
glucoside 
98.7 +/- 0.4 98.3 +/- 0.4 
Kampherol 99.5 +/- 0.8 99.2 +/- 0.4 
Quercetin-
glucuronide 
98.9 +/- 0.6 99.4 +/- 0.9 
 
6.7.2 Quercetin decreases hepatocellular and myocardial iron in a time and 
concentration-dependent manner. 
Table 16 Percentage iron release from hepatocyte (HuH7) and cardiomyocyte (H9C2) cells 
following 8 hours of treatment with commercially available chelators at 30μΜ ibe and quercetin at 
30μΜ.  Cells were loaded with iron as described in methods.  Adherent cells were rinsed 
four times, including one wash containing DFO at 30µM ibe and 3 x PBS washes, and 
subsequently exposed to chelators for 8 hours.  Chelator supernatants were then 
removed, and the cells washed four times as above before lysing with 200mM NaOH.  
Intracellular iron concentration was then determined using the ferrozine assay and 
normalised for total cellular protein in each well. Results shown are expressed as the % 
of T0 cellular iron released and are the mean ± SEM of 4 replicates in one 
experiment.Table 16 shows percentage iron release from hepatocyte (HuH7) and 
cardiomyocyte (H9C2) cells following 8 hours of treatment with commercially 
available chelators and quercetin. The cells were exposed to two 10 hour treatment 
periods with RPMI/DMEM containing 10% FBS to iron load the cells, and were then 
incubated with media without FBS, but with chelators at 30µM ibe or quercetin 30μΜ 
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for 8 hours.  Following an 8 hour treatment, the iron removal was relatively similar for 
all three commercially available iron chelators in each cell type. Iron mobilisation with 
quercetin was found to be at 16.6% and 41.9% of total cellular iron in cardiomyocytes 
and hepatocytes respectively, making it only mildly a less effective chelator than DFO, 
DFX, and DFP in this model (Table 16). Given the availability of the all three ‘iron-
binding motifs’ on the flavonoid structure; (1) 3-hydroxyl and carbonyl site (C ring) 2) 
5-hydroxyl and carbonyl site (A and C rings) and 3) 3′,4′-dihydroxy site on the B-ring, 
with a high affinity for binding of Fe(II) and Fe(III), the intracellular iron mobilisation 
noted in both cell types is not surprising. 
Table 16 Percentage iron release from hepatocyte (HuH7) and cardiomyocyte (H9C2) cells 
following 8 hours of treatment with commercially available chelators at 30μΜ ibe and quercetin at 
30μΜ.  Cells were loaded with iron as described in methods.  Adherent cells were rinsed four times, 
including one wash containing DFO at 30µM ibe and 3 x PBS washes, and subsequently exposed to 
chelators for 8 hours.  Chelator supernatants were then removed, and the cells washed four times as above 
before lysing with 200mM NaOH.  Intracellular iron concentration was then determined using the 
ferrozine assay and normalised for total cellular protein in each well. Results shown are expressed as the 
% of T0 cellular iron released and are the mean ± SEM of 4 replicates in one experiment.  
 
 
 
% cellular iron removed following 8 hours of quercetin 30μΜ 
monotherapy compared with other chelators at 30μΜ ibe 
 
Hepatocytes  (HUH7) Cardiomyocytes  
(H9C2) 
DFO 47.3 +/- 2.9 22.2 +/- 1.3 
DFP 44.6 +/- 1.2 17.5 +/- 0.9 
DFX 44.4 +/- 2.3 27.6 +/- 1.7 
Quercetin 41.9 +/- 0.7 16.6 +/- 0.6 
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6.7.3 Cellular iron mobilisation by Quercetin metabolites. 
The iron mobilisation properties of quercetin metabolites were next investigated.  
These included quercetin-3-glucoside and metabolites isorhamnetin, kaempherol and 
quercetin glucuronide.  This allowed close interrogation of the effects of substitution 
of different hydroxyl groups at the iron binding sites on metal binding as a function of 
time and concentration. It can be seen that cellular iron is decreased by quercetin as 
early as 1h and at 3µM and 30μΜ.  As expected, quercetin which has all three ‘iron-
binding’ motifs available was the most effective at mobilising cellular iron in a time 
(Figure 46) as well as concentration-dependent fashion (Figure 47).   Iron 
mobilisation sharply increases with as little as 3μΜ Quercetin (Figure 47) and appears 
to slow down after 4 hours at 30μΜ (Figure 46), similarly to DFO, DFX and DFP at 
30μΜ ibe (Figure 18 B) . Quercetin-3- glucuronide, which has a glucuronide 
substitution at site 3 on the C ring (Figure 42), produced an only minimal reduction 
in cellular iron at 8 hours.  Interestingly, quercetin-3 glucoside which has a glucose 
substitution at the same site was also inefficient at iron mobilisation. The efficacy of 
tested compounds increased in the following order: quercetin-3-glucuronide, 
kampherol, quercetin-3-glucoside, isorhamnetin, and quercetin. Isorhamnetin 
mobilised 34.7%  following 8 hours of treatment (vs. 41.9% with quercetin treatment) 
(Figure 47). The inhibition of iron chelating function of quercetin noted here by 
substitution of site 3 on the C ring in particular, following metabolism, for example to 
the glucuronide and glucoside structures, highlights the importance of this particular 
site which is known to be preferred in iron chelation (Guo et al, 2007).  It is also noted 
that Kampherol, that has no substitution on the C-ring and hence at site 3 or at site 5 
on the A ring, is also is also poor at iron mobilisation. However, in the case of 
Kaempherol, the hydroxyl group on the 3’ site of the B ring is absent. This finding 
highlights that iron mobilisation is not only dependent on substitutions at the known 
iron binding sites, but the configuration of the molecule and number of hydroxyl 
groups is also of pivotal importance for a molecule to function as an iron chelator 
and/or to shift iron from the intracellular to  the extracellular compartment. 
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Figure 46 Time course of change in intracellular iron content using monotherapy with 
quercetin and its metabolites at (A) 3 μΜ and (B) 30μΜ and in HuH7 cells. Cells were loaded 
with iron, treated with chelators and intracellular iron concentration determines as in (Table 16). 
Results shown are the mean ± SEM of 4 replicates in one experiment. 
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6.7.4 Quercetin and its metabolites rapidly decreases ROS compared with other 
chelators 
Following a close look at the effect of substitutions at the iron chelating motifs of the 
quercetin molecule and the impact on iron mobilisation, we wished to evaluate ROS 
scavenging properties of quercetin glucoside and the quercetin metabolites. The 
capacity of flavonoids to act as antioxidants is one that is very well recognised. A cell-
permeable oxidation and hydrolysis sensitive fluorescent probe was used for this 
purpose as described in methods. After iron loading cells as previously described, they 
were preloaded with the non-fluorescent DCFH-DA (Molecular Probes, Leiden, 
Netherlands) for 30 minutes at 370C, allowing time for commencement of hydrolysis 
to the highly fluorescent DCFH. Compounds were added to each well and then placed 
into the plate reader where fluorescence was recorded over 1 hour at 37oC. The interval 
between addition of chelators and commencing ROS recording on the plate reader was 
between 3 and 5 minutes.  
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Figure 47 Concentration dependence for change in cellular iron at 8h after monotherapy with 
quercetin and its metabolites in HuH7 cells. Cells were loaded with iron, treated with chelators and 
intracellular iron concentration determines as in (Table 16). Results shown are the mean ± SEM of 4 
replicates in one experiment. 
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In Figure 48 the concentration dependence of ROS inhibition by Quercetin-3-
glucoside, Quercetin as well as all its metabolites in HuH7 and H9C2 cells is shown 
together with the commercially available chelators DFO, DFX, and DFP. 
Interestingly, the rate of ROS production at 1 hour is suppressed very effectively and 
equally amongst the flavonoids and the commercially used iron chelators. 
  
Figure 48 Concentration dependent ROS inhibition by Quercetin and its metabolites and 
commercially available chelators in cardiomyocytes (A) and hepatocytes (B). Cells were iron 
loaded and then rinsed four times as described in (Table 16). Chelators were then added, and the rate 
of change of ROS production was recorded as fluorescence change (excitation at 504 nm, emission 
at 526 nm) continuously over 1 hour in the plate reader at 37oC. DFO, DFP, and DFX were used at 
1, 10, 30μM ibe, and Quercetin and its metabolites at 1, 10,30μΜ.  
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In (Figure 49) it can be seen that from the first measurable time-points, the 
fluorescence signal with all metabolites was less than control, suggesting very rapid 
entry of compounds to decrease ROS.  Looking more closely at the time course of 
ROS production (Figure 49), despite all chelators decreasing ROS production at a 
comparable rate (i.e. the slope of the curve if the initial T0 value is normalised), it 
can be seen that in terms of absolute ROS amounts, the most potent scavengers were 
quercetin, quercetin-3-glucuronide, and quercetin-3-glucoside (cellular protein 
comparable between wells). Interestingly, Kaempherol and Isorhamnetin (molecule 
which effectively mobilises iron) which have substitutions at the 3’site of the B-ring 
lag behind, with rates comparable to DFO, when looking at absolute amounts of 
ROS. This could reflect slower uptake of these compounds into cells, comparable 
to those of DFO, or an inherently lower capacity to scavenge ROS.  This highlights 
the importance of the hydroxyl groups in the 3’ and 4’ position of the B ring in terms 
of radical scavenging and provides structure-to-function insight regarding iron 
chelation and antioxidant capacity (see discussion). 
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Figure 49 The time-course for ROS inhibition by DFO 1μΜ ibe, Quercetin, Quercetin-3-glucoside 
and Quercetin metabolites at 1μΜ in HuH7 cells. Cells were loaded iron, and ROS generation recorded 
over 1 hours as described in (Figure 48). 
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6.7.5 Quercetin and its metabolites decrease intracellular ferritin 
It was important to understand how the decrease in cellular iron and ROS generation 
seen above reflects in the mobilisation of storage iron (ferritin).  HuH7 cells and H9C2 
cells were iron-loaded as described in the methods section above using two media 
changes containing 10% FBS. This increased tissue ferritin by 75% in hepatocytes and 
by 33% in cardiomyocytes (Figure 22), and increased total cellular iron by 4 and 2.5 
fold respectively. Cells were then treated with DFO/DFP/DFX/quercetin monotherapy 
for 8 hours and cellular ferritin assayed as described in methods.  
In HuH7, quercetin achieved a dose-dependent decrease in ferritin at 10μΜ and 30μΜ. 
At 30μΜ it was, in fact, more effective than all 3 commercially available iron chelators 
at mobilising cellular ferritin, reducing the total concentration by 45% (Figure 50).  In 
cardiomyocytes, quercetin was particularly effective at decreasing ferritin at 10μΜ 
(75.4%) (Figure 50), similar to DFX at 10μΜ ibe (70.1%). Thus chelation with 
quercetin decreases both total cellular iron (Table 16) and cellular ferritin (Figure 50) 
in both cell types with ferritin decrements being proportionately greater in HuH7 than 
H9C2 cells. Evidently, therefore, hepatocyte ferritin is more responsive, both to iron 
loading and iron unloading than in cardiomyocytes, which is consistent with the 
known high iron storage capacity of hepatocytes compared with cardiomyocytes. 
Ferritin decrements at 8h with quercetin compared with DFO/DFP/DFX in (A) 
cardiomyocyte H9C2 cells (B) hepatocyte HuH7 are shown in Figure 50.  
 
 
 
 
 
 
 171 
Figure 50 Ferritin decrements at 8h with quercetin or DFX, DFP or DFO in (A) cardiomyocyte 
H9C2 cells and (B) in hepatocyte HuH7. Following iron loading as described in the methods section, 
the cells were rinsed four times including one wash containing DFO at 30µM ibe and 3 PBS washes and 
subsequently exposed to chelators over an 8 hour period. At the end of the incubation, the supernatant 
was removed, and the cells further washed four times as above. Ferritin was quantified using 
commercially available ELISA kits appropriate for our rat and human cell lines, as described in methods. 
The results are the mean ± SEM of 3 replicates in one experiment. 
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The effects of flavonoids, some of which had showed little iron binding and removal 
were then examined (Figure 51). quercetin-glucuronide, Kampherol, quercetin-3-
glucoside, and isorhamnetin were also effective at mobilising storage iron (ferritin).  
Interestingly in both cell types, all derivatives are able to decrease ferritin 
concentration in a dose-dependent manner at 10 and 30μΜ, being nearly as effective 
as the unmetabolised ligand. While the effectiveness of for example quercetin and 
isorhamnetin could be attributed to cytoplasmic iron chelation leading to mobilisation 
of Fe(III) from ferritin, this is less likely when considering the weaker chelation 
properties of quercetin-glucuronide  (Figure 47). Therefore, some of the ferritin 
decreasing effects could be unrelated directly to iron chelation and may relate to their 
strong antioxidant effects demonstrated above. This could occur because reduction in 
ROS levels is known to increase iron-responsive elements (IRP) which leads to a 
decrease in ferritin synthesis (see discussion) (Cairo et al, 1998).   
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Figure 51 Ferritin decrements at 8h with quercetin and its metabolites in (A) 
cardiomyocyte H9C2 cells and (B) in hepatocyte HuH7. Cells were loaded with iron, treated 
with chelators and ferritin determines as described in Figure 50. The results are the mean ± SEM 
of 3 replicates in one experiment. 
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6.7.6 Synergistic iron mobilisation by combinations of Quercetin or its 
metabolites with clinically available chelators.  
In principle the addition of Quercetin containing foods to standard clinically used 
chelation regimens could enhance the efficacy of the latter.  In this section, the effects 
of Quercetin alone is compared with those of Quercetin when combined with clinically 
available iron chelators in terms of intracellular iron mobilisation.  
6.7.7 Iron mobilisation by quercetin and its metabolites combined with 
commercially available chelators in HuH7 cells 
The relative effects of combining flavonoids at increasing concentrations with DFO, 
DFP, and DFX at 10μΜ ibe on cellular iron removal from HuH7 cells are shown in 
Figure 52. Cells were loaded with iron as described in methods, with two media 
changes containing 10% FBS for 10 hours.  Adherent cells were rinsed four times, 
including one wash containing DFO at 30µM ibe and 3 x PBS washes, and 
subsequently exposed to chelators for 12 hours. 
When quercetin or its metabolites were combined with either DFO, DFP or DFX at 
10μΜ ibe, quercetin produced greater increase in cellular iron mobilisation than all 
other quercetin derivatives. For example, at the lowest concentration tested of 3μM, 
Quercetin improved mobilisation by 2.6, 2.5 and 2.3 fold when combined with DFO, 
DFX or DFP at 10μM ibe.  
The metabolite isorhamnetin was also particularly effective, in contrast to for example 
quercetin-glucuronide which only mildly enhanced iron mobilisation when combined 
with 10μΜ ibe of commercially available chelators. As isorhamnetin is one of the 
main metabolites of quercetin in human plasma (Burak et al, 2015), we wished to 
examine its potential to act as a shuttle for iron(III) more extensively when combined 
with DFO/DFX/DFP, in hepatocytes. Cells were loaded with iron as described in 
methods and treated with chelator combinations for 8 hours.  Intracellular iron 
concentration was then determined using the ferrozine assay and normalised for total 
cellular protein. Figure 53 shows that isorhamnetin is able to enhance iron 
mobilisation when combined with DFO/DFX/DFP in a concentration-dependent 
manner. Following 8 hours of treatment at only 1μΜ it enhances iron decrements by 
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2.1, 1.3 and 1.6 fold when combined with 10μΜ ibe of DFO, DFP and DFX 
respectively, making it almost as potent as quercetin in enhancing iron mobilisation at 
small concentrations. 
Overall this data suggest that quercetin and its derivatives possess the ability to 
increase iron mobilisation from cells when combined with clinically available 
chelators. The relative efficacy of the derivatives of quercetin when combined with 
other chelators, reflect the relative efficacy of these compounds when used alone. The 
data obtained comparing different metabolites show the importance of preservation of 
the hydroxyl group in site 3 of the C ring for effective iron chelation (see Figure 42).  
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Figure 53. Decrements in cellular iron in H9C2 cells by combinations of Isorhamnetin with clinically 
available iron chelators following 8 hours of treatment. (A) DFO-Isorhamnetin, (B) DFP-Isorhamnetin, (C) 
DFX-Isorhamnetin. Cells were loaded with iron, treated with chelators and intracellular iron concentration 
determines as in Figure 47. Results are the mean ± SEM of 3 replicates in one experiment. 
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6.7.8 Quercetin isobolograms and the synergy index α 
 
The issue of synergy vs. additivity of action of quercetin and commercially available 
iron chelators was further addressed by the use of isobolograms. As discussed in the 
methods section, the isobologram is a mathematical model used to distinguish between 
the synergistic, additive or subadditive response of drug combinations (Tallarida, 
2006) where rectangular coordinates of dose combinations (a,b) that produce the same 
chosen effect level are shown; in this case 50% of the maximum response.  Figure 53 
shows the isobolograms for combinations of the three commercially used chelators for 
a 50% chelation effect with quercetin. HuH7 cells were iron loaded with serial media 
changes as previously described and treated with chelators for 8 hours. In all three 
cases, a curved response was produced below the line of additivity, indicating a 
synergistic action. The axis intercepts again represent the IC50 for each chelator 
compound when used in isolation (i.e., the potency; e.g., 16.7μΜ ibe for DFP). The 
degree of synergism was further examined below by looking at the synergy index α. 
 
As previously discussed (Section 4.6.1), this index is a representation of how much of 
the obtained effect exceeds that expected by additivity of the two compounds. It is 
equivalent to  (1 − 1/) 	 100  where R = difference of area under the line and area 
under the curve of the isobologram (Tallarida, 2001) and was derived using data 
generated from the program ‘Prism 5’. It was noted that when quercetin and DFO are 
combined, 56.3% of the chelation effect is due to synergy. In the quercetin-DFP 
combination, 60.6 % of the total effect was due to synergy and interestingly this 
appears to be the most synergistic combination, even when comparing commercially 
available iron chelator combinations. The synergy of action noted is very likely to be 
attributed to the potential of quercetin to act as an effective ‘shuttle’ of iron to a ‘sink’. 
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  Figure 54 Quercetin and commercially available chelator combination isobolograms in 
HuH7 cells. 
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Table 17 Synergy Index ‘α’ for the combination treatment of commercially available chelators with 
quercetin in cardiomyocyte (H9C2) cells. This index is a representation of how much of the obtained 
effect exceeds that expected by additivity of the two compounds (Section 4.6.1). 
 
 
Chelator 
Combination 
Synergy Index (α) 
DFO - DFX 37.0 +/- 2.1 
DFO - DFP 47.4 +/-3.2 
DFX - DFP 51.5 +/- 2.9 
Quercetin - 
DFO 
56.3 +/- 3.2 
Quercetin - 
DFP 
60.6 +/- 1.9 
Quercetin - 
DFX 
45.9 +/- 2.7 
6.8 Synergistic chelation of Quercetin combined with otherwise ineffective 
hydroxyyridinone CP40 
To demonstrate synergistic iron chelation and distinguish from ‘additivity’ of action 
when quercetin is combined with a second chelator, we examined CP40 (a 
hydroxypyridone chelator with a high iron binding constant that is ineffective at 
mobilising cellular iron due to its inability to permeate cell membranes) (Porter et al, 
1988; Porter et al, 1990).  In Figure 55 , it can be seen that CP40 alone does not 
enhance cellular iron removal, confirming previous observations in Chapter 4 in 
primary hepatocytes (Porter et al, 1988; Porter et al, 1990). When CP40 was combined 
with quercetin, however, an increase in cellular iron removal was seen, greater than 
with quercetin alone.   This provides further mechanistic insight into how 
combinations of commercial chelators with quercetin interact. It supports the concept 
that quercetin in combined therapy has the potential to act as a shuttle here donating 
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iron chelated intracellularly to the extracellular CP40. Since CP40 has very little 
access to intracellular iron when used alone, it cannot act as an intracellular iron shuttle 
but as a passive extracellular acceptor of iron within cells by another chelator.  The 
increase in cellular iron mobilisation observed when CP40 33μΜ ibe was combined 
with quercetin 3μΜ is likely due to an increase in the ‘sink’ total concentration in the 
extracellular medium. Therefore, quercetin can act as an intracellular shuttle onto 
CP40, which remains exclusively in the extracellular compartment.  
  
Figure 55 Cellular iron mobilisation is shown in previously iron loaded HuH7 cells, after 8 
hours of exposure to quercetin 3μΜ and/or CP40 33μΜ ibe as single agents and combination. 
Chelator supernatants were then removed and cellular iron determined as described above.  Results 
are the mean ± SEM of 4 replicates in one experiment. 
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6.9 Discussion 
In this chapter, naturally occurring iron chelators, present in human diet, that are also 
known to be potent antioxidants were used to interrogate the relationship between the 
structure and function of naturally occurring flavonoid chelators in terms of iron 
mobilisation and ROS scavenging properties. The progressive removal of total cellular 
iron by quercetin in hepatocyte (HuH7) and cardiomyocyte (H9C2) cell lines has been 
shown. Surprisingly, quercetin monotherapy at 30μΜ proved only just inferior at 
mobilising cellular iron in the cardiomyocytes (16.6%) and hepatocytes cell line 
(41.9%) to DFP for example which mobilised 44.6% of hepatocyte and 17.5% of total 
cardiomyocyte iron at 30μΜ ibe following 8 hours of treatment (Table 16).  
 
With respect to metabolites of quercetin, even with a low concentrations of 3μΜ of 
the quercetin aglycone, mobilisation of iron is seen as early as 1 hour of treatment 
(Figure 46).  Closely investigating the iron mobilisation properties of isorhamnetin, 
quercetin-glucoside, kaempherol and quercetin glucuronide further, sheds light on the 
different iron binding motifs of phenolics and their importance for effective iron 
chelation. Isorhamnetin, which has a methyl group substituted at the 3’ hydroxyl group 
on the B ring, is almost as effective in iron mobilisation as the quercetin aglycone in 
hepatocytes (34.7% vs. 41.9%). However, substitution of a glucuronide or a glucoside 
at site 3 on the C ring decreases iron mobilisation to 13% and 26% respectively 
following 8 hours of treatment in HuH7 cells at 30μΜ (Figure 46). The above results 
confirm that the preferred Fe(II) iron binding motif is indeed the 3-hydroxyl and 
carbonyl site on the C ring. Furthermore, it is not only key for iron chelation but also 
pivotal in iron binding and enabling the molecule to act as a shuttle. Isorhamnetin 
proved to at only 1μΜ enhance iron mobilisation by 2.1, 1.3 and 1.6 fold (quercetin 
enhanced by 2.6, 2.5 and 2.3) when combined with 10μΜ ibe of DFO, DFP, and DFX 
respectively. The synergistic potential of quercetin was once again confirmed by 
utilising the extracellular iron chelator CP40, which has no inherent iron mobilisation 
effects of its own, and lead to enhancement of iron mobilisation when it is combined 
with quercetin (Figure 55). This experiment provides evidence that quercetin indeed 
acts as a true 'shuttle' of iron out of cells. As CP40 cannot enter cells (Porter et al, 
1988; Porter et al, 1990) and has no inherent iron mobilising properties the only way 
in which cellular iron mobilisation can be enhanced is by quercetin chelating iron 
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within cells and then donating iron(III) to the extracellular 'sink' that is CP40. We 
predict that quercetin binds more weakly to iron(III) than CP40 at low concentrations, 
as seen by the iron shuttling with quercetin at  3μΜ and CP40 33μΜ ibe, however 
speciation plots using increasing quercetin concentrations are required in order to 
predict at what concentration quercetin will begin to compete with CP40 for iron(III) 
binding.  
 
The effect on ROS scavenging of the structurally related flavonoids that are 
metabolites of quercetin, provides insight into the rates of access of these compounds 
to intracellular iron pools as well as to the differences and similarities of antioxidant 
and chelating effects of these compounds.  The findings adds insight into the 
relationship between the structure and function in this respect. The kinetics of rate of 
ROS inhibition with all tested compounds are very rapid, occurring at the first 
measurable time point (Figure 48) confirming that the hydroxyl groups on the B ring 
(Figure 44) is crucial for scavenging ROS, and as previously quoted in the literature 
the 3’and 4’ hydroxyl groups are the ones to readily donate a hydrogen and an electron 
to neutralise radicals (Cao et al, 1997). Stable radical formation is favoured by the 
carbon backbone structure of flavonoids that allow for free movement of an electron 
across it (delocalisation), increasing stability. In terms of absolute values of ROS, it is 
noted that Kaempherol and Isorhamnetin are the least effective scavengers, once again 
highlighting the importance of the 3’ hydroxyl group on the B ring (Figure 44). There 
is limited knowledge to date on the structure-activity relationship of quercetin (Brown 
et al, 1998), and this is the first report investigating this in the quercetin metabolites 
with regards to their iron mobilising and antioxidant/antiradical activity. Importantly, 
while quercetin glucuronide and quercetin-3-glucoside are effective ROS scavengers 
(Figure 48) they are ineffective at mobilising cellular iron (Figure 46). While this 
could in principle be due to the inability of iron complexes of these compounds to 
egress from cells, it is more likely that these compounds are ineffective iron chelators 
because as discussed above they are metabolised at the iron-binding sites of the C ring. 
This demonstrates therefore that metabolites of quercetin and presumably those of 
quercetin itself possess free radical scavenging properties that are independent of the 
iron chelating properties. Thus, with regards to iron mobilisation, the 3-hydroxyl and 
carbonyl site on the C-ring allows iron binding and enhances the property of a 
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flavonoid to act as an iron shuttle, but inhibition of this function is not correlated with 
antioxidant activity as this is mostly dependent on the 3’ hydroxyl group on the B ring. 
 
However, prediction of the physiochemical activity of a molecule is not purely based 
on its configuration and availability of hydroxyl groups. An important contributor to 
the pro/antioxidant activity of molecules is their partition coefficients (log P), where 
P is the ratio of the concentration of the molecule in octanol to the aqueous 
concentration at pH 7.4. The partition coefficient is used as an indicator of the affinity 
of a compound to cross membranes in vivo and determine their absorption, 
distribution, and biological effects. The partition coefficient and the ability to diffuse 
through plasma membranes cannot be considered similar for all flavonoids given their 
variation in structure and physiochemical properties. Only molecules of appropriate 
lipophilicity can diffuse across phospholipid membranes, and in general, flavonoids 
aglycones tend to be more lipophilic than any conjugates. Quercetin has a partition 
coefficient of 1.82 +/- 0.32 vs. Kaempherol 3.11 +/- 0.54 and quercetin-3-glucoside 
0.32 +/-0.02, demonstrating the approximately equal distribution of quercetin between 
aqueous and lipophilic compartments. Quercetin-3-glucoside will, however, permeate 
cells more readily than both the quercetin aglycone and Kaempherol, and this is a 
property that can contribute to the enhanced ROS scavenging of quercetin-3-glucoside 
and quercetin-3-glucuronide noted above. 
 
We wished to understand how the decrease in cellular iron and ROS generation seen 
above reflects in the mobilisation of storage iron (ferritin).  In HuH7, quercetin 
achieved a dose-dependent decrease in ferritin at 10μΜ and 30μΜ. At 30μΜ it was, 
in fact, more effective than all 3 commercially available iron chelators at mobilising 
cellular ferritin, reducing the total concentration by 45% (Figure 50).  Given the strong 
iron mobilisation properties of quercetin, this is not surprising. Interestingly in both 
cell types, all the structurally related flavonoids tested were able to decrease ferritin 
concentration in a dose-dependent manner at 10 and 30μΜ, being nearly as effective 
as the unmetabolised ligand. There are a number of potential explanations for this 
discussed below.  
Ferritin stores Fe(III) in a 24 subunit multimer that is a combination of light and heavy 
chains. Iron must be released from ferritin to be biologically active. Ferritin 
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degradation involves autophagic and non-autophagic pathways, which are 
evolutionary pathways essential for maintaining iron homeostasis. Turnover of the 
ferritin protein is a constant process in the cell. Autophagy through lysosomal 
mechanisms appears to be the main degradation in iron deficiency; where-as non-
autophagic pathways dominate in iron sufficiency. Recently, the nuclear receptor 
coactivator 4 (NCOA4) was identified as a key protein for mediation of ferritin 
autophagy (Mancias et al, 2014). Chelators such as DFO and DFX (Mancias et al, 
2014) have been shown to activate NCOA4 mediating ferritin autophagy. Considering 
the iron chelating properties of our flavonoids, mediation of NCOA4 levels and 
stimulation of the ferritin autophagy pathway is a possible explanation for the low 
levels of ferritin noted following 8 hours of treatment in hepatocytes and 
cardiomyocytes (Figure 51). 
Alternatively, some of the ferritin decrements may be unrelated to iron chelation and 
demonstrate a response to the strong antioxidant effects of the flavonoids 
demonstrated above. (This is consistent with data showing how some of ferritin 
synthesis is controlled by factors independent of iron that are more dependent on free 
radicals). Excess iron is ‘sensed’ by iron-responsive proteins (IRP) which bind to iron 
responsive elements (IRE) on the ferritin molecule modulating synthesis. IRP has been 
previously shown to be regulated by the redox state in vitro as well as in cell cultures 
(Hentze et al, 1989; Müllner et al, 1992). Furthermore, it has been demonstrated in 
rats that ferritin synthesis in the liver is stimulated by oxidative stress, and there is 
down-regulation of IRP binding. This effect could be partly modulated by iron 
chelation, however, it can also be attributed to ROS independently as they play a 
fundamental role in the maintenance of the conformation of IRP, being a direct target 
for ROS (Philpott et al, 1993). ROS lowers IRP levels, increasing iron sequestration 
(Cairo et al, 1998). In our model, the marked reduction in ROS is likely to lead to an 
increase in IRP and a reduction of ferritin synthesis/increased degradation. Our data 
suggest there may be differences between different cell types in the relative 
dependence of iron or free radical induced ferritin synthesis. Thus in the H9C2 cells 
all metabolites of quercetin are approximately as effective as each other in decreasing 
ferritin synthesis. In contrast, in HuH7 cell quercetin is the most effective. Since 
quercetin is also the most effective at iron mobilisation, and it is possible that ferritin 
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synthesis in the hepatocytes, like in HuH7 cells where iron is stored, is relatively more 
dependent on iron than in cardiomyocytes that are not significant sites of iron storage. 
6.10 Conclusion 
In this chapter, we have demonstrated the iron mobilising properties of quercetin and 
its principle metabolites from cells for the first time and demonstrated their ability to 
act as an iron ‘shuttle’ when combined with clinically available chelators. Metabolism 
of quercetin will not abolish its iron mobilisation properties as a large number of its 
metabolites share its iron chelating properties. The doses of quercetin, alone or in 
combination with other chelators, are sufficiently low and clinically achievable to 
suggest quercetin could be used as an adjunct to iron chelation, with the DFP-
Quercetin combination appearing to be the most synergistic. Furthermore, we have 
provided a unique structure-function analysis of flavonoids with regards to iron 
mobilisation and antioxidant capacity as a function of Fe(II) binding. 
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Chapter 7 DEVELOPMENT OF AN IRON-OVERLOADED 
MOUSE MODEL FOR TESTING THE ORAL EFFICACY OF 
IRON MOBILISATION WITH FLAVONOIDS ALONE OR IN 
COMBINATION WITH OTHER IRON CHELATION  
7.1 Rationale for developing a murine model where cardiac iron overload is 
achieved 
The current clinical management of β thalassaemia major involves a lifelong 
dependence on regular blood transfusions, a consequence of which is systemic iron 
overload which most importantly includes the liver and heart, and chronic use of iron 
chelators in order to manage this complication. Until very recently, death secondary to 
heart failure resulting from cardiac iron overload is the leading cause of mortality in 
patients with β thalassaemia major.  A key requirement of iron chelators is the removal 
and prevention of excess cardiac iron loading. Therefore, a critical aspect of a putative 
model to study iron overload is cardiac iron loading within cardiomyocytes and not only 
in the interstitium of the myocardium and the epicardium. 
7.2 Mouse models of cardiac iron-overload  
Early models for evaluating iron loading have been described in Section 1.6.5. Here we 
review some of the recent models using iron dextran, ferrocene and carbonyl iron to 
load iron into the heart. 
The effect of DFX and DFO treatment has been studied on iron loaded gerbils with 
respect to cardiac iron (Wood et al, 2006). In this work, iron dextran 200mg/kg was 
injected (ip) weekly for 10 weeks to induce iron loading, and was followed by an iron 
redistribution period of 13 days. On Perls stain of the hearts, iron was noted to be absent 
from within the myocytes and likely accumulated within macrophages in the 
extracellular matrix. It may be possible that gerbils may excrete iron via the faecal route 
twice as rapidly as mice,  therefore, a protocol of daily injections may have been more 
appropriate in the animal. Furthermore, 13 days may not have been sufficient for the 
iron from the iron dextran to have accumulated and be redistributed within the 
myocardium, and hence a longer re-equilibration period may need consideration. 
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In a heterozygous β thalassaemia mouse model (Yatmark et al, 2014), mice were 
injected with a total of 180mg of iron (20mg/daily) for two weeks, and there was a 3 
day re-equilibration period prior to a 7-day treatment with DFO and DFP to investigate 
effects on liver and cardiac iron. A group of mice were sacrificed 10 days following the 
end of iron dextran treatment. The histology Perls stain images show large clumps of 
iron dextran making it difficult to assess the location of iron within the myocardium. 
Following 7 days of chelator treatment, small deposits are possibly seen within the 
myocytes, supporting the use of a heterozygous thalassaemic mouse and iron dextran 
as a medium for iron loading, but also supporting the notion for a longer time period for 
iron equilibration and re-distribution. Another group (Moon et al, 2011) found no 
relationship between iron loading non-thalassaemic mice and cardiac function, and 
administered daily injections of 10mg/day iron dextran, up to a total of either 100mg, 
200mg or 300mg. Between two and four weeks were allowed for iron redistribution 
prior to animal culling, with the implication that mice that were more heavily iron 
loaded had the shortest re-equilibration period as all animals were sacrificed at the same 
time. Histology slides demonstrate iron depositions in the cardiac interstitium, but none 
is visible in the myocardium. This supports the hypothesis that the use of a thalassaemic 
mouse model and a longer re-equilibration period would have resulted in iron deposition 
within the cardiomyocytes, similar to that seen in human transfusional iron overload. 
In another model, wild type mice were fed a ferrocene-supplemented diet (0.2%w/w) 
over a period of two months to induce iron overload and were then treated with DFP or 
curcumin for 4 months (Thephinlap et al, 2011). Although dietary iron supplementation 
is less technically challenging and time consuming than i.p. injections of iron dextran, 
and furthermore mice receive daily treatment, this study showed only minimal iron 
deposits in the cardiac interstitium. 
 In a haemochromatosis mouse model (Santos et al, 2000) fed a 2.5% (w/w) carbonyl 
iron diet for 12 weeks, a small amount of iron deposits were noted within lysosomes in 
the cardiomyocytes using an electron microscope. On examination of the histology 
Perls stain images, the majority of iron appears to be in the interstitium and there is no 
clear iron deposition within the cardiomyocyte. This study does however provide 
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promising evidence in support of the use of carbonyl iron as a vehicle for iron loading, 
however longer treatment periods may be necessary. 
Given the short-comings of these various methodologies, iron dextran was chosen as 
the iron administration vehicle, at a dose of 10mg/day for 5 days/week, for 4 weeks. An 
extended iron re-equilibration period of 4 weeks was incorporated into the study 
protocol, and a group of animals was randomly selected for culling at the end of the iron 
dextran loading period for comparison of heart, liver and spleen tissue iron, in order to 
assess the effects of re-equilibration on iron distribution at an organ and cellular level 
(Section 7.3.2). 
7.2.1 Rationale for using a beta thalassaemia mouse model. 
One of the goals of this work was to produce a murine model of thalassaemia that would 
develop cardiac iron loading within cardiomyocyte and represent the pathology of 
transfusional iron overload and its response to chelation as closely as possible to that 
seen in humans. Animal models for the study of iron overload and the effects of iron 
chelators are described in Section 1.6.5. In addition, several iron-containing vehicles 
have been used to induce iron overload (Table 3), but convincing evidence of iron 
loading within cardiomyocytes of these models is lacking. Described in this chapter is 
the development of an iron loading protocol utilising iron dextran, studied in a 
humanised β thalassaemia mouse model. In contrast to humans, iron overloaded wild-
type mice rapidly unload excess iron in their faeces (Musumeci et al, 2014). By iron-
loading humanised β thalassaemia mice, the ineffective erythropoiesis that occurs from 
the thalassaemic gene is predicted to change the balance between iron loss and iron 
absorption in favour of iron retention. This would predict a model where iron overload, 
particularly extra-hepatically, is obtained more readily than in wild-type mice. 
7.2.2 Murine models of thalassaemia  
Modelling thalassaemia in mice is complicated by the fact that mice lack true fetal 
haemoglobin. Following birth, human erythroid cells undergo a fetal to adult 
haemoglobin switch. However, mice do not undergo such a change and continue 
expressing the same adult globin genes that were synthesised during fetal development. 
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The ideal mouse model of thalassaemia should demonstrate the following features: (a) 
only express human haemoglobin, (b) complete in a similar fashion to humans the 
transition from expression of fetal γ to adult β genes following birth, (c) synthesise no 
functioning adult β globin chains, (d) be transfusion dependent for life, (e) be heritable, 
(f) accumulate iron in cardiomyocytes and hepatocytes, and (g) lack a mechanism of 
iron excretion. 
The humanised thalassaemia mouse model (Heterozygous knockin γHPFHδβ0/γβA ) 
which was generated by Huo et al (Huo et al, 2010) was chosen. This is, a relatively 
novel mouse model, created in 2008 (Huo et al, 2009), and represents one of the most 
clinically accurate models of β thalassaemia in a mouse to date. In this mouse, the adult 
β globin gene has been replaced by a human fetal to adult haemoglobin-switching 
cassette. In the homozygous form, the mice die around day 18 of life due to lethal 
anaemia, and life can only be sustained by repeated blood transfusions. However this is 
expensive, time consuming and requires great expertise. The heterozygous form 
exhibits a β thalassaemia intermedia-like phenotype and mice develop microcytic 
anaemia with mean haemoglobin of 7.9gd/L, compared to that of 13.8g/dL in wild-type 
mice. On blood film examination, there are hypochromic red cells with marked 
anisopoikilocytosyis, and a 9-fold increase in the reticulocyte count. These mice also 
demonstrate erythroid hyperplasia as well as, similarly to humans, extramedullary 
haematopoiesis as a consequence of anaemia. Furthermore, there is splenomegaly with 
the enlargement of the spleen averaging 6-fold. Lastly, the premature destruction of 
erythroid cells leads to iron release, and there is mild iron deposition noted in the bone 
marrow, liver and spleen (Huo et al, 2009) but not the heart. In view of the ineffective 
erythropoiesis, this model is predicted to favour iron retention and more readily show 
iron accumulation extra-hepatically. Following a review of the currently available iron 
loading techniques (Table 3), intraperitoneal injections of iron dextran were chosen in 
an attempt to induce iron loading into the heart as described in the methods below, in 
the heterozygous mouse (Figure 56). 
7.2.3 Value of MRI in assessing tissue iron in iron overloaded models.  
The use of clinical magnetic resonance imaging (MRI) to assess the extent of iron 
loading in organs has revolutionised the diagnosis, management, and treatment of β 
 191 
thalassaemia major patients (Papakonstantinou et al, 2009; Tanner et al, 2006; 
Voskaridou et al, 2004; Wood et al, 2005a). MRI has two primary advantages over other 
imaging or invasive diagnostic techniques; accurate measurement of cardiac structure 
and function; and direct quantification of iron loading due to shortening of magnetic 
relaxation times T1, T2, and T2* in the presence of iron. In this chapter we show the 
application of clinically relevant MRI assessment methods to the novel γHPFHδβ0 
knockin mouse model of β thalassaemia in the presence of iron overload, and its 
correlation with tissue iron. We used the opportunity to collaborate with the Centre for 
Advanced Biomedical Imaging, also at UCL. 
There is an urgent need for accurate non-invasive methods that will detect and quantify 
iron load, so that new therapies can be directly assessed in vivo, and this lead to the 
development of an MRI iron monitoring technique to determine changes in iron status. 
Ultimately, MRI iron monitoring will lead to reduction in animal use and a more 
effective short as well as long-term monitoring of iron status.  
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7.3 Development of the iron overloaded murine mouse model 
7.3.1 Materials and Methods  
As stated earlier, collaboration was established with the Centre for Advanced 
Biomedical Imaging, University College London, to correlate iron overloaded murine 
tissue iron and histological findings with non-invasive and in vivo MRI (see below). I 
performed iron loading of mice, animal culling and blood sampling, tissue fixation, post 
mortem quantification of tissue iron, acquisition, and analysis of histology images and 
correlation of tissue iron with MRI findings. All imaging was carried out by Laurence 
Jackson, at University College London (UCL), as part of his doctoral studies. Blood 
sample analysis was performed by the Veterinary Clinical Pathology Lab, University of 
Cambridge. 
7.3.2 Iron loading of humanized β thalassaemic mice 
The humanised thalassaemia mouse model (Heterozygous knockin γHPFHδβ0/γβA ) was 
kindly donated by Dr. Anna David, Institute of Women’s Health, University College 
London. Male heterozygous knockin mice (γHPFHδβ0/γβA) were housed in stainless steel 
cages in a temperature and humidity controlled environment with 12 hour light/dark 
cycles. The mice had access to water and standard chow diet ad libidum. All animal 
work was performed in accordance with the UK Home Office Animals Scientific 
Procedures Act (1986) and institutional guidelines. Twelve thalassaemic mice and 
seven control mice (γβA/γβA) were randomized at 4 months of age to receive either iron 
dextran or PBS intraperitoneal (ip) injections for 5 out of 7days/week for a total of 4 
weeks to induce iron loading (Figure 56). The treatment groups are further annotated 
below. Three iron-loaded mice and 3 control thalassaemia as well as 2 humanised 
control mice were culled straight after the loading period. A further 4 week period was 
allowed for iron re-equilibration prior to MRI and animal sacrifice for tissue iron 
determination of the rest of the mice (Section 2.8.3, Section 2.8.4). 
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a) Humanised  Control:  Humanised γβA/γβA control mice (n=7). 0.1ml of ip PBS 
5 days/week for 4 weeks. 
b) Control Thalassaemia: Heterozygous knockin γHPFHδβ0/γβA thalassaemia mice 
(n=6). 0.1ml of ip PBS 5 days/week for 4 weeks. 
c) Iron-loaded Thalassaemia Heterozygous knockin γHPFHδβ0/γβA thalassaemia mice 
(n=6) received ip injections of iron dextran solution 
(10mg/day for 4 weeks (5 days/week)) to induce iron 
loading. 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.3 Iron quantification, histology and blood sampling 
Following MRI imaging I sacrificed the animals and fixed tissue samples of the heart, 
spleen and liver in 4% Paraformaldehyde for analysis. I measured non-haem tissue iron 
concentration using the iron assay described by Bothwell et al. (Bothwell et al, 1979) 
(Section 2.8.5) and iron deposits were observed histologically by Perls’ staining carried 
out at the Veterinary Clinical Pathology Lab, University of Cambridge (Section 2.8.6). 
I scanned the slides using the slide scanner at the Biosciences division at UCL to 
Figure 56 Schematic representation of mouse iron loading model 
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visualise tissue iron staining and further analysed the extent of iron deposition using the 
software ‘Image J’. Blood samples were taken by me during animal culling. 
7.3.4 MRI measurements 
To correlate the histological findings of iron overloaded tissue with, non-invasive and 
in vivo preclinical MRI was used. Imaging was performed by Laurence Jackson prior 
to me culling the mice, using a 9.4T MR system (Agilent Technologies, Santa Clara, 
USA). A small animal physiological monitoring system (SA Instruments, Stony Brook, 
NY) was used to record the ECG tracing, respiration rate, and temperature during the 
scan. Animals were anesthetised for the MRI by Laurence Jackson under a mixture of 
isoflurane and oxygen with physiological measurements monitored to maintain the 
depth of anaesthesia. A number of measurements were obtained by Laurence Jackson 
during the scan: 
 
I. Spleen volume 
In control and non-loaded thalassaemia mice these readings were easily obtained, 
however in iron-loaded mice due to the ultra-short T2/T2* relaxation in the spleen, this 
proved initially more challenging. The ratio of spleen volume to total animal mass was 
used as a quantitative and animal-independent value for spleen size. 
II. MRI Relaxometry 
Transverse relaxation mechanisms T2 and T2* are the time constants describing the rate 
of transverse MRI signal decay that depends on the microscopic magnetic environment 
in tissue. The large paramagnetic influence of molecules containing iron causes 
perturbations to the magnetic environment regardless of its biomolecular form. This 
results in faster transverse spin relaxation in direct proportion to iron concentration, 
making T2/T2* quantifiable markers for iron-overload (Carpenter et al, 2014; Carpenter 
et al, 2011). T1 was also recorded using a different sequence. 
III. Cardiac Function 
Cardiac function was assessed with a gradient echo MRI sequence with the number of 
cine frames matched to cover the complete cardiac cycle. The left ventricular blood pool 
was segmented at systole and (Heiberg et al, 2010) the corresponding volumes used to 
calculate left ventricular ejection fraction (EF), stroke volume (SV) and end 
systolic/diastolic volumes (ESV/EDV) (Stuckey et al, 2012). 
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7.4 Results 
7.4.1 Tissue iron and histology 
Histological sections of spleen, heart and liver are shown in Figure 57 A, from animals 
culled 4 weeks post completion of the iron dextran iron loading regimen in the group of 
iron-loaded β thalassaemic mice, and 4 weeks after completion of PBS treatment in 
humanised control and β thalassaemic control mice. There is no iron deposition in the 
spleen, liver nor heart of humanised control mice. Small iron deposits are visible as blue 
regions in the liver and spleen of thalassaemia control group in the absence of iron 
loading, but there is no accumulation of iron in cardiomyocytes. This iron distribution 
in the non-iron loaded control heterozygous β-thalassaemic mouse is consistent with 
early stage organ iron deposition secondary to haemolytic iron release where the iron 
has not spread beyond the macrophage system of the liver and spleen. In the iron loaded 
thalassaemia group there are large iron deposits in the liver and spleen, but most 
importantly iron is also visible in cardiac macrophages, epicardium, and the 
myocardium (Figure 58).   
Iron tissue concentration determined by the Bothwell non-haem assay for each organ 
examined in the respective study groups is shown in Figure 57 B. Control thalassaemia 
hearts did not show significantly higher iron content than humanised controls, but iron 
loaded thalassaemia animals showed large cardiac iron depositions (Figure 57 B, 
Figure 58).  Hepatic iron content was higher than humanised controls in control 
thalassaemia and iron-loaded animals, while splenic iron showed an increasing trend 
but the results did not reach statistical significance. These results match the T2/T2* 
relaxometry measurements presented below. Table 18  shows the tissue iron in the heart, 
liver, and spleen of animals culled directly after completion of iron dextran treatment 
compared to the group which underwent a 4 week iron redistribution period. 
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Figure 57 Iron in the heart, liver and spleen following iron-loading in mice and a 4 week re-equilibration period. 
(A)Perls stain showing iron deposits in the spleen, liver and heart. Iron loading is noted in the cardiomyocytes only following 
iron treatment. Results of the Bothwell iron assay (B) show that iron content significantly increases following treatment with 
iron dextran in all three organs. 
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7.4.2 The effect of a immediate culling vs. following a 4 week re-equilibration 
period 
Three of the six β thalassaemic mice that received i.p. injections of iron dextran for 5 
days/week at 10mg/day for 4 weeks, were sacrificed at the end of the iron loading 
regimen. The remaining 3 mice were culled 4 weeks after the end of the treatment, to 
allow for iron redistribution. Tissue iron was quantified using the Bothwell non-heam 
iron quantification method (Section 2.8.4). Interestingly, in the animals maintained for 
4 weeks after iron loading for iron redistribution, the cardiac iron concentration 
increased significantly, by 2.2 fold (from 1.91 to 3.09, p<0.05) (Table 18). This is 
clearly visible in the Perl stains in Figure 59, where the myocardial iron is present at 
low levels initially, followed by iron dextran deposition in the interstitium as well as 
myocardium 4 weeks later. Both liver iron and spleen tissue iron concentration showed 
a decreasing trend in tissue iron from 5.04 to 4.83 (p>0.05) and 3.94 to 2.41 (p <0.05) 
Figure 58 Perls stain of the heart of iron loaded mice demonstrating iron in the myocardium. (20x 
magnification).The mice were iron loaded with IP injections of iron dextran 10mg/day for 5 days/ week and a 
4 week period was allowed for iron re-equilibration.  
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(Table 18). These findings clearly demonstrate iron redistribution from the spleen/liver 
to the heart, commonly by macrophages. 
Table 18 Heart, liver and spleen tissue iron. Heterozygous β thalassaemic mice (iron loaded with 
10mg/day of iron dextran for 5 days/week for 4 weeks. Mice were either culled after completion of iron 
dextran treatment or after a further 4 week period for iron re-equilibration. Errors represent SEM. 
 
 
Heart iron 
[mg/g(dry 
weight)] 
Liver iron iron 
[mg/g(dry weight)] 
Spleen iron iron 
[mg/g(dry 
weight)] 
Culled straight 
after iron 
treatment (n=3) 
1.91 +/- 0.25 5.04 +/- 0.65 3.94 +/- 0.41 
Culled 4 weeks 
post treatment 
(n=3) 
4.28 +/- 0.81 4.83 +/- 0.11 2.41 +/- 0.51 
Average of 
above animals 
(n=6) 
3.09 +/- 0.71 4.93 +/-  0.51 3.17 +/- 0.42 
 
 
 
 
 
 
 
 
 
 
 
Figure 59 Perls stain of the heart of iron loaded mice demonstrating iron in the myocardium in mice sacrificed 
directly after the 4 week iron loading treatment or 4 weeks later. 
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7.4.3 Haematological parameters following iron dextran treatment 
Following animal sacrifice either directly after the four week iron loading period with 
iron dextran or following 4 weeks allowed for iron re-equilibration, blood samples were 
taken by me during the culling process. FBC analysis of these samples was performed 
at the Veterinary Clinical Pathology Lab, University of Cambridge and the results can 
be seen in Table 19. Iron treatment significantly increased the haemoglobin (Hb) from 
8.53 to 10.27 g/dL in control vs. treatment (p=0.01), approaching the average level for 
the humanised control mice 11.3 g/dL. Red blood cell count (RBC) significantly 
increased from 6.86 to 9.62x1012/L (p=0.009). The mean corpuscular volume (MCV) 
and mean corpuscular haemoglobin (MCH) remained unaffected by iron dextran 
treatment, however, there was a significant increase in haematocrit from 30.17 to 35.45, 
which was slightly mean value of 38.13 for the humanised control group. Of note, the 
reticulocyte proportion was more than two-fold higher in untreated compared to treated 
mice (15.89% vs. 6.90%), and the mean reticulocytes proportion was recorded as 3.85% 
in the humanised controls. Furthermore, iron treatment appeared to induce a significant 
increase in white cell count (15.19 x109/L vs. 3.16 x109/L) coupled by an increase in 
neutrophils (3.52 x109/L vs. 0.18 x109/L) as well as lymphocytes (9.60 x109/L vs 2.83 
x109/L). The interpretation of the above findings is discussed in Section 7.5. 
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Table 19 Changes in haematological parameters secondary to iron loading with iron dextran. 
Heterozygous β thalassaemic mice were iron loaded with 10mg/day of iron dextran for 5 days/week for 4 weeks. 
Thalassaemia control mice and humanised controls were treated with PBS for 4 weeks. Mice were either culled 
after completion of iron dextran/PBS treatment or a further 4 week period for was allowed prior to culling. * 
indicates p<0.05 when comparing the mean of thalassaemia iron loaded and the mean of thalassaemia control 
mice. 
 
Thalassaemia iron 
loaded 
Thalassaemia control  Humanised control 
 Mean Culled 
4w 
Culled 
8w 
Mean Culled 
4w 
Culled 
8w 
Mean Culled 4w Culled 
8w 
Hb 
(g/dL) 
10.27* 10.1 10.43 8.53 8.53 8.53 11.3 11.17 11.80 
MCV 
(fL) 
41.20 40.2 42.2 43.9 45.20 43.25 45.7 46.40 44.50 
MCH 
(pg) 
12.4 12.40 12.40 11.93 11.40 12.20 12.93 12.85 13.10 
RBC 
(x1012/L) 
9.62* 9.04 8.20 6.86 6.66 6.97 8.33 7.99 9.02 
WBC 
(x109/L) 
15.19* 12.83 17.54 3.16 5.95 1.76 1.74 2.40 0.43 
Neutrophils 
(x109/L) 
3.52* 4.39 2.65 0.18 0.18 0.18 0.13 0.17 0.05 
Lymphocytes 
(x109/L) 
9.60* 6.10 13.1 2.83 5.60 1.45 1.47 2.00 0.40 
Haematocrit 
(L/L) 
35.45* 36.3 34.6 30.17 30.1 30.20 38.13 37.15 40.10 
Platelets 
(x109/L) 
1538 1518 1558 1613 1917 1462 1285 1071 1715 
% 
Reticulocytes 
6.90* 5.71 8.08 15.89 24.36 11.66 3.85 2.73 4.96 
reticulocytes 589* 516 662 1023 1622 723.80 319 190 447 
 
 201 
7.4.4 Comparison of the weight of mice (A) and their heart, liver and spleen 
weights (B) post sacrifice.   
Neither the weight (Figure 60 A) nor the heart size of β thalassaemic mice (Figure 60 
B) was significantly different. The thalassaemic control mice had a 3-fold larger spleen 
compared to humanised controls (0.26g vs. 0.08g) (p<0.01). However, iron loading did 
not appear to further increase spleen size (Figure 60 B). These findings were also 
confirmed by MRI spleen volume measurements (Section 7.4.5). The liver weight was 
more than double in iron-loaded mice compared to thalassaemic controls (Figure 60 B) 
(p<0.04). 
  
Figure 60 Comparison of the weight of mice (A) and their heart, liver and spleen weights (B) post sacrifice. 
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7.4.5 Spleen volume by MRI (performed by Laurence Jackson) 
A significant increase in spleen size was observed in the presence of the γHPFHδβ0 
gene (Figure 61). Figure 61 shows a comparison of the axial spleen images and 
highlights the enlarged spleens in iron loaded and control thalassaemia mice. 
Spleen volume normalised to body mass was significantly increased in control 
thalassaemia (9.5±1.2mm3/g) and iron loaded thalassaemia mice (9.1±1.3mm3/g) 
relative to humanised control mice (4.0±0.4mm3/g), however, there was no 
significant change in volume between iron loaded and control thalassaemia. This 
suggests that splenomegaly in this animal is probably a result of erythrocyte 
phagocytosis present in our heterozygous mouse model already.  
Figure 61 Mice spleen volumes. Spleens (S) were significantly enlarged relative to humanised controls 
in control and iron-loaded thalassaemia mice. The spleen can be identified by its speckled texture due to 
the dense trabeculae. This was quantified by the ratio of spleen volume to animal mass (**p<0.01). 
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7.4.6 T2/T2* relaxation (performed by Laurence Jackson) 
Measurements of cardiac, hepatic and splenic T2 and T2* are shown in Figure 62 and 
Figure 63 respectively, along with representative images from each group at identical 
echo time. Myocardial T2 was shortened in iron-loaded thalassaemia mice (3.3±0.3ms) 
versus humanised controls (18.0±0.8ms) and thalassaemia controls (17.2±2.1ms). 
Similarly, myocardial T2* in iron overload (0.7±0.2ms) was shortened relative to 
humanised controls (11.5±4.3ms) and thalassaemia controls (10.1±5.2ms). This data 
demonstrates that T2 and T2* measures are sensitive to iron loading in this animal 
model. It can be inferred from this that the heterozygous phenotype does not have any 
cardiac siderosis.  
Hepatic T2 was shortened in both the control thalassaemia (9.4±2.9ms) and iron-loaded 
thalassaemia mice (1.3±0.3ms) relative to humanised controls (13.2±01.0ms). 
Similarly, hepatic T2* was shortened in the control thalassaemia (4.7±1.5ms) and iron-
loaded thalassaemia mice (0.6±0.2ms) models relative to humanised controls 
(7.6±1.9ms). This shortening of T2 and T2* in the non-iron loaded thalassaemia group 
can be attributed to the premature destruction of erythroid cells leading to iron release 
and iron/ferritin deposition in the liver. 
The role of the spleen in breaking down senescent erythrocytes renders it hyperactive 
in thalassaemia where a large population of erythrocytes is defective. Iron deposition is 
a byproduct of the metabolism of the hemoglobin in the spleen. The shortened T2 and 
T2* in both thalassaemia groups reflects this process. Splenic T2 was shortened in 
control thalassaemia mice (3.9±0.8ms) and iron-loaded thalassaemia (1.7±0.9ms) 
compared with humanised controls (6.2±0.8ms).  Splenic T2* was shortened in iron 
overload mice (0.8±0.1ms) and control thalassaemia mice (0.6±0.5ms) relative to 
humanized controls (1.5±0.3ms).  
Iron accumulation occurs initially in the macrophage system of the spleen, liver and 
bone marrow but subsequently in hepatocytes and ultimately in the heart and endocrine 
systems. These MRI measurements show that, in the absence of iron loading, at 5 
months of age the liver and spleen are showing signs of iron loading, but the process 
has not saturated in order to accumulate iron in th
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Figure 62 T2 relaxation times in iron-loaded mice. T2 was shortened in the control thalassaemia 
animals and more severely shortened in the case of iron-loaded thalassaemia mice (*p<0.05, **p<0.01, 
***p<0.001). 
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Figure 63 T2* relaxation times in iron-loaded mice. T2* relaxation was shortest in the iron-loaded 
thalassaemia animals in the heart, liver, and spleen (*p<0.05, **p<0.01, ***p<0.001). 
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7.4.7 T1 relaxation (performed by Laurence Jackson) 
T1 values were significantly shorter in the presence of iron loading (Figure 64). Cardiac 
T1 was shorter in iron-loaded mice (620±125ms) relative to control thalassaemia mice 
(1041±261ms) and humanised control animals (928±115ms). This was also the case for 
hepatic T1, with iron loaded thalassaemia animals having shorter T1 (456±85ms) than 
control thalassaemia (1014±255ms) and humanised control animals (929±117ms). This 
data shows that T1 is sensitive to the presence of iron loading, however, T1 changes in 
the presence of iron require direct interaction with ferric molecules, making its 
sensitivity lower than T2/T2*. T1 measurements could be most useful at particularly 
high iron concentrations where T2/T2* can be too short to accurately quantify tissue 
iron.  
Figure 64 T1 relaxation times in iron-loaded mice. T1 relaxation in the heart and liver was significantly 
shortened in iron-loaded mice. 
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7.4.8 Cardiac function (performed by Laurence Jackson) 
Quantitative values describing left ventricular function are shown in Figure 65. Left 
ventricular end diastolic, end systolic and stroke volumes (SV) were preserved between 
groups. Cardiac output (CO), measured as the product of stroke volume and heart rate 
was not significantly altered in control thalassaemia mice (14.1±2.1ml/min) relative to 
humanised controls (15.6±1.1ml/min) and iron-loaded mice (12.4±1.5ml/min) 
indicating that at 5 months of age the heterozygous mouse has not developed the 
pathological high output state characteristic of anemia. Left ventricular ejection fraction 
(EF) was also unchanged in iron-loaded mice (70±2%) relative to control thalassaemia 
mice (57±4%) and humanised control animals (65±2%).  
Figure 65 Cardiac function following iron loading. No significant changes in cardiac volumes were 
observed between groups, although the iron-loaded thalassaemia animals had an elevated ejection 
fraction relative to thalassaemia control mice (*p<0.05). 
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7.4.9 Iron calibration 
The tissue iron measurements generated by myself and the cardiac T2* recorded by 
Laurence Jackson were used to generate a calibration curve to estimate the iron content 
of dry tissue. This relationship can be modeled using the following formula:  =
(1  2∗⁄  1  2#
∗⁄  $⁄  where T2* is the measured T2* value, T20* is the T2* of the 
heart in the absence of iron loading and Kdry is a proportionality constant for dry tissue 
(Wood et al, 2005b). This curve was generated by Laurence Jackson who used the 
average T2* of humanised controls as T20* and fitted Kdry to the measured T2* and dry 
iron concentrations. A representation of how the resulting calibration curve fits 
measured values is shown in Figure 66. It shows a sharp increase in estimated tissue 
iron at T2* < 2ms. This is in agreement with the data of Carpenter et al, 2011 who 
correlated T2* with tissue iron of 12 human hearts following retrieval from patients 
either post death or following cardiac transplantation (Carpenter et al, 2011). The 
process can be repeated for T2 measurements by substituting T2 for T2* and in this case 
the iron concentration increases sharply at T2 < 5ms. 
Figure 66 Cardiac T2* to iron calibration curve. Points show individual animals, humanized 
controls(■), Thalassaemia controls(▲) and iron-loaded thalassaemia(•), grey/black points correspond to 
the T2/T2* measurements respectively.  
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7.5 Discussion and conclusion 
The goal of this work was to produce a quantitative platform for the assessment of β 
thalassaemia in a clinically relevant humanised mouse model which demonstrates 
cardiac iron siderosis, with the intention of accelerating the development of clinical 
therapies. Following administration of a total of 200mg of iron dextran 5days/week over 
a period of 4 weeks, we have managed to present the first model to our knowledge 
showing convincing evidence of iron loading within the cardiomyocytes of 
heterozygous β thalassaemic mice, and not simply within the interstitium. The total 
cardiac iron increased from 0.02 ±0.001 to 3.09 ±0.6 (Figure 57 B) and clear deposition 
within the myocardium is noted on Perls staining following 4 weeks of iron re-
equilibration (Figure 58). The importance of allowing a long period for iron re-
equilibration is highlighted by tissue iron measurements (Table 18) which show an 
increase from 1.91 ±0.25 to 4.23 ±0.81 before and after the re-equilibration period. 
Histology findings demonstrate that this time period is critical for allowing 
accumulation of iron in the cardiac myocytes, as noted by the increasing blue deposits 
on Perl staining (Figure 59). 
Iron administration in our model interestingly resulted to an increase in Hb from 8.53 
to 10.27 g/dL in control vs. treatment (p=0.01). RBC significantly increased from 6.86 
x1012/L to 9.62 x1012/L cells/L (p=0.009) but MCV and MCH remained unaffected by 
iron treatment. These findings were coupled by a significant increase in haematocrit 
from 30.17 to 35.45 and a 2-fold decrease in reticulocyte count. It would therefore be 
possible to speculate that the increase in haematocrit could be attributed to an increase 
in RBC. Iron treatment appeared to also induce a significant increase in white cell count 
(15.19 x109/L vs. 3.16 x109/L) (Table 19). The increase in haemoglobin following iron 
administration has been noted previously, where iron dextran was administered 5 
days/week for 4 weeks for a total of 130mg per animal in a transfusion independent 
model of β thalassaemia (Hbbth1/th1) (Ginzburg et al, 2009). The mean haemoglobin 
increase was 1.3g/dL and statistically significant, and compared to 1.7g/dL in the 
current work. Similarly, no change in MCH was noted, but a significant increase in 
MCV was observed. Furthermore, reticulocyte count was noted to increase from 2344 
to 3613 cells/L, contrary to our study where the reticulocyte count dropped from 1023 
to 589 cells/L following iron dextran administration. Ginzburg et al also noted an 
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expansion in extramedullary haematopoiesis in the liver and spleen, which in the liver 
was proportional to the dose of iron administered. This increase was not noted in the 
bone marrow and was coupled with a decrease in the erythroid precursor apoptosis 
(there is a known higher degree of apoptosis in haematopoietic erythroid precursors in 
thalassaemia) (Pootrakul et al, 2000; Yuan et al, 1993). Alternative explanations for the 
increase in Hb could relate to changes in red blood cell survival, or changes to hepcidin 
levels affecting gut iron uptake (which are already abnormally low in thalassaemia), but 
no further speculation is possible with the current available data. A further study 
administered recombinant human erythropoietin 3 times per week along with ferrous 
fumarate 305mg and folic acid 5mg daily for 11 months to 10 patients homozygous for 
β thalassaemia. Investigators noted an increase of Hb from 7.1 to 9.3g/dL, although it 
is difficult to comment on the isolated effect of iron administration in this context 
(Rachmilewitz et al, 1995).  
The heterozygous thalassaemic mouse model was noted to have 3-fold heavier spleen 
at baseline, but this did not change following iron loading (Figure 60 B), and 
splenomegaly was also confirmed on MRI (Figure 61). This was originally described 
by (Huo et al, 2009), and has been attributed to the increase in extramedullary 
erythropoiesis in the spleen. Monitoring of cardiac function during MRI by Laurence 
Jackson showed no evidence of cardiac dysfunction with no change to SV, EDV, ESV, 
EF and CO. Other investigators similarly did not demonstrate any compromise in 
cardiac function following iron loading with ip iron dextran (Moon et al, 2011).   
Changes in the quantitative MRI relaxation times T1, T2, and T2* performed by 
Laurence Jackson were observed in the heart, liver, and spleen in our mouse model 
(Figure 62, Figure 63, Figure 64) following iron loading. The tissue iron data showed 
a strong correlation to MRI relaxation times (R=0.99) (Figure 66). The T2 and T2* 
calibration curves fitted in Figure 66 are representative of calibration curves seen in 
humans (Carpenter et al, 2011) and this is a promising sign that the animal model is 
clinically representative and that serial measurements of tissue iron by MRI can 
establish trends in tissue iron loading/ unloading, enabling more clinically useful 
interpretation of efficacy of treatment and allowing for scarcer animal culling.  
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In conclusion, these results show a novel protocol for iron loading of an established β 
thalassaemia model demonstrating convincing evidence of cardiac siderosis. This 
model shows the importance of iron dextran as a vehicle for successful cardiac iron 
loading and highlights the importance of a long iron re-equilibaration period prior to 
experimentation. Following a collaboration with the Centre for Advanced Biomedical 
Imaging, UCL, derivative calibration curves closely correlated tissue iron with cardiac 
T1, T2 and T2*. Future preclinical studies into the safety of new agents will greatly 
benefit from this iron-overloaded mouse model and integration of MRI assessments, 
and will parallel investigation of toxicity and iron chelation efficacy serially in vivo. 
7.6 Testing the flavonoid quercetin in our animal model 
In this experiment, the relationship between the in vitro effects of quercetin in the 
hepatocyte and cardiomyocyte cellular models and its oral efficacy with regards to iron 
mobilisation, was studied in the novel in vivo model. Given that quercetin proved 
extremely effective at mobilising total cellular iron and demonstrated synergy when 
combined with all three commercially available iron chelators, the potential beneficial 
effects of this naturally occurring compound in terms of iron mobilisation from the 
heart, liver and spleen when in combination with the oral chelator DFX were examined. 
The materials and methods used have been described in Section 7.3.1. In principle, mice 
are iron loaded with iron dextran and thereafter are allowed a period of time for iron to 
be redistributed from mononuclear cells, where it is first taken up, into hepatocytes and 
then cardiomyocytes. Figure 67 shows a schematic representation of the iron loading 
period with i.p. injections of iron dextran (10mg/daily, 5 days per week), and thereafter 
the re-equilibration 4 week period followed by the 4 days of chelator treatment by 
gavage. The mice were separated into 4 groups, namely: (a) control (vehicle gavage) 
(n=7), (b) Quercetin 300mg/kg/day (n=5), (c) DFX 30mg/kg/day (n=7), (d) DFX 
30mg/kg/day + Quercetin 300mg/kg/day (n=7).  
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Figure 67  Schematic representation of DFX/Quercetin combination treatment in iron-overloaded 
mice. 
 
 
 
 
 
 
 
 
 
 
7.6.1 Combination treatment of Quercetin and DFX in iron overloaded mice 
Following iron loading with iron dextran and a re-equilibration period of four weeks, as 
described above, the mice received 4 days of treatment by gavage either with vehicle, 
Quercetin 300mg/kg/day, DFX 30mg/kg/day or a combination of Quercetin + DFX. All 
treatments were well tolerated with no noted toxicity during the time period. Figure 68 
shows a statistically significant reduction in total cardiac iron concentration between 
DFX (87.1 μg/g wet tissue) and DFX + Quercetin (82.6 μg/g wet tissue) (p=0.026), and 
both treatments were significantly lower than control (A). In the liver (B), the control 
mice liver iron concentration was 1102 μg/g tissue,  which was reduced to 1028 μg/g in 
DFX treated and 963 μg/g tissue in DFX + Quercetin treated animals respectively, 
however this was not statistically significant. Similarly, in the spleen (C) tissue iron was 
reduced from 52μg/g tissue in control animals to 49.46 μg/g tissue in DFX treated 
animals and 47.69 μg/g tissue in DFX + Quercetin; however, the difference was not 
significant.  
Figure 69 shows the Perl stain slides of the heart, liver, and spleen following treatment. 
Inspection of the images suggests that there is a general improvement in tissue iron in 
combination therapy compared to control in all tissues. In order to quantify this 
observation, the images were analysed using the software ‘Image J’. Table 20 and 
Table 21 show the results of Perls stain iron quantification by comparing the blue area 
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(iron deposition) in the slides or the number of blue pixels, respectively. Cardiac iron is 
50 (arbitrary units) in control animals and 17 in DFX treatment, and this is further 
reduced to 2 in DFX + Quercetin treatment when comparing the blue area in the slides 
(Table 20). These findings are re-itterated by blue pixel counting in Table 21. In both 
the liver and spleen there is a notable reduction in tissue iron when comparing DFX 
treatment alone to combination with Quercetin. In the liver, quercetin appeared to 
increase tissue iron, however, the accuracy of this finding is uncertain in view of the 
large iron dextran deposits noted on this particular slide.  
Quercetin has previously been studied in Sprague-Dawley male rats as a single dose of 
50mg/kg where it was shown to modulate iron absorption in the duodenum by 
increasing apical iron uptake by decreasing subsequent basolateral iron efflux as well 
as ferroportin expression (Lesjak et al, 2014). Quercetin supplemented as 1% in the diet 
and fed to mice for 45 days, has been shown to reduce liver iron significantly and 
increase faecal iron excretion. The flavonoid curcumin has also been shown to be 
beneficial in the removal of interstitial cardiac iron and plasma NTBI following two 
months of treatment in BKO mice fed with a ferrocene-supplemented diet (Thephinlap 
et al, 2011). Notably, there is no study to date addressing iron mobilisation in 
cardiomyocytes by quercetin with or without a commercially used iron chelator (Zhang 
et al, 2006), and demonstrating the beneficial effects of this naturally occurring 
compound in terms of enhancing cardiac iron removal when in combination with a 
commercially available iron chelator. A potential future experiment would combine 
quercetin treatment with the other commercially available iron chelators and compare 
dosing and time of treatment to cardiac iron mobilisation. The MRI technique described 
earlier could prove valuable in monitoring response to treatment. It was not adopted in 
this particular case due to cost limitations.   
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Figure 68 Tissue iron content of the (A) heart, (B) liver and (C) spleen of iron-loaded mice treated 
with DFX/Quercetin. The mice were iron loaded with IP injections of iron dextran 10mg/day for 5 days/ 
week and a 4 week period was allowed for iron re-equilibration. The mice were then treated for 4 days 
with vehicle, quercetin 300mg/kg daily, DFX 30mg/kg daily or a combination of DFX/Quercetin at the 
above concentrations. Tissue iron was quantified using the Bothwell method (McLaren, 1980). 
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Figure 70  Perls stain images from Figure 69, following Image J modification to enable blue stained iron pixel quantification
(Acknowledgement to Prof Richard Naftalin, King’s College London, for generating this suggestion) 
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Table 20 Total 'blue' iron containing area count from the histology images in Figure 70 . 
Total ‘blue’ Area Heart  Liver  Spleen  
Control 178 11340 1607 
DFX 54 150 519 
Quercetin 10 10465 18 
DFX + Quercetin 3 78 57 
 
 
 
Table 21 Total number of 'blue' pixels in the histology images in Figure 70 . 
Number of ‘blue’ 
pixels 
Heart  Liver  Spleen  
Control 50 1217 284 
DFX 17 65 95 
Quercetin 7 2209 15 
DFX + Quercetin 2 42 35 
 
 
 
 
7.6.2 Conclusions 
This novel mouse model was used to study the hypothesis that iron chelating 
compounds are effective at mobilising tissue iron when administered by the oral route, 
and to determine of the relative efficacy of addition of a flavonoid such as quercetin to 
commercially available oral treatment in terms of mobilising cardiac iron. It is clear 
from the above results that there could be value in the combination of DFX treatment 
with oral quercetin to improve iron mobilisation. Performing dose escalation of the 
flavonoid in addition to commercially used doses of DFX as well as assessing tissue 
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iron at longer time points will allow a more detailed study of the extent of iron 
mobilisation with potential reduction in experimental error. The Quercetin compound 
was selected on the basis of previous data using hepatocyte and cardiomyocyte cell 
cultures (Chapter 6) which demonstrated promising results in terms of iron 
mobilisation. It can be concluded that the findings in this chapter show that there is a 
close relationship between the efficacy of quercetin in cell culture and in the iron-
overloaded mouse. The findings support the contention that 
hepatocytes/cardiomyocytes are a useful first model for screening new compounds both 
for their toxicity and efficacy. The cellular models are limited however in that they 
cannot be used to study eventualities such as oral efficacy and inactivation by 
metabolism. 
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Chapter 8 CONCLUSIONS AND FUTURE PERSPECTIVES 
8.1 The value of the in vitro cultures and in vivo mouse model for investigating 
iron chelators 
The work in this thesis has characterised an in vitro model of iron loading that can 
evaluate iron chelators and their interactions in hepatocytes as well as cardiomyocytes. 
The value of this model has been tested by studying the optimal use for clinically 
available iron chelators to mobilise cardiac and hepatic iron. This model is also relevant 
to the development of new chelators as it has a number of features, detailed below, 
which are highly applicable in the early evaluation of novel compounds. Firstly, small 
quantities of chelator are required for screening, in contrast to animal models where at 
least 10 times the quantity of the drug is required. Furthermore, a number of compounds 
can be screened in one experiment, which is not readily applicable to the use of 
laboratory mice, where many more animals are required for in vivo screening. 
Therefore, compounds can be evaluated and excluded from further consideration 
without the potentially costly need to first scale up their synthesis. At the same time, 
compounds which are toxic to cells can be identified at an early stage and excluded 
from further development. Thus, as a first step in the evaluation of new compounds, this 
model has a number of advantages over in vivo systems. Of the in vitro systems 
available, it is clear that the hepatocyte and cardiomyocyte models are the most relevant 
for studying cellular iron mobilisation by iron chelators as hepatocytes are the cell type 
with the largest iron storage in transfusional iron overload, and removal of iron from 
the heart is one of the biggest challenges in reducing mortality from transfusional 
cardiac siderosis. 
 
The cellular model was primarily used to elucidate several principles about the 
interactions of chelators within cells. It allowed for the first time a detailed interrogation 
of synergy as opposed to additivity of action of licensed chelators when used in 
combination, which has now been published. In HuH7 and H9C2 cells, all combinations 
of commercially available iron chelators showed synergistic cellular iron mobilisation 
at 8 hours, with most importantly, at clinically achievable concentrations of the ‘sink’ 
and ‘shuttle’ chelator. Interestingly, the greatest synergism was achieved by combining 
DFP with DFX, where about 60 and 65% of the mobilised iron was attributable to 
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synergistic interaction in hepatocytes and cardiomyocytes respectively. In our model, 
the dose of DFX had to be reduced by 3.8 fold to produce a half-maximal chelation 
effect when the concentration of DFP was just 1μΜ in HuH7 cells. Furthermore, it was 
noted that the presence of 5μΜ DFP could reduce the dose of DFX required to produce 
a 50% of the maximal chelation effect by 17.9 mg/kg in H9C2 cells.  This concentration 
of DFP is clinically achievable (Limenta et al, 2011a). These studies confirm that for 
synergistic cellular iron mobilisation, one chelator must have the physicochemical 
properties to enter cells, chelate intracellular iron and subsequently donate iron to a 
second ‘sink’ chelator.   
 
In this work, I demonstrate for the first time the iron binding properties of ELT in 
solution, a drug used to manage ITP, as well as its iron mobilising properties from cells.  
It was noted that remarkably low concentrations of ELT are required to mobilise cellular 
iron and as a single agent, ELT is at least as effective as clinically licensed iron chelators 
at mobilising cardiomyocyte iron. Additive or synergistic intracellular chelation is 
shown when ELT is combined with clinically available chelators. The doses of ELT, 
alone or in combination with other chelators, are sufficiently low and clinically 
achievable, suggesting that ELT could be used to enhance iron chelation in patients who 
are not thrombocytopenic.  
I also investigated iron mobilising properties by the naturally occurring flavonoid 
quercetin and its principle metabolites. For the first time I show that quercetin can act 
as an iron ‘shuttle’ when combined with licensed iron chelators. Metabolism of 
quercetin does not abolish its iron mobilisation properties as a large number of its 
metabolites share its iron chelating properties. Once again, the doses of quercetin, alone 
or in combination with other chelators, are sufficiently low and clinically achievable to 
suggest quercetin could be used as an adjunct to iron chelation therapy, with the DFP-
Quercetin combination appearing to be the most synergistic. Furthermore, I have shown 
a unique structure-function analysis of flavonoids with regards to iron and ferritin 
mobilisation and antioxidant capacity as a function of Fe(II) binding using our cellular 
models. 
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In the final two chapters of this thesis, I present a humanised model of β thalassaemia 
with cardiac iron loading that is highly suited for evaluating iron chelators and in 
conjunction with the MRI techniques developed on this model by our collaborators in 
the Centre for Advanced Biomedical Imaging, UCL, it should prove valuable in the 
assessment and prediction of response to novel clinical treatments in humans. This 
works shows novel and clear evidence of iron loading within the heart myocytes 
following ip administration of iron dextran. A number of modes of administration and 
forms of iron have been attempted to induce pathological iron overload including 
dietary carbonyl and ferrocene iron, however, the pattern of iron deposition has not been 
shown to include intracellular cardiomyocyte deposition. This could either be due to 
frequency of treatment, duration of treatment or inadequate time allowed for iron re-
equilibration. 
This novel mouse model was used to study the hypothesis that iron chelating 
compounds are effective at mobilising tissue iron when administered by the oral route, 
and to determine the relative efficacy of addition of a flavonoid such as quercetin to 
commercially available oral treatment in terms of mobilising cardiac iron. It is clear 
from the results in Chapter 7 that there could be value in the combination of DFX 
treatment with oral quercetin to improve iron mobilisation. Performing dose escalation 
of the flavonoid in addition to commercially used doses of DFX as well as assessing 
tissue iron at longer time points will allow a more detailed study of the extent of iron 
mobilisation with potential reduction in experimental error. The quercetin compound 
was selected following results in cell culture (Chapter 6). It can be concluded that there 
is a close relationship between the efficacy of quercetin in cell culture and in the iron-
overloaded mouse, and therefore the findings support the contention that our cellular 
models provide useful first screening of compounds for their toxicity and efficacy.  
8.2 Limitations of the cellular culture system in investigating iron chelators 
From the discussions above, it appears that our cellular models are both predictive and 
relevant, but like all models, they have limitations and these must be considered. 
 
An important aspect of the efficacy of chelators which may not be adequately addressed 
in cell cultures is the influence of their metabolism on this variable. Cultured 
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hepatocytes lose their cytochrome P450 progressively unless special culture conditions 
are maintained (Naughton et al, 1995; Tong et al, 1994). Thus, when using cell lines, 
the levels of cytochrome P450 are likely to have fallen to a fraction of physiological 
levels. This enzyme is important in ‘Phase I’ metabolism which includes oxidation of 
drugs in the liver through a process requiring NADPH and oxygen. This is unlikely to 
be of major significance with regards to hydroxypyridinones examined clinically, 
namely DFP (CP20), as the most important metabolic route occurs in ‘Phase II 
metabolism’ by glucuronidation, independently of cytochrome P450 (Choudhury & 
Singh, 1995; Hoyes & Porter, 1993). Similarly, the metabolism of DFX is heavily 
dependent on glucuronidation, and only a small fraction (<8%) is oxidative (cytochrome 
P450 dependent) in humans (Waldmeier et al, 2010). 
 
The importance of determining chelator metabolism is further demonstrated by the 
interspecies variability for example in the case of the hydroxypiridinone (CP94). CP94 
is extremely effective in mobilising liver iron in rats but by contrast, in guinea-pigs, the 
compound lacked any liver iron mobilisation effects. Close examination of the 
metabolism of this compound reveals that this can be attributed directly to inactivation 
of the iron binding site of the molecule by glucuronidation in the guinea pig (Porter et 
al, 1993; Waldmeier et al, 2010). The importance of drug metabolism is further 
demonstrated when looking at the effect of CP94 in thalassaemic patients. Due to rapid 
glucuronidation, its efficacy was once again poor when compared to DFO (Porter et al, 
1994). Interestingly this was in contrast to the findings in Cebus monkeys, where CP94 
was more effective than DFO (Bergeron et al, 1992). Furthermore, the widely used and 
effective iron chelator DFP used in humans had little impact in rats and monkeys 
(Bergeron et al, 1992). 
 
Therefore any findings with respect to the efficacy of chelators in the mouse or cellular 
model should ideally be confirmed with metabolism studies in other species or using 
primary human cells. The way in which this is approached will depend on the resources 
available and the questions being addressed. Pharmacokinetic and metabolism studies 
can be performed in several species of laboratory animals to determine whether 
inactivation is likely to be problematic (Choudhury & Singh, 1995; Porter et al, 1993). 
Alternatively, metabolism of compounds in freshly isolated human hepatocytes or 
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human hepatocyte cultures (Gibson-D'Ambrosio et al, 1993) can be undertaken under 
special conditions so as to maintain cytochrome P450 levels if necessary (Gomez-
Lechon et al, 1990; Naughton et al, 1995; Tong et al, 1994). 
 
Finally, while the cellular models described in this work are a useful early step in 
screening for the unwanted toxic effects on cells, these cannot be expected to screen for 
all the toxic effects of iron chelators. It is known that iron chelators have important 
inhibitory effects on cell proliferation, affecting DNA synthesis and the cell cycle, as 
well as apoptosis, with clinical manifestations such as bone marrow suppression. This 
model is not intended to examine these effects. The novel mouse model could provide 
further insight on the above although animal and cellular models should be used 
together to best predict both beneficial and adverse effects of novel chelators for clinical 
use.  
 
Numerous animal models have been developed to study iron loading and chelation, 
utilising different methodologies to model iron overload and its related complications. 
Rodent models are imperfect surrogates for studying the efficacy of chelators in humans 
as there are differences in iron accessibility and storage as well as in drug metabolism 
and half-life, which limits the extrapolation of results to humans. One such limitation 
of the humanised thalassaemia mouse model used in this work is that iron loading with 
iron-dextran leads to cardiac iron deposition, with a significant proportion occurring 
interstitially with subsequent redistribution into the myocyte. Although interstitial iron 
deposition in the heart is universal in thalassaemia patients (Buja & Roberts, 1971), it 
is less prominent than in rodents.  
 
Furthermore, in rodents cardiac and liver iron appears to be much more closely 
correlated than in humans (WOOD et al, 2011), which suggests less asymmetry in the 
loading of organs as well as iron clearance compared to humans (Anderson et al, 2004; 
Wood et al, 2004). A further limitation of the mouse model is that no animal model 
accurately mimics human iron loading and often the loading follows a more strenuous 
regimen in experimental animals compared to patients. Furthermore, certain animals 
such as the gerbil spontaneously eliminate iron at high rates and this loss can potentially 
cause drug specific alterations and iron distribution effects that cannot be extrapolated 
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to human disease. In humans, iron loading secondary to transfusions overlaps with 
chelation protocols, thus introducing further variation and difficulty in creating a model. 
8.3 Future developments and perspectives 
A further test of the value of the cellular and animal models is their future use beyond 
the immediate circumstances for which they were developed. The cellular models 
continue to be in use in the author’s laboratory for identifying new compounds to 
improve the therapeutic safety margin of currently commercially available chelation 
therapy. Recent work in progress involves developing a pancreatic ‘insulinoma’ cell 
line model to investigate the impact of chelation treatment on insulin secretion. We aim 
in the near future to use our humanised β thalassaemia iron-overloaded mouse model to 
study the effects on cardiac iron overload by studying the addition of ELT to chelation 
treatment, such as, for example, the oral chelator DFX. 
8.4 Conclusion 
In conclusion, the novel cellular models presented in this work are representative of 
‘unphysiological’ iron overload and provide a useful initial step in the identification of 
new chelators which can mobilise iron, particularly when small quantities of novel 
drugs are available or when large numbers of compounds need to be primarily assessed. 
Furthermore, they can provide great insight into the interactions between chelators and 
their predicted additive/synergistic effects. These models are predictive of the iron 
mobilising properties of compounds with in vivo models and are extremely valuable in 
identifying principles concerning chelators’ interactions with cardiomyocyte as well as 
hepatocyte iron pools. Both these models are currently in use in our laboratory at UCL 
and we have used them to generate data in support of the use of ELT as well as quercetin 
to enhance iron mobilisation by licensed chelators. 
 
The novel humanised β thalassaemia iron-overloaded mouse model demonstrating 
cardiac iron loading is a first-in-kind developmnent, and the novel application of MRI 
to ascertain T2* in the mouse heart and liver, will provide a useful tool for studying iron 
chelators, the pathophysiology and disease progression, blood transfusion regimens and 
cellular/gene therapy in iron overload in the future.   
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